

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
16 May 2002 (16.05.2002)

PCT

(10) International Publication Number  
**WO 02/38794 A2**

(51) International Patent Classification<sup>7</sup>:

**C12Q**

(74) Agents: **PLUMER, Elizabeth, R.** et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(21) International Application Number: PCT/US01/46816

(22) International Filing Date:

8 November 2001 (08.11.2001)

(81) Designated States (*national*): AU, CA, JP.

(25) Filing Language:

English

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(26) Publication Language:

English

**Published:**

— without international search report and to be republished upon receipt of that report

(30) Priority Data:

60/247,457 9 November 2000 (09.11.2000) US

(71) Applicant: **THE BRIGHAM AND WOMEN'S HOSPITAL, INC.** [US/US]; 75 Francis Street, Boston, MA 02115 (US).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(72) Inventor: **LEE, Richard, T.**; 4 Country Drive, Weston, MA 02493 (US).

(54) Title: **CARDIOVASCULAR DISEASE DIAGNOSTIC AND THERAPEUTIC TARGETS**

(57) Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.

BEST AVAILABLE COPY



**WO 02/38794 A2**

## **CARDIOVASCULAR DISEASE DIAGNOSTIC AND THERAPEUTIC TARGETS**

### **Related Applications**

This application claims priority under 35 U.S.C. §119(e) from Provisional U.S. Patent Application Serial No. 60/247,457 filed on November 9, 2000, entitled CARDIOVASCULAR DISEASE DIAGNOSTIC AND THERAPEUTIC TARGETS. The contents of the provisional application are hereby expressly incorporated by reference.

### **Field of the Invention**

This invention relates to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.

### **Background of the Invention**

Despite significant advances in therapy, cardiovascular disease remains the single most common cause of morbidity and mortality in the developed world. Thus, prevention and therapy of cardiovascular conditions such as myocardial infarction and stroke is an area of major public health importance. Currently, several risk factors for future cardiovascular disorders have been described and are in wide clinical use in the detection of individuals at high risk. Such screening tests include evaluations of total and HDL cholesterol levels. However, a large number of cardiovascular disorders occur in individuals with apparently low to moderate risk profiles, and ability to identify such patients is limited. Moreover, accumulating data suggests that the beneficial effects of certain preventive and therapeutic treatments for patients at risk for or known to have cardiovascular disorders differs in magnitude among different patient groups. At this time, however, data describing diagnostic tests to determine whether certain therapies can be expected to be more or less effective are lacking.

### **Summary of the Invention**

This invention provides methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, a number of genes were identified that are upregulated in cardiac cells when the cells are subjected to mechanically-induced deformation.

In view of these discoveries, it is believed that the molecules of the present invention can be used to treat vascular and cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.

Additionally, methods for using these molecules in the diagnosis of any of the foregoing vascular and cardiovascular conditions, are also provided.

Furthermore, compositions useful in the preparation of therapeutic preparations for the treatment of the foregoing conditions, are also provided.

The present invention thus involves, in several aspects, polypeptides, isolated nucleic acids encoding those polypeptides, functional modifications and variants of the foregoing, useful fragments of the foregoing, as well as therapeutics and diagnostics relating thereto.

According to one aspect of the invention, a method of diagnosing a condition characterized by aberrant expression of a nucleic acid molecule or an expression product thereof (or of unique fragments of the foregoing molecules thereof), is provided. The method involves contacting a biological sample from a subject with an agent, wherein said agent specifically binds to said nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof, and measuring the amount of bound agent and determining therefrom if the expression of said nucleic acid molecule or of an expression product thereof is aberrant, aberrant expression being diagnostic of the disorder, wherein the nucleic acid molecule is at least one nucleic acid molecule selected from the group consisting of Fit-1 (SEQ ID NOs: 1 and 2 for Fit-1S; SEQ ID NOs: 3 and 4 for Fit-1M), vacuolar ATPase (SEQ ID NOs: 5 and 6), CD44 (SEQ ID NOs: 7 and 8), Lot-1 (SEQ ID NOs: 9 and 10), AA892598 (SEQ ID NO: 11), and Mrg-1 (SEQ ID NO: 12). In some embodiments, the disorder is a cardiovascular condition selected from the group consisting of myocardial infarction, stroke, arteriosclerosis, and heart failure. In one embodiment, the disorder is cardiac hypertrophy. In certain embodiments, biological samples include biopsy samples, and biological fluids such as blood.

According to still another aspect of the invention, a method for determining a stage (e.g., regression, progression or onset) of a cardiovascular condition in a subject characterized by aberrant expression of a nucleic acid molecule or an expression product thereof (or of unique fragments of the foregoing molecules thereof), is provided. The method involves monitoring a sample from a patient for a parameter selected from the group consisting of (i) a nucleic acid molecule selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1 (or a unique fragment thereof), (ii) a polypeptide encoded by the

nucleic acid, (iii) a peptide derived from the polypeptide (or of a unique fragment thereof), and (iv) an antibody which selectively binds the polypeptide or peptide (or a unique fragment thereof), as a determination of a stage (e.g., regression, progression or onset) of said cardiovascular condition in the subject. In some embodiments, the sample is a biological fluid or a tissue as described in any of the foregoing embodiments. In certain embodiments, the step of monitoring comprises contacting the sample with a detectable agent selected from the group consisting of (a) an isolated nucleic acid molecule which selectively hybridizes under stringent conditions to the nucleic acid molecule of (i), (b) an antibody which selectively binds the polypeptide of (ii), or the peptide of (iii), and (c) a polypeptide or peptide which binds the antibody of (iv). The antibody, polypeptide, peptide, or nucleic acid can be labeled with a radioactive label or an enzyme. In further embodiments, the method further comprises assaying the sample for the peptide. In still further embodiments, monitoring the sample occurs over a period of time.

According to another aspect of the invention, a kit is provided. The kit comprises a package containing an agent that selectively binds to any of the foregoing isolated nucleic acids (Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1), or expression products thereof, and a control for comparing to a measured value of binding of said agent any of the foregoing isolated nucleic acids or expression products thereof. In some embodiments, the control is a predetermined value for comparing to the measured value. In certain embodiments, the control comprises an epitope of the expression product of any of the foregoing isolated nucleic acids.

According to one aspect of the invention, a method for treating a cardiovascular condition, is provided. The method involves administering to a subject in need of such treatment a molecule selected from the group consisting of Fit-1 (alternatively referred to herein as T1/ST2), CD44, Lot-1, AA892598, and Mrg-1, in an amount effective to treat the cardiovascular condition. In certain embodiments, the cardiovascular condition is selected from the group consisting of myocardial infarction, stroke, arteriosclerosis, and heart failure. In one embodiment, the molecule administered is vacuolar ATPase. In some embodiments, the method further comprises co-administering an agent selected from the group consisting of an anti-inflammatory agent, an anti-thrombotic agent, an anti-platelet agent, a fibrinolytic agent, a lipid reducing agent, a direct thrombin inhibitor, a glycoprotein IIb/IIIa receptor inhibitor, an agent that binds to cellular adhesion molecules and inhibits the ability of white blood cells to attach to such molecules, a calcium channel blocker, a beta-adrenergic receptor blocker, a cyclooxygenase-2 inhibitor, or an angiotensin system inhibitor.



According to another aspect of the invention, a method for treating cardiac hypertrophy, is provided. The method involves administering to a subject in need of such treatment an agent that increases expression of a nucleic acid molecule selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1, or an expression product thereof, in an amount effective to treat cardiac hypertrophy in the subject.

According to a further aspect of the invention, a method for treating a subject to reduce the risk of a cardiovascular condition developing in the subject, is provided. The method involves administering to a subject that expresses decreased levels of a molecule selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1, an agent for reducing the risk of the cardiovascular disorder in an amount effective to lower the risk of the subject developing a future cardiovascular disorder, wherein the agent is an anti-inflammatory agent, an anti-thrombotic agent, an anti-platelet agent, a fibrinolytic agent, a lipid reducing agent, a direct thrombin inhibitor, a glycoprotein IIb/IIIa receptor inhibitor, an agent that binds to cellular adhesion molecules and inhibits the ability of white blood cells to attach to such molecules, a calcium channel blocker, a beta-adrenergic receptor blocker, a cyclooxygenase-2 inhibitor, or an angiotensin system inhibitor, or an agent that increases expression of a molecule selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1.

According to one aspect of the invention, a method for identifying a candidate agent useful in the treatment of a cardiovascular condition, is provided. The method involves determining expression of a set of nucleic acid molecules in a cardiac cell or tissue under conditions which, in the absence of a candidate agent, permit a first amount of expression of the set of nucleic acid molecules, wherein the set of nucleic acid molecules comprises at least one nucleic acid molecule selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1, contacting the cardiac cell or tissue with the candidate agent, and detecting a test amount of expression of the set of nucleic acid molecules, wherein an increase in the test amount of expression in the presence of the candidate agent relative to the first amount of expression indicates that the candidate agent is useful in the treatment of the cardiovascular condition. In certain embodiments, the cardiovascular condition is selected from the group consisting of cardiac hypertrophy (e.g., maladaptive hypertrophy), myocardial infarction, stroke, arteriosclerosis, and heart failure. In some embodiments, the set of nucleic acid molecules comprises at least two, at least three, at least four, or even at least five nucleic

acid molecules, each selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1.

According to another aspect of the invention, a pharmaceutical composition is provided. The composition comprises an agent comprising an isolated nucleic acid molecule  
5 selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1, or an expression product thereof, in a pharmaceutically effective amount to treat a cardiovascular condition, and a pharmaceutically acceptable carrier. In some embodiments, the agent is an expression product of the isolated nucleic acid molecule selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1. In certain  
10 embodiments, the cardiovascular condition is selected from the group consisting of cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.

According to a further aspect of the invention, methods for preparing medicaments useful in the treatment of a cardiovascular condition are also provided.

According to still another aspect of the invention, a solid-phase nucleic acid molecule  
15 array, is provided. The array consists essentially of a set of nucleic acid molecules, expression products thereof, or fragments (of either the nucleic acid or the polypeptide molecule) thereof, wherein at least two and as many as all of the nucleic acid molecules selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1 (including expression products thereof, or fragments thereof), are fixed to a solid substrate. In some  
20 embodiments, the solid-phase array further comprises at least one control nucleic acid molecule. In certain embodiments, the set of nucleic acid molecules comprises at least three, at least four, or even at least five nucleic acid molecules, each selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1. In preferred embodiments, the set of nucleic acid molecules comprises a maximum number of 100 different nucleic acid  
25 molecules. In important embodiments, the set of nucleic acid molecules comprises a maximum number of 10 different nucleic acid molecules.

In certain embodiments, the solid substrate includes a material selected from the group consisting of glass, silica, aluminosilicates, borosilicates, metal oxides such as alumina and  
nickel oxide, various clays, nitrocellulose, and nylon. Preferably the substrate is glass. In some  
30 embodiments, the nucleic acid molecules are fixed to the solid substrate by covalent bonding.

These and other objects of the invention will be described in further detail in connection with the detailed description of the invention.

### **Brief Description of the Sequences**

SEQ ID NO:1 is the nucleotide sequence of the rat Fit-1S cDNA.

SEQ ID NO:2 is the predicted amino acid sequence of the translation product of rat Fit-  
5 1S cDNA (SEQ ID NO:1).

SEQ ID NO:3 is the nucleotide sequence of the rat Fit-1M cDNA.

SEQ ID NO:4 is the predicted amino acid sequence of the translation product of the rat  
Fit-1M cDNA (SEQ ID NO:3).

SEQ ID NO:5 is the nucleotide sequence of the rat vacuolar ATPase cDNA (GenBank  
10 Acc. No. Y12635).

SEQ ID NO:6 is the predicted amino acid sequence of the translation product of the rat  
vacuolar ATPase cDNA (SEQ ID NO:5).

SEQ ID NO:7 is the nucleotide sequence of the rat glycoprotein CD44 cDNA  
(GenBank Acc. No. M61875).

15 SEQ ID NO:8 is the predicted amino acid sequence of the translation product of the rat  
glycoprotein CD44 cDNA (SEQ ID NO:7).

SEQ ID NO:9 is the nucleotide sequence of the rat Lot-1 cDNA (GenBank Acc. No.  
U72620).

SEQ ID NO:10 is the predicted amino acid sequence of the translation product of the rat  
20 Lot-1 cDNA (SEQ ID NO:9).

SEQ ID NO:11 is the nucleotide sequence of the rat AA892598 (EST196401) cDNA.

SEQ ID NO:12 is the nucleotide sequence of the rat Mrg-1 cDNA (GenBank Acc. No.  
AA900476).

25 SEQ ID NO:13 is the nucleotide sequence of the mouse ST2 cDNA (GenBank Acc. No.  
Y07519).

SEQ ID NO:14 is the nucleotide sequence of the mouse ST2L cDNA (GenBank Acc.  
No. D13695).

SEQ ID NO:15 is the nucleotide sequence of the bovine vacuolar H<sup>+</sup>-ATPase cDNA  
30 (GenBank Acc. No. M88690).

SEQ ID NO:16 is the nucleotide sequence of the human vacuolar H<sup>+</sup>-ATPase cDNA  
(GenBank Acc. No. NM\_001693).

SEQ ID NO:17 is the nucleotide sequence of the mouse vacuolar H<sup>+</sup>-ATPase cDNA (GenBank Acc. No. NM\_007509).

SEQ ID NO:18 is the nucleotide sequence of the human vacuolar H<sup>+</sup>-ATPase cDNA (56,000 subunit -HO57) (GenBank Acc. No. L35249).

5 SEQ ID NO:19 is the nucleotide sequence of the human vacuolar H<sup>+</sup>-ATPase cDNA (B subunit) (GenBank Acc. No. M60346).

SEQ ID NO:20 is the nucleotide sequence of the bovine vacuolar H<sup>+</sup>-ATPase cDNA (B subunit) (GenBank Acc. No. M83131).

10 SEQ ID NO:21 is the nucleotide sequence of the gallus vacuolar H<sup>+</sup>-ATPase cDNA (GenBank Acc. No. U61724).

SEQ ID NO:22 is the nucleotide sequence of the human CD44R cDNA (GenBank Acc. No. X56794).

SEQ ID NO:23 is the nucleotide sequence of the human CD44 cDNA (GenBank Acc. No. U40373).

15 SEQ ID NO:24 is the nucleotide sequence of the mouse CD44 cDNA (GenBank Acc. No. M27129).

SEQ ID NO:25 is the nucleotide sequence of the hamster CD44 cDNA (GenBank Acc. No. M33827).

20 SEQ ID NO:26 is the nucleotide sequence of the human LOT1 cDNA (GenBank Acc. No. U72621).

SEQ ID NO:27 is the nucleotide sequence of the human ZAC zinc finger protein cDNA (GenBank Acc. No. AJ006354).

SEQ ID NO:28 is the nucleotide sequence of the mouse ZAC1 zinc finger protein cDNA (GenBank Acc. No. AF147785).

25 SEQ ID NO:29 is the nucleotide sequence having GenBank Acc. No. AF191918.1.

SEQ ID NO:30 is the nucleotide sequence of the human putative nucleotide binding protein, estradiol-induced (E2IG3) cDNA (GenBank Acc. No. NM\_014366).

SEQ ID NO:31 is the nucleotide sequence of the mouse mrg-1 cDNA (GenBank Acc. No. Y15163).

30 SEQ ID NO:32 is the nucleotide sequence of the human p35srj cDNA (GenBank Acc. No. AF129290).

SEQ ID NO:33 is the nucleotide sequence of the human p35srj (mrg-1) cDNA (GenBank Acc. No. AF109161).

### Brief Description of the Drawings

Figure 1 depicts by a Northern Blot the effects of 8% cyclic mechanical strain on the expression of Fit-1 in cultured cardiac myocytes over the course of time.

Figure 2 depicts by a Northern Blot the effects of 8% cyclic mechanical strain,  
5 angiotensin receptor blockade, angiotensin II, IL-1b, and phorbol ester, on the expression of Fit-1 in cultured cardiac myocytes over the course of time.

Figure 3 depicts by a Northern Blot the effects of 8% cyclic mechanical strain, hydrogen peroxide, and TIRON, on the expression of Fit-1 in cultured cardiac myocytes over the course of time.

10 Figure 4 depicts by a Northern Blot the effects of actinomycin D and cyclohexamide on the induction of Fit-1 expression during an 8% cyclic mechanical strain on cardiac myocytes over the course of time.

Figure 5 depicts by a Northern Blot the effects of 8% cyclic mechanical strain alone and in combination with IL-1b, and phorbol ester in the absence of strain, on the expression of Fit-1  
15 in cultured cardiac myocytes over the course of time.

Figure 6 depicts by a Northern Blot the effects of an 8% cyclic mechanical strain on the expression of vacuolar ATPase in cultured cardiac myocytes over the course of time.

Figure 7 depicts a kit embodying features of the present invention.

Figure 8 depicts early (left) and late (right) time course of the mRNA induction of  
20 T2/ST2 by mechanical strain in cardiac myocytes. Maximal induction occurs at 3 hours, is sustained for 9 hours and declines by 15 hours. Top panels, T1/ST2 RNA; bottom panels, ethidium bromide. No str, no strain.

Figure 9 depicts mRNA induction of T1/ST2 by mechanical strain (8%), interleukin-1 (10 ng/ml) and phorbol ester (PMA, 200 nM) at 1 and 3 hours. PMA>strain>IL-1. Top panel,  
25 T1/ST2 mRNA, bottom panel, ethidium bromide.

Figure 10 depicts T1/ST2 may be a gene induced by NF- $\kappa$ B activation during IL-1/IL-receptor signaling in cardiac myocytes. IL-1 and strain induced T1/ST2 mRNA in the presence of infection with control adenovirus (left). With infection of I $\kappa$ B adenovirus (right), which decreases NF- $\kappa$ B DNA binding activity, the IL-1 induction of T1/ST2 was blocked. The strain  
30 induction of T1/ST2 was partially blocked by I $\kappa$ B infection suggesting another pathway for induction of T1/ST2 by strain. Top panel, T1/ST2 mRNA; bottom panel, ethidium bromide.

Figure 11 shows expression of T1/st2 protein following myocardial infarction in mice by immunohistochemistry at 1 day but not 3 days after infarction. 40X magnification.

### **Detailed Description of the Invention**

The invention involves the discovery of a number of genes that are upregulated in cardiac cells when the cells are subjected to a mechanically-induced strain deformation. In view of this discovery, it is believed that the molecules of the present invention can be used to  
5 treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and/or heart failure.

Additionally, methods for using these molecules in the diagnosis of any of the foregoing cardiovascular conditions, are also provided.

Furthermore, compositions useful in the preparation of therapeutic preparations for the  
10 treatment of the foregoing conditions, are also provided.

“Upregulated,” as used herein, refers to increased expression of a gene and/or its encoded polypeptide. “Increased expression” refers to increasing (i.e., to a detectable extent) replication, transcription, and/or translation of any of the nucleic acids of the invention (Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1), since upregulation of any of these  
15 processes results in concentration/amount increase of the polypeptide encoded by the gene (nucleic acid). Conversely, “downregulation,” or “decreased expression” as used herein, refers to decreased expression of a gene and/or its encoded polypeptide. The upregulation or downregulation of gene expression can be directly determined by detecting an increase or decrease, respectively, in the level of mRNA for the gene, or the level of protein expression of  
20 the gene-encoded polypeptide, using any suitable means known to the art, such as nucleic acid hybridization or antibody detection methods, respectively, and in comparison to controls.

A “cardiac cell,” as used herein, refers to a cardiomyocyte.

A “molecule,” as used herein, embraces both “nucleic acids” and “polypeptides.”

“Expression,” as used herein, refers to nucleic acid and/or polypeptide expression.

25 As used herein, a “subject” is a mammal or a non-human mammal. In all embodiments human nucleic acids, polypeptides, and human subjects are preferred. Although only rat sequences are exemplified in the Sequence Listing and the Examples section, it is believed that the results obtained using such compositions are predictive of the results that may be obtained using homologous human sequences.

30 In general human homologs and alleles typically will share at least 80% nucleotide identity and/or at least 85% amino acid identity to the characterized rat sequences of the invention. In further instances, human homologs and alleles typically will share at least 90%, 95%, or even 99% nucleotide identity and/or at least 95%, 98%, or even 99% amino acid

identity to the characterized rat sequences, respectively. The homology can be calculated using various, publicly available software tools developed by NCBI (Bethesda, Maryland). Exemplary tools include the heuristic algorithm of Altschul SF, *et al.*, (*J Mol Biol*, 1990, 215:403-410), also known as BLAST. Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydropathic analysis can be obtained using public (EMBL, Heidelberg, Germany) and commercial (e.g., the MacVector sequence analysis software from Oxford Molecular Group/Genetics Computer Group, Madison, WI, Accelrys, Inc., San Diego, CA). Watson-Crick complements of the foregoing nucleic acids also are embraced by the invention.

In screening for human related genes, such as homologs and alleles of the rat sequences described elsewhere herein, a Southern blot may be performed using stringent conditions, together with a probe. The term "stringent conditions" as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, *et al.*, eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, *et al.*, eds., John Wiley & Sons, Inc., New York. For example, stringent conditions may refer to hybridization at 65 °C in 6 x SSC. Alternatively, stringent conditions, as used herein, may refer, for example, to hybridization at 65 °C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH<sub>2</sub>PO<sub>4</sub>(pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetra acetic acid. After hybridization, the membrane upon which the DNA is transferred is washed at 2 x SSC at room temperature and then at 0.1 x SSC/0.1 x SDS at temperatures up to 68 °C. In a further example, an alternative to the use of an aqueous hybridization solution is the use of a formamide hybridization solution. Stringent hybridization conditions can thus be achieved using, for example, a 50% formamide solution and 42 °C.

There are other conditions, reagents, and so forth which can be used, and would result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of human homologs and alleles of the rat nucleic acids of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

Given the teachings herein of full-length rat cDNA clones, other mammalian sequences such as the human (mouse, bovine, etc.) cDNAs corresponding to the related rat nucleic acids can be isolated from cDNA libraries using standard colony hybridization techniques, or can be identified using a homology search, for example, in GenBank using any of the algorithms  
5 described elsewhere herein. For example, sequences with GenBank Accession numbers Y07519.1 (SEQ ID NO:13) and D13695.1 (SEQ ID NO:14) for Fit-1 homologs), M88690.1 (SEQ ID NO:15), NM\_001693.1 (SEQ ID NO:16), NM\_007509.1 (SEQ ID NO:17), L35249.1 (SEQ ID NO:18), M60346.1 (SEQ ID NO:19), M83131.1 (SEQ ID NO:20 and U61724.1 (SEQ ID NO:21) for vacuolar ATPase homologs), X56794.1 (SEQ ID NO:22), U40373.1 (SEQ ID NO:23), M27129.1 (SEQ ID NO:24), and M33827.1 (SEQ ID NO:25) for CD44 homologs),  
10 U72621.3 (SEQ ID NO:26), AJ006354.1 (SEQ ID NO:27), and AF147785.1 (SEQ ID NO:28) for Lot-1 homologs), AF191918.1 (SEQ ID NO:29) and NM\_014366.1 (SEQ ID NO:30) for AA892598 homologs), and Y15163.1 (SEQ ID NO:31), AF129290.1 (SEQ ID NO:32), and AF109161.1 (SEQ ID NO:33) for Mrg-1 homologs), can be used interchangeably with the  
15 homologous rat sequences of the invention, in all aspects of the invention without departing from the essence of the invention.

As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example,  
20 chemical synthesis. An isolated nucleic acid is one which is readily manipulated by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated, but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be  
25 substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulated by standard techniques known to those of ordinary skill in the art.

30 According to the invention, expression of any of the foregoing nucleic acids (i.e., Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1), including unique fragments of the foregoing, can be determined using different methodologies. A "unique fragment," as used herein, with respect to a nucleic acid is one that is a "signature" for the larger nucleic acid. For



example, the unique fragment is long enough to assure that its precise sequence is not found in molecules within the human genome outside of the sequence for each nucleic acid defined above (Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1, including their human alleles). Those of ordinary skill in the art may apply no more than routine procedures to  
5 determine if a fragment is unique within the human genome. Unique fragments, however, exclude fragments completely composed of nucleotide sequences previously published as of the filing date of this application.

Unique fragments can be used as probes in Southern and Northern blot assays to identify such nucleic acids, or can be used in amplification assays such as those employing  
10 PCR. As known to those skilled in the art, large probes such as 200, 250, 300 or more nucleotides are preferred for certain uses such as Southern and Northern blots, while smaller fragments will be preferred for other uses such as PCR. Unique fragments also can be used to produce fusion proteins for generating antibodies, or determining binding of the polypeptide fragments, or for generating immunoassay components. Likewise, unique fragments can be  
15 employed to produce nonfused fragments of, for example, the Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1 polypeptides, useful, for example, in the preparation of antibodies, immunoassays or therapeutic applications. Unique fragments further can be used as antisense molecules to inhibit the expression of the foregoing nucleic acids and polypeptides respectively.

20 As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions of SEQ ID NOs: 1, 3, 5, 7, 9, 11 and 12, and complements will require longer segments to be unique while others will require only short segments, typically between 12 and 32 nucleotides long (e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32 bases) or more, up to the  
25 entire length of each of the disclosed sequences. As mentioned above, this disclosure intends to embrace each and every fragment of each sequence, beginning at the first nucleotide, the second nucleotide and so on, up to 8 nucleotides short of the end, and ending anywhere from nucleotide number 8, 9, 10 and so on for each sequence, up to the very last nucleotide, (provided the sequence is unique as described above). For example, virtually any segment of  
30 the region of SEQ ID NO:1 beginning at nucleotide 1 and ending at nucleotide 2586, or SEQ ID NO:3 beginning at nucleotide 1 and ending at nucleotide 2065, or complements thereof, that is 20 or more nucleotides in length will be unique. Those skilled in the art are well versed in methods for selecting such sequences, typically on the basis of the ability of the unique

fragment to selectively distinguish the sequence of interest from other sequences in the human genome of the fragment to those on known databases typically is all that is necessary, although *in vitro* confirmatory hybridization and sequencing analysis may be performed.

As used herein with respect to polypeptides, the term "isolated" means separated from  
5 its native environment in sufficiently pure form so that it can be manipulated or used for any one of the purposes of the invention. Thus, isolated means sufficiently pure to be used (i) to raise and/or isolate antibodies, (ii) as a reagent in an assay, (iii) for sequencing, (iv) as a therapeutic, etc.

In certain aspects, the invention embraces antisense oligonucleotides that selectively  
10 bind to a nucleic acid molecule encoding a polypeptide, to decrease the polypeptide's activity.

As used herein, the terms "antisense molecules," "antisense oligonucleotide," and "antisense" describe an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an  
15 mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of an antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific  
20 target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that an antisense oligonucleotide be constructed and arranged so as to bind selectively with a target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon SEQ ID NOs: 1, 3, 5, 7, 9, 11 and 12, or upon allelic or  
25 homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as  
30 short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner *et al.*, *Nat. Med.*, 1995, 1(11):1116-1118; *Nat. Biotech.*, 1996, 14:840-844). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA

transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted by antisense oligonucleotides. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative  
5 mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio *et al.*, *Cell Mol. Neurobiol.* 14(5):439-457, 1994) and at which proteins are not expected to bind. Finally, although, SEQ ID NOs: 1, 3, 5, 7, 9, 11 and 12 disclose cDNA sequences, one of ordinary skill in the art may easily derive the genomic DNA corresponding to the foregoing sequences. Thus, the present  
10 invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to SEQ ID NOs: 1, 3, 5, 7, 9, 11 and 12. Similarly, antisense to allelic or homologous human cDNAs and genomic DNAs are enabled without undue experimentation.

In one set of embodiments, the antisense oligonucleotides of the invention may be  
15 composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by  
20 vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

25 The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred  
30 synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamidates, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose in place of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding the polypeptides with SEQ ID NOs: 2, 4, 6, 8, and/or 10, together with pharmaceutically acceptable carriers.

Antisense oligonucleotides may be administered as part of a pharmaceutical composition. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art. The compositions should be sterile and contain a therapeutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art.

The invention also involves expression vectors coding for proteins encoded by the nucleic acids corresponding to SEQ ID NOs: 1, 3, 5, 7, 9, 11 and/or 12, fragments and variants thereof, and host cells containing those expression vectors. Virtually any cells, prokaryotic or eukaryotic, which can be transformed with heterologous DNA or RNA and which can be grown or maintained in culture, may be used in the practice of the invention. Examples include bacterial cells such as *Escherichia coli* and mammalian cells such as mouse, hamster, pig, goat, primate, etc. They may be of a wide variety of tissue types, including mast cells, fibroblasts, oocytes and lymphocytes, and they may be primary cells or cell lines. Specific examples include CHO cells and COS cells. Cell-free transcription systems also may be used in lieu of cells.

As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to, plasmids, phagemids and virus genomes. A cloning vector is one which is able to replicate in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g.,  $\beta$ -galactosidase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be "operably joined" when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding

sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Such 5' non-transcribed regulatory sequences will often include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen, Carlsbad, CA), which contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 $\alpha$ , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nuc. Acids Res.* 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol. Cell. Biol.* 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J. Clin. Invest.* 90:626-630, 1992). The use of the adenovirus as an

Adeno.P1A recombinant is disclosed by Warnier *et al.*, in intradermal injection in mice for immunization against P1A (*Int. J. Cancer*, 67:303-310, 1996).

The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of each of the previously discussed coding sequences. Other components may be added, as desired, as long as the previously mentioned sequences, which are required, are included.

It will also be recognized that the invention embraces the use of the above described SEQ ID NOs: 1, 3, 5, 7, 9, 11 and/or 12 cDNA sequence-containing expression vectors, to transfect host cells and cell lines, be these prokaryotic (e.g., *Escherichia coli*), or eukaryotic (e.g., CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as mouse, hamster, pig, goat, primate, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. Specific examples include dendritic cells, U293 cells, peripheral blood leukocytes, bone marrow stem cells and embryonic stem cells.

The invention also provides isolated polypeptides (including whole proteins and partial proteins), encoded by the foregoing nucleic acids (SEQ ID NOs: 1, 3, 5, 7, 9, 11 and 12), and include the polypeptides of SEQ ID NOs: 2, 4, 6, 8, and/or 10, and unique fragments thereof. Such polypeptides are useful, for example, alone or as part of fusion proteins to generate antibodies, as components of an immunoassay, etc. Polypeptides can be isolated from biological samples including tissue or cell homogenates, and can also be expressed recombinantly in a variety of prokaryotic and eukaryotic expression systems by constructing an expression vector appropriate to the expression system, introducing the expression vector into the expression system, and isolating the recombinantly expressed protein. Short polypeptides, including antigenic peptides (such as are presented by MHC molecules on the surface of a cell for immune recognition) also can be synthesized chemically using well-established methods of peptide synthesis.

A unique fragment for each of the foregoing polypeptide, in general, has the features and characteristics of unique fragments as discussed above in connection with nucleic acids. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon factors such as whether the fragment constitutes a portion of a conserved protein domain. Thus, some regions of a polypeptide will require longer segments to be unique while others will require only short segments, typically between 5 and 12 amino acids (e.g. 5, 6, 7, 8, 9, 10,

11 and 12 amino acids long or more, including each integer up to the full length of each polypeptide).

Unique fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the polypeptide. Functional capabilities which can be retained in a unique fragment of a polypeptide include interaction with antibodies, interaction with other polypeptides or fragments thereof, interaction with other molecules, etc. One important activity is the ability to act as a signature for identifying the polypeptide. Those skilled in the art are well versed in methods for selecting unique amino acid sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from non-family members. A comparison of the sequence of the fragment to those on known databases typically is all that is necessary.

The invention embraces variants of the polypeptides described above. As used herein, a "variant" of a polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a natural (e.g., "wild-type": a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, and 10) polypeptide. Modifications which create a polypeptide variant are typically made to the nucleic acid which encodes the polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and addition of amino acids or non-amino acid moieties to: (1) reduce or eliminate an activity of a polypeptide; (2) enhance a property of a polypeptide, such as protein stability in an expression system or the stability of protein-ligand binding; (3) provide a novel activity or property to a polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety; or (4) to provide equivalent or better binding to a polypeptide receptor or other molecule. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the polypeptide's amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus "design" a variant polypeptide according to known methods. One example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87, 1997, whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary only a portion of the polypeptide sequence. By applying the computational methods of Dahiyat and Mayo, specific variants of any of the foregoing polypeptides can be proposed and tested to determine whether the variant retains a desired conformation.



5 Variants can include polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

10 Mutations of a nucleic acid which encodes a polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such a hairpins or loops, which can be deleterious to expression of the variant polypeptide.

15 Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with the desired properties. Further mutations can be made to variants (or to non-variant polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *Escherichia coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a gene or cDNA clone to enhance expression of the polypeptide.

20 The skilled artisan will realize that conservative amino acid substitutions may be made in any of the foregoing polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e., the variants retain the functional capabilities of each polypeptide. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not significantly alter the the tertiary structure and/or activity of the polypeptide.

25 Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art, and include those that are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, *et al.*, eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, *et al.*, eds., John Wiley & Sons, Inc., New York.

30 Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

Thus functionally equivalent variants of polypeptides, i.e., variants of polypeptides which retain the function of the natural ("wild-type") polypeptides, are contemplated by the invention. Conservative amino acid substitutions in the amino acid sequence of polypeptides to produce functionally equivalent variants of each polypeptide typically are made by alteration of a nucleic acid encoding the polypeptide. Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc. Nat. Acad. Sci. U.S.A.* 82: 488-492, 1985), or by chemical synthesis of a gene encoding a polypeptide. The activity of functionally equivalent fragments of polypeptides can be tested by cloning the gene encoding the altered polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered polypeptide, and testing for a functional capability of the polypeptides as disclosed herein

The invention as described herein has a number of uses, some of which are described elsewhere herein. First, the invention permits isolation of polypeptides. A variety of methodologies well-known to the skilled artisan can be utilized to obtain isolated molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation of mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce polypeptides. Those skilled in the art also can readily follow known methods for isolating polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

The invention also provides, in certain embodiments, "dominant negative" polypeptides derived from polypeptides. A dominant negative polypeptide is an inactive variant of a protein, which, by interacting with the cellular machinery, displaces an active protein from its interaction with the cellular machinery or competes with the active protein, thereby reducing the effect of the active protein. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand. Likewise, a dominant negative catalytically-inactive kinase which interacts normally with target proteins but does not

phosphorylate the target proteins can reduce phosphorylation of the target proteins in response to a cellular signal. Similarly, a dominant negative transcription factor which binds to a promoter site in the control region of a gene but does not increase gene transcription can reduce the effect of a normal transcription factor by occupying promoter binding sites without  
5 increasing transcription.

The end result of the expression of a dominant negative polypeptide in a cell is a reduction in function of active proteins. One of ordinary skill in the art can assess the potential for a dominant negative variant of a protein, and use standard mutagenesis techniques to create one or more dominant negative variant polypeptides. See, e.g., U.S. Patent No. 5,580,723 and  
10 Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in a selected activity and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a protein will be apparent to one of ordinary skill in the art.

The isolation of the cDNAs of the invention also makes it possible for the artisan to  
15 diagnose a disorder characterized by an aberrant expression of any of the foregoing cDNAs. These methods involve determining expression of each of the identified nucleic acids, and/or polypeptides derived therefrom. In the former situation, such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction, or  
20 assaying with labeled hybridization probes as exemplified below. In the latter situation, such determination can be carried out via any standard immunological assay using, for example, antibodies which bind to the secreted protein.

The invention also embraces isolated peptide binding agents which, for example, can be antibodies or fragments of antibodies ("binding polypeptides"), having the ability to selectively  
25 bind to any of the polypeptides of the invention (e.g., SEQ ID NO: 2, 4, 6, 8, or 10). Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology.

Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark,  
30 W.R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been

enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')<sub>2</sub> fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding  
5 sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

10 Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated  
15 respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

It is now well-established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies while retaining  
20 the epitopic specificity of the original antibody. This is most clearly manifested in the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. See, e.g., U.S. Patent Nos. 4,816,567; 5,225,539; 5,585,089; 5,693,762 and 5,859,205. Thus, for example, PCT International Publication Number WO 92/04381 teaches the production and use of  
25 humanized murine RSV antibodies in which at least a portion of the murine FR regions have been replaced by FR regions of human origin. Such antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')<sub>2</sub>, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR  
30 and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab')<sub>2</sub> fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the

FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies.

5        Thus, the invention involves polypeptides of numerous size and type that bind specifically to polypeptides of the invention (e.g., SEQ ID NO: 2, 4, 6, 8, or 10), and complexes of both the polypeptides and their binding partners. These polypeptides may be derived also from sources other than antibody technology. For example, such polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared  
10 in solution, in immobilized form, as bacterial flagella peptide display libraries or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptides and non-peptide synthetic moieties.

      The invention further provides efficient methods of identifying agents or lead  
15 compounds for agents active at the level of a polypeptide or polypeptide fragment dependent cellular function. In particular, such functions include interaction with other polypeptides or fragments. Generally, the screening methods involve assaying for compounds which interfere with the activity of a polypeptide of the invention, although compounds which enhance such activity also can be assayed using the screening methods. Such methods are adaptable to  
20 automated, high throughput screening of compounds. Target indications include cellular processes modulated by such polypeptides, for example, overexpression in cells under mechanical strains.

      A wide variety of assays for candidate (pharmacological) agents are provided, including, labeled *in vitro* protein-ligand binding assays, electrophoretic mobility shift assays,  
25 immunoassays, cell-based assays such as two- or three-hybrid screens, expression assays, etc. The transfected nucleic acids can encode, for example, combinatorial peptide libraries or cDNA libraries. Convenient reagents for such assays, e.g., GAL4 fusion proteins, are known in the art. An exemplary cell-based assay involves transfecting a cell with a nucleic acid encoding a polypeptide of the invention fused to a GAL4 DNA binding domain and a nucleic  
30 acid encoding a reporter gene operably joined to a gene expression regulatory region, such as one or more GAL4 binding sites. Activation of reporter gene transcription occurs when the reporter fusion polypeptide binds an agent such as to enable transcription of the reporter gene. Agents which modulate polypeptide mediated cell function are then detected through a change

in the expression of reporter gene. Methods for determining changes in the expression of a reporter gene are known in the art.

Polypeptide fragments used in the methods, when not produced by a transfected nucleic acid are added to an assay mixture as an isolated polypeptide. Polypeptides preferably are produced recombinantly, although such polypeptides may be isolated from biological extracts. Recombinantly produced polypeptides include chimeric proteins comprising a fusion of a protein of the invention with another polypeptide, e.g., a polypeptide capable of providing or enhancing protein-protein binding, sequence specific nucleic acid binding (such as GAL4), enhancing stability of the polypeptide of the invention under assay conditions, or providing a detectable moiety, such as green fluorescent protein or a Flag epitope.

The assay mixture is comprised of a natural intracellular or extracellular binding target capable of interacting with a polypeptide of the invention. While natural polypeptide binding targets may be used, it is frequently preferred to use portions (e.g., peptides or nucleic acid fragments) or analogs (i.e., agents which mimic the polypeptide's binding properties of the natural binding target for purposes of the assay) of the polypeptide binding target so long as the portion or analog provides binding affinity and avidity to the polypeptide fragment measurable in the assay.

The assay mixture also comprises a candidate agent. Typically, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a different response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration of agent or at a concentration of agent below the limits of assay detection. Candidate agents encompass numerous chemical classes, although typically they are organic compounds. Preferably, the candidate agents are small organic compounds, i.e., those having a molecular weight of more than about 50 yet less than about 2500, preferably less than about 1000 and, more preferably, less than about 500. Candidate agents comprise functional chemical groups necessary for structural interactions with polypeptides and/or nucleic acids, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups and more preferably at least three of the functional chemical groups. The candidate agents can comprise cyclic carbon or heterocyclic structure and/or aromatic or polyaromatic structures substituted with one or more of the above-identified functional groups. Candidate agents also can be biomolecules such as peptides, saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the like. Where the agent is a nucleic acid, the agent

typically is a DNA or RNA molecule, although modified nucleic acids as defined herein are also contemplated.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including  
5 expression of randomized oligonucleotides, synthetic organic combinatorial libraries, phage display libraries of random peptides, and the like. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural and synthetically produced libraries and compounds can be modified  
10 through conventional chemical, physical, and biochemical means. Further, known (pharmacological) agents may be subjected to directed or random chemical modifications such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs of the agents.

A variety of other reagents also can be included in the mixture. These include reagents  
15 such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to facilitate optimal protein-protein and/or protein-nucleic acid binding. Such a reagent may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease inhibitors, nuclease inhibitors, antimicrobial agents, and the like may also be used.

The mixture of the foregoing assay materials is incubated under conditions whereby,  
20 but for the presence of the candidate agent, the chosen polypeptide of the invention specifically binds a cellular binding target, a portion thereof or analog thereof. The order of addition of components, incubation temperature, time of incubation, and other parameters of the assay may be readily determined. Such experimentation merely involves optimization of the assay  
25 parameters, not the fundamental composition of the assay. Incubation temperatures typically are between 4 °C and 40 °C. Incubation times preferably are minimized to facilitate rapid, high throughput screening, and typically are between 0.1 and 10 hours.

After incubation, the presence or absence of specific binding between the polypeptide and one or more binding targets is detected by any convenient method available to the user.

30 For cell free binding type assays, a separation step is often used to separate bound from unbound components. The separation step may be accomplished in a variety of ways. Conveniently, at least one of the components is immobilized on a solid substrate, from which the unbound components may be easily separated. The solid substrate can be made of a wide

variety of materials and in a wide variety of shapes, e.g., microtiter plate, microbead, dipstick, resin particle, etc. The substrate preferably is chosen to maximize signal to noise ratios, primarily to minimize background binding, as well as for ease of separation and cost.

Separation may be effected for example, by removing a bead or dipstick from a  
5 reservoir, emptying or diluting a reservoir such as a microtiter plate well, rinsing a bead, particle, chromatographic column or filter with a wash solution or solvent. The separation step preferably includes multiple rinses or washes. For example, when the solid substrate is a microtiter plate, the wells may be washed several times with a washing solution, which typically includes those components of the incubation mixture that do not participate in specific  
10 bindings such as salts, buffer, detergent, a non-specific protein, etc. When the solid substrate is a magnetic bead(s), the bead(s) may be washed one or more times with a washing solution and isolated using a magnet.

Detection may be effected in any convenient way for cell-based assays such as two- or three-hybrid screens. The transcript resulting from a reporter gene transcription assay of a  
15 polypeptide interacting with a target molecule typically encodes a directly or indirectly detectable product, e.g.,  $\beta$ -galactosidase activity, luciferase activity, and the like. For cell free binding assays, one of the components usually comprises, or is coupled to, a detectable label. A wide variety of labels can be used, such as those that provide direct detection (e.g., radioactivity, luminescence, optical or electron density, etc), or indirect detection (e.g., epitope  
20 tag such as the FLAG epitope, enzyme tag such as horseshoe peroxidase, etc.). The label may be bound to a binding partner of the polypeptide, or incorporated into the structure of the binding partner.

A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the  
25 solid substrate or subsequent to separation from the solid substrate. Labels may be directly detected through optical or electron density, radioactive emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, streptavidin-biotin conjugates, etc. Methods for detecting the labels are well known in the art.

The invention provides polypeptide-specific binding agents, methods of identifying and  
30 making such agents, and their use in diagnosis, therapy and pharmaceutical development. For example, polypeptide-specific pharmacological agents are useful in a variety of diagnostic and therapeutic applications, especially where disease or disease prognosis is associated with altered polypeptide binding characteristics. Novel polypeptide-specific binding agents include



polypeptide-specific antibodies, cell surface receptors, and other natural intracellular and extracellular binding agents identified with assays such as two hybrid screens, and non-natural intracellular and extracellular binding agents identified in screens of chemical libraries and the like.

5 In general, the specificity of polypeptide binding to a specific molecule is determined by binding equilibrium constants. Targets which are capable of selectively binding a polypeptide preferably have binding equilibrium constants of at least about  $10^7 \text{ M}^{-1}$ , more preferably at least about  $10^8 \text{ M}^{-1}$ , and most preferably at least about  $10^9 \text{ M}^{-1}$ . A wide variety of cell based and cell free assays may be used to demonstrate polypeptide-specific binding. Cell  
10 based assays include one, two and three hybrid screens, assays in which polypeptide-mediated transcription is inhibited or increased, etc. Cell free assays include protein binding assays, immunoassays, etc. Other assays useful for screening agents which bind polypeptides of the invention include fluorescence resonance energy transfer (FRET), and electrophoretic mobility shift analysis (EMSA).

15 According to still another aspect of the invention, a method of diagnosing a disorder characterized by aberrant expression of a nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof, is provided. The method involves contacting a biological sample isolated from a subject with an agent that specifically binds to the nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof,  
20 and determining the interaction between the agent and the nucleic acid molecule or the expression product as a determination of the disorder, wherein the nucleic acid molecule is selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1. In some embodiments, the disorder is a cardiovascular condition selected from the group consisting of myocardial infarction, stroke, arteriosclerosis, and heart failure. In one  
25 embodiment, the disorder is cardiac hypertrophy.

In the case where the molecule is a nucleic acid molecule, such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction, or assaying with labeled hybridization probes as exemplified herein. In the case where the molecule is an expression product of the nucleic acid molecule, or a fragment of an  
30 expression product of the nucleic acid molecule, such determination can be carried out via any standard immunological assay using, for example, antibodies which bind to any of the polypeptide expression products.

“Aberrant expression” refers to decreased expression (underexpression) or increased expression (overexpression) of any of the foregoing molecules (Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1, nucleic acids and/or polypeptides) in comparison with a control (i.e., expression of the same molecule in a healthy or “normal” subject). A “healthy subject,” as  
5 used herein, refers to a subject who is not at risk for developing a future cardiovascular condition (see earlier discussion and Harrison’s Principles of Experimental Medicine, 13th Edition, McGraw-Hill, Inc., N.Y.- hereinafter “Harrison’s”). Healthy subjects also do not otherwise exhibit symptoms of disease. In other words, such subjects, if examined by a medical professional, would be characterized as healthy and free of symptoms of a  
10 cardiovascular disorder or at risk of developing a cardiovascular disorder.

When the disorder is a cardiovascular condition selected from the group consisting of cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure, decreased expression of any of the foregoing molecules in comparison with a control (e.g., a healthy individual) is indicative of the presence of the disorder, or indicative of the risk for developing  
15 such disorder in the future.

The invention also provides novel kits which could be used to measure the levels of the nucleic acids of the invention, or expression products of the invention.

In one embodiment, a kit comprises a package containing an agent that selectively binds to an isolated nucleic acid selected from the group consisting of Fit-1, vacuolar ATPase, CD44,  
20 Lot-1, AA892598, and Mrg-1, or expression products thereof, and a control for comparing to a measured value of binding of said agent any of the foregoing isolated nucleic acids or expression products thereof. Kits are generally comprised of the following major elements: packaging, an agent of the invention, a control agent, and instructions. Packaging may be a box-like structure for holding a vial (or number of vials) containing an agent of the invention, a  
25 vial (or number of vials) containing a control agent, and instructions. Individuals skilled in the art can readily modify the packaging to suit individual needs. In some embodiments, the control is a predetermined value for comparing to the measured value. In certain embodiments, the control comprises an epitope of the expression product of any of the foregoing isolated nucleic acids.

30 In the case of nucleic acid detection, pairs of primers for amplifying a nucleic acid molecule of the invention can be included. The preferred kits would include controls such as known amounts of nucleic acid probes, epitopes (such as Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1 expression products) or anti-epitope antibodies, as well as instructions

or other printed material. In certain embodiments the printed material can characterize risk of developing a cardiovascular condition based upon the outcome of the assay. The reagents may be packaged in containers and/or coated on wells in predetermined amounts, and the kits may include standard materials such as labeled immunological reagents (such as labeled anti-IgG antibodies) and the like. One kit is a packaged polystyrene microtiter plate coated with any of the foregoing proteins of the invention and a container containing labeled anti-human IgG antibodies. A well of the plate is contacted with, for example, a biological fluid, washed and then contacted with the anti-IgG antibody. The label is then detected. A kit embodying features of the present invention, generally designated by the numeral 11, is illustrated in Figure 7. Kit 11 is comprised of the following major elements: packaging 15, an agent of the invention 17, a control agent 19, and instructions 21. Packaging 15 is a box-like structure for holding a vial (or number of vials) containing an agent of the invention 17, a vial (or number of vials) containing a control agent 19, and instructions 21. Individuals skilled in the art can readily modify packaging 15 to suit individual needs.

The invention also embraces methods for treating a cardiovascular condition. In some embodiments, the method involves administering to a subject in need of such treatment a molecule selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1, in an amount effective to treat the cardiovascular condition. In certain embodiments, the method involves administering to a subject in need of such treatment an agent that increases expression of any of the foregoing molecules (Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1), in an amount effective to treat the cardiovascular condition.

"Agents that increase expression" of a nucleic acid or a polypeptide, as used herein, are known in the art, and refer to sense nucleic acids, polypeptides encoded by the nucleic acids, and other agents that enhance expression of such molecules (e.g., transcription factors specific for the nucleic acids that enhance their expression). Any agents that increase expression of a molecule (and as described herein, increase its activity), are useful according to the invention.

In certain embodiments, the molecule is a nucleic acid. In some embodiments the nucleic acid is operatively coupled to a gene expression sequence which directs the expression of the nucleic acid molecule within a cardiomyocyte. The "gene expression sequence" is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the nucleic acid to which it is operably joined. The gene expression sequence may, for example, be a mammalian

or viral promoter, such as a constitutive or inducible promoter. Constitutive mammalian promoters include, but are not limited to, the promoters for the following genes: hypoxanthine phosphoribosyl transferase (HPTR), adenosine deaminase, pyruvate kinase,  $\alpha$ -actin promoter and other constitutive promoters. Exemplary viral promoters which function constitutively in eukaryotic cells include, for example, promoters from the simian virus, papilloma virus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus, cytomegalovirus, the long terminal repeats (LTR) of Moloney leukemia virus and other retroviruses, and the thymidine kinase promoter of herpes simplex virus. Other constitutive promoters are known to those of ordinary skill in the art. The promoters useful as gene expression sequences of the invention also include inducible promoters. Inducible promoters are activated in the presence of an inducing agent. For example, the metallothionein promoter is activated to increase transcription and translation in the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.

In general, the gene expression sequence shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined nucleic acid. The gene expression sequences optionally includes enhancer sequences or upstream activator sequences as desired.

Preferably, any of the nucleic acid molecules of the invention (e.g., Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1) is linked to a gene expression sequence which permits expression of the nucleic acid molecule in a cell such as a cardiomyocyte and/or a vascular endothelial cell (including a smooth muscle cell). More preferably, the gene expression sequence permits expression of the nucleic acid molecule in a cardiomyocyte, and does not permit expression of the molecule in a cell selected from the group consisting of a neuronal cell, a fibroblast, and a cell of hematopoietic origin. A sequence which permits expression of the nucleic acid molecule in a cardiomyocyte, is one which is selectively active in such a cell type, thereby causing expression of the nucleic acid molecule in the cell. The cardiac myosin heavy chain gene promoter, for example, can be used to express any of the foregoing nucleic acid molecules of the invention in a cardiomyocyte. Those of ordinary skill in the art will be able to easily identify alternative promoters that are capable of expressing a nucleic acid molecule in a cardiomyocyte.

The nucleic acid sequence and the gene expression sequence are said to be “operably joined” when they are covalently linked in such a way as to place the transcription and/or translation of the nucleic acid coding sequence under the influence or control of the gene expression sequence. If it is desired that the nucleic acid sequence be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5’ gene expression sequence results in the transcription of the nucleic acid sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the nucleic acid sequence, and/or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a gene expression sequence would be operably linked to a nucleic acid sequence if the gene expression sequence were capable of effecting transcription of that nucleic acid sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The molecules of the invention can be delivered to the preferred cell types of the invention alone or in association with a vector. In its broadest sense, a “vector” is any vehicle capable of facilitating: (1) delivery of a molecule to a target cell and/or (2) uptake of the molecule by a target cell. Preferably, the vectors transport the molecule into the target cell with reduced degradation relative to the extent of degradation that would result in the absence of the vector. Optionally, a “targeting ligand” can be attached to the vector to selectively deliver the vector to a cell which expresses on its surface the cognate receptor for the targeting ligand. In this manner, the vector (containing a nucleic acid or a protein) can be selectively delivered to a cardiomyocyte cell in, e.g., the myocardium. Methodologies for targeting include conjugates, such as those described in U.S. Patent 5,391,723 to Priest. Another example of a well-known targeting vehicle is a liposome. Liposomes are commercially available from Gibco BRL (Life Technologies Inc., Rockville, MD). Numerous methods are published for making targeted liposomes. Preferably, the molecules of the invention are targeted for delivery to cardiomyocytes, and/or vascular endothelial cells.

In general, the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the nucleic acid sequences of the invention, and additional nucleic acid fragments (e.g., enhancers, promoters) which can be attached to the nucleic acid sequences of the invention. Viral vectors are a preferred type of vector and include, but are not limited to, nucleic acid sequences from the following viruses: adenovirus;

adeno-associated virus; retrovirus, such as Moloney murine leukemia virus; Harvey murine sarcoma virus; murine mammary tumor virus; rouse sarcoma virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA viruses such as a retrovirus. One can readily employ other vectors not named  
5 but known in the art.

A particularly preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus is capable of infecting a wide range of cell types and species and can be engineered to be replication-deficient i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle. It  
10 further has advantages, such as heat and lipid solvent stability, high transduction frequencies in cells of diverse lineages, including hematopoietic cells, and lack of superinfection inhibition thus allowing multiple series of transductions. Reportedly, the adeno-associated virus can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression. In addition, wild-type  
15 adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

In general, other preferred viral vectors are based on non-cytopathic eukaryotic viruses  
20 in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. Adenoviruses and retroviruses have been approved for human gene therapy trials. In general, the retroviruses are replication-deficient. Such genetically altered retroviral expression vectors  
25 have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell line with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in  
30 Kriegler, M., "Gene Transfer and Expression, A Laboratory Manual," W.H. Freeman C.O., New York (1990) and Murry, E.J. Ed. "Methods in Molecular Biology," vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

Another preferred retroviral vector is the vector derived from the Moloney murine leukemia virus, as described in Nabel, E.G., *et al.*, *Science*, 1990, 249:1285-1288. These vectors reportedly were effective for the delivery of genes to all three layers of the arterial wall, including the media. Other preferred vectors are disclosed in Flugelman, *et al.*, *Circulation*,  
5 1992, 85:1110-1117. Additional vectors that are useful for delivering molecules of the invention are described in U.S. Patent No. 5,674,722 by Mulligan, *et al.*

In addition to the foregoing vectors, other delivery methods may be used to deliver a molecule of the invention to a cell such as a cardiomyocyte and/or a vascular endothelial cell, and facilitate uptake thereby.

10 A preferred such delivery method of the invention is a colloidal dispersion system. Colloidal dispersion systems include lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system of the invention is a liposome. Liposomes are artificial membrane vessels which are useful as a delivery vector *in vivo* or *in vitro*. It has been shown that large unilamellar vessels (LUV), which range in size  
15 from 0.2 - 4.0  $\mu\text{m}$  can encapsulate large macromolecules. RNA, DNA, and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, *et al.*, *Trends Biochem. Sci.*, 1981, 6:77). In order for a liposome to be an efficient gene transfer vector, one or more of the following characteristics should be present: (1) encapsulation of the gene of interest at high efficiency with retention of biological activity;  
20 (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information.

Liposomes may be targeted to a particular tissue, such as the myocardium or the vascular cell wall, by coupling the liposome to a specific ligand such as a monoclonal antibody,  
25 sugar, glycolipid, or protein. Ligands which may be useful for targeting a liposome to the vascular wall include, but are not limited to, the viral coat protein of the Hemagglutinating virus of Japan. Additionally, the vector may be coupled to a nuclear targeting peptide, which will direct the nucleic acid to the nucleus of the host cell.

Liposomes are commercially available from Gibco BRL, for example, as  
30 LIPOFECTIN<sup>TM</sup> and LIPOFECTACE<sup>TM</sup>, which are formed of cationic lipids such as N-[1-(2, 3-dioleoyloxy)-propyl]-N,N,N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many publications. Liposomes also have been reviewed by

Gregoriadis, G. in *Trends in Biotechnology*, V. 3, p. 235-241 (1985). Novel liposomes for the intracellular delivery of macromolecules, including nucleic acids, are also described in PCT International application no. PCT/US96/07572 (Publication No. WO 96/40060, entitled "Intracellular Delivery of Macromolecules").

5 In one particular embodiment, the preferred vehicle is a biocompatible micro particle or implant that is suitable for implantation into the mammalian recipient. Exemplary bioerodible implants that are useful in accordance with this method are described in PCT International application no. PCT/US/03307 (Publication No. WO 95/24929, entitled "Polymeric Gene Delivery System", which claims priority to U.S. Patent Application Serial No. 213,668, filed 10 March 15, 1994). PCT/US/03307 describes a biocompatible, preferably biodegradable polymeric matrix for containing an exogenous gene under the control of an appropriate promoter. The polymeric matrix is used to achieve sustained release of the exogenous gene in the patient. In accordance with the instant invention, the nucleic acids described herein are encapsulated or dispersed within the biocompatible, preferably biodegradable polymeric matrix 15 disclosed in PCT/US/03307. The polymeric matrix preferably is in the form of a micro particle such as a micro sphere (wherein a nucleic acid is dispersed throughout a solid polymeric matrix) or a microcapsule (wherein a nucleic acid is stored in the core of a polymeric shell). Other forms of the polymeric matrix for containing the nucleic acids of the invention include films, coatings, gels, implants, and stents. The size and composition of the polymeric matrix 20 device is selected to result in favorable release kinetics in the tissue into which the matrix device is implanted. The size of the polymeric matrix device further is selected according to the method of delivery which is to be used, typically injection into a tissue or administration of a suspension by aerosol into the nasal and/or pulmonary areas. The polymeric matrix composition can be selected to have both favorable degradation rates and also to be formed of a 25 material which is bioadhesive, to further increase the effectiveness of transfer when the device is administered to a vascular surface. The matrix composition also can be selected not to degrade, but rather, to release by diffusion over an extended period of time.

Both non-biodegradable and biodegradable polymeric matrices can be used to deliver the nucleic acids of the invention to the subject. Biodegradable matrices are preferred. Such 30 polymers may be natural or synthetic polymers. Synthetic polymers are preferred. The polymer is selected based on the period of time over which release is desired, generally in the order of a few hours to a year or longer. Typically, release over a period ranging from between a few hours and three to twelve months is most desirable. The polymer optionally is in the



Another preferred retroviral vector is the vector derived from the Moloney murine leukemia virus, as described in Nabel, E.G., *et al.*, *Science*, 1990, 249:1285-1288. These vectors reportedly were effective for the delivery of genes to all three layers of the arterial wall, including the media. Other preferred vectors are disclosed in Flugelman, *et al.*, *Circulation*,  
5 1992, 85:1110-1117. Additional vectors that are useful for delivering molecules of the invention are described in U.S. Patent No. 5,674,722 by Mulligan, *et al.*

In addition to the foregoing vectors, other delivery methods may be used to deliver a molecule of the invention to a cell such as a cardiomyocyte and/or a vascular endothelial cell, and facilitate uptake thereby.

10 A preferred such delivery method of the invention is a colloidal dispersion system. Colloidal dispersion systems include lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system of the invention is a liposome. Liposomes are artificial membrane vessels which are useful as a delivery vector *in vivo* or *in vitro*. It has been shown that large unilamellar vessels (LUV), which range in size  
15 from 0.2 - 4.0  $\mu\text{m}$  can encapsulate large macromolecules. RNA, DNA, and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, *et al.*, *Trends Biochem. Sci.*, 1981, 6:77). In order for a liposome to be an efficient gene transfer vector, one or more of the following characteristics should be present: (1) encapsulation of the gene of interest at high efficiency with retention of biological activity;  
20 (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information.

Liposomes may be targeted to a particular tissue, such as the myocardium or the vascular cell wall, by coupling the liposome to a specific ligand such as a monoclonal antibody,  
25 sugar, glycolipid, or protein. Ligands which may be useful for targeting a liposome to the vascular wall include, but are not limited to, the viral coat protein of the Hemagglutinating virus of Japan. Additionally, the vector may be coupled to a nuclear targeting peptide, which will direct the nucleic acid to the nucleus of the host cell.

Liposomes are commercially available from Gibco BRL, for example, as  
30 LIPOFECTIN<sup>TM</sup> and LIPOFECTACE<sup>TM</sup>, which are formed of cationic lipids such as N-[1-(2, 3-dioleoyloxy)-propyl]-N,N,N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many publications. Liposomes also have been reviewed by

Gregoriadis, G. in *Trends in Biotechnology*, V. 3, p. 235-241 (1985). Novel liposomes for the intracellular delivery of macromolecules, including nucleic acids, are also described in PCT International application no. PCT/US96/07572 (Publication No. WO 96/40060, entitled "Intracellular Delivery of Macromolecules").

5 In one particular embodiment, the preferred vehicle is a biocompatible micro particle or implant that is suitable for implantation into the mammalian recipient. Exemplary bioerodible implants that are useful in accordance with this method are described in PCT International application no. PCT/US/03307 (Publication No. WO 95/24929, entitled "Polymeric Gene Delivery System", which claims priority to U.S. Patent Application Serial No. 213,668, filed  
10 March 15, 1994). PCT/US/03307 describes a biocompatible, preferably biodegradable polymeric matrix for containing an exogenous gene under the control of an appropriate promoter. The polymeric matrix is used to achieve sustained release of the exogenous gene in the patient. In accordance with the instant invention, the nucleic acids described herein are encapsulated or dispersed within the biocompatible, preferably biodegradable polymeric matrix  
15 disclosed in PCT/US/03307. The polymeric matrix preferably is in the form of a micro particle such as a micro sphere (wherein a nucleic acid is dispersed throughout a solid polymeric matrix) or a microcapsule (wherein a nucleic acid is stored in the core of a polymeric shell). Other forms of the polymeric matrix for containing the nucleic acids of the invention include films, coatings, gels, implants, and stents. The size and composition of the polymeric matrix  
20 device is selected to result in favorable release kinetics in the tissue into which the matrix device is implanted. The size of the polymeric matrix device further is selected according to the method of delivery which is to be used, typically injection into a tissue or administration of a suspension by aerosol into the nasal and/or pulmonary areas. The polymeric matrix composition can be selected to have both favorable degradation rates and also to be formed of a  
25 material which is bioadhesive, to further increase the effectiveness of transfer when the device is administered to a vascular surface. The matrix composition also can be selected not to degrade, but rather, to release by diffusion over an extended period of time.

Both non-biodegradable and biodegradable polymeric matrices can be used to deliver the nucleic acids of the invention to the subject. Biodegradable matrices are preferred. Such  
30 polymers may be natural or synthetic polymers. Synthetic polymers are preferred. The polymer is selected based on the period of time over which release is desired, generally in the order of a few hours to a year or longer. Typically, release over a period ranging from between a few hours and three to twelve months is most desirable. The polymer optionally is in the

form of a hydrogel that can absorb up to about 90% of its weight in water and further, optionally is cross-linked with multi-valent ions or other polymers.

In general, the nucleic acids of the invention are delivered using the bioerodible implant by way of diffusion, or more preferably, by degradation of the polymeric matrix. Exemplary synthetic polymers which can be used to form the biodegradable delivery system include:

5 polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terephthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyglycolides, polysiloxanes, polyurethanes and co-polymers thereof, alkyl cellulose, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitrocelluloses, polymers of acrylic and methacrylic esters, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxy-

10 propyl methyl cellulose, hydroxybutyl methyl cellulose, cellulose acetate, cellulose propionate, cellulose acetate butyrate, cellulose acetate phthalate, carboxylethyl cellulose, cellulose triacetate, cellulose sulphate sodium salt, poly(methylmethacrylate), poly(ethylmethacrylate), poly(butylmethacrylate), poly(isobutylmethacrylate), poly(hexylmethacrylate),

15 poly(isodecylmethacrylate), poly(laurylmethacrylate), poly(phenylmethacrylate), poly(methylacrylate), poly(isopropylacrylate), poly(isobutylacrylate), poly(octadecylacrylate), polyethylene, polypropylene, poly(ethyleneglycol), poly(ethyleneoxide), poly(ethyleneterephthalate), poly(vinyl alcohols), polyvinyl acetate, poly vinyl chloride, polystyrene and polyvinylpyrrolidone.

20 Examples of non-biodegradable polymers include ethylene vinyl acetate, poly(meth)acrylic acid, polyamides, copolymers and mixtures thereof.

Examples of biodegradable polymers include synthetic polymers such as polymers of lactic acid and glycolic acid, polyanhydrides, poly(ortho)esters, polyurethanes, poly(butic acid), poly(valeric acid), and poly(lactide-cocaprolactone), and natural polymers such as

25 alginate and other polysaccharides including dextran and cellulose, collagen, chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art), albumin and other hydrophilic proteins, zein and other prolamines and hydrophobic proteins, copolymers and mixtures thereof. In general, these materials degrade either by enzymatic

30 hydrolysis or exposure to water *in vivo*, by surface or bulk erosion.

Bioadhesive polymers of particular interest include bioerodible hydrogels described by H.S. Sawhney, C.P. Pathak and J.A. Hubell in *Macromolecules*, 1993, 26, 581-587, the teachings of which are incorporated herein, polyhyaluronic acids, casein, gelatin, glutin,

polyanhydrides, polyacrylic acid, alginate, chitosan, poly(methyl methacrylates), poly(ethyl methacrylates), poly(butylmethacrylate), poly(isobutyl methacrylate), poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecyl acrylate). Thus, the invention provides a composition of the above-described molecules of the invention for use as a medicament, methods for preparing the medicament and methods for the sustained release of the medicament *in vivo*.

Compaction agents also can be used in combination with a vector of the invention. A “compaction agent”, as used herein, refers to an agent, such as a histone, that neutralizes the negative charges on the nucleic acid and thereby permits compaction of the nucleic acid into a fine granule. Compaction of the nucleic acid facilitates the uptake of the nucleic acid by the target cell. The compaction agents can be used alone, e.g., to deliver an isolated nucleic acid of the invention in a form that is more efficiently taken up by the cell or, more preferably, in combination with one or more of the above-described vectors.

Other exemplary compositions that can be used to facilitate uptake by a target cell of the nucleic acids of the invention include calcium phosphate and other chemical mediators of intracellular transport, microinjection compositions, electroporation and homologous recombination compositions (e.g., for integrating a nucleic acid into a preselected location within the target cell chromosome).

The invention also provides methods for the diagnosis and therapy of vascular and cardiovascular disorders. Such disorders include myocardial infarction, stroke, arteriosclerosis, heart failure, and cardiac hypertrophy.

The methods of the invention are useful in both the acute and the prophylactic treatment of any of the foregoing conditions. As used herein, an acute treatment refers to the treatment of subjects having a particular condition. Prophylactic treatment refers to the treatment of subjects at risk of having the condition, but not presently having or experiencing the symptoms of the condition.

In its broadest sense, the terms “treatment” or “to treat” refer to both acute and prophylactic treatments. If the subject in need of treatment is experiencing a condition (or has or is having a particular condition), then treating the condition refers to ameliorating, reducing or eliminating the condition or one or more symptoms arising from the condition. In some preferred embodiments, treating the condition refers to ameliorating, reducing or eliminating a specific symptom or a specific subset of symptoms associated with the condition. If the subject

in need of treatment is one who is at risk of having a condition, then treating the subject refers to reducing the risk of the subject having the condition.

Stroke (also referred to herein as ischemic stroke and/or cerebrovascular ischemia) is often cited as the third most common cause of death in the industrial world, ranking behind  
5 ischemic heart disease and cancer. Strokes are responsible for about 300,000 deaths annually in the United States and are a leading cause of hospital admissions and long-term disabilities. Accordingly, the socioeconomic impact of stroke and its attendant burden on society is practically immeasurable.

“Stroke” is defined by the World Health Organization as a rapidly developing clinical  
10 sign of focal or global disturbance of cerebral function with symptoms lasting at least 24 hours. Strokes are also implicated in deaths where there is no apparent cause other than an effect of vascular origin.

Strokes are typically caused by blockages or occlusions of the blood vessels to the brain or within the brain. With complete occlusion, arrest of cerebral circulation causes cessation of  
15 neuronal electrical activity within seconds. Within a few minutes after the deterioration of the energy state and ion homeostasis, depletion of high energy phosphates, membrane ion pump failure, efflux of cellular potassium, influx of sodium chloride and water, and membrane depolarization occur. If the occlusion persists for more than five to ten minutes, irreversible damage results. With incomplete ischemia, however, the outcome is difficult to evaluate and  
20 depends largely on residual perfusion and the availability of oxygen. After a thrombotic occlusion of a cerebral vessel, ischemia is rarely total. Some residual perfusion usually persists in the ischemic area, depending on collateral blood flow and local perfusion pressure.

Cerebral blood flow can compensate for drops in mean arterial blood pressure from 90 to 60 mm Hg by autoregulation. This phenomenon involves dilatation of downstream resistant  
25 vessels. Below the lower level of autoregulation (about 60 mm Hg), vasodilatation is inadequate and the cerebral blood flow falls. The brain, however, has perfusion reserves that can compensate for the fall in cerebral blood flow. This reserve exists because under normal conditions only about 35% of the oxygen delivered by the blood is extracted. Therefore, increased oxygen extraction can take place, provided that normoxia and normocapnea exist.  
30 When distal blood pressure falls below approximately 30 mm Hg, the two compensatory mechanisms (autoregulation and perfusion reserve) are inadequate to prevent failure of oxygen delivery.

As blood flow drops below the ischemic threshold of 23 ml/100g/minute, symptoms of tissue hypoxia develop. Severe ischemia may be lethal. When the ischemia is moderate, it will result in "penumbra." In the neurological context, penumbra refers to a zone of brain tissue with moderate ischemia and paralyzed neuronal function, which is reversible with  
5 restoration of adequate perfusion. The penumbra forms a zone of collaterally perfused tissue surrounding a core of severe ischemia in which an infarct has developed. In other words, the penumbra is the tissue area that can be saved, and is essentially in a state between life and death.

Although an ischemic event can occur anywhere in the vascular system, the carotid  
10 artery bifurcation and the origin of the internal carotid artery are the most frequent sites for thrombotic occlusions of cerebral blood vessels, which result in cerebral ischemia. The symptoms of reduced blood flow due to stenosis or thrombosis are similar to those caused by middle cerebral artery disease. Flow through the ophthalmic artery is often affected sufficiently to produce amaurosis fugax or transient monocular blindness. Severe bilateral internal carotid  
15 artery stenosis may result in cerebral hemispheric hypoperfusion. This manifests with acute headache ipsilateral to the acutely ischemic hemisphere. Occlusions or decrease of the blood flow with resulting ischemia of one anterior cerebral artery distal to the anterior communicating artery produces motor and cortical sensory symptoms in the contralateral leg and, less often, proximal arm. Other manifestations of occlusions or underperfusion of the  
20 anterior cerebral artery include gait ataxia and sometimes urinary incontinence due to damage to the parasagittal frontal lobe. Language disturbances manifested as decreased spontaneous speech may accompany generalized depression of psychomotor activity.

Most ischemic strokes involve portions or all of the territory of the middle cerebral artery with emboli from the heart or extracranial carotid arteries accounting for most cases.  
25 Emboli may occlude the main stem of the middle cerebral artery, but more frequently produce distal occlusion of either the superior or the inferior branch. Occlusions of the superior branch cause weakness and sensory loss that are greatest in the face and arm. Occlusions of the posterior cerebral artery distal to its penetrating branches cause complete contralateral loss of vision. Difficulty in reading (dyslexia) and in performing calculations (dyscalculia) may follow  
30 ischemia of the dominant posterior cerebral artery. Proximal occlusion of the posterior cerebral artery causes ischemia of the branches penetrating to calamic and limbic structures. The clinical results are hemisensory disturbances that may chronically change to intractable pain of the defective side (thalamic pain).

A subject having a stroke is so diagnosed by symptoms experienced and/or by a physical examination including interventional and non-interventional diagnostic tools such as CT and MR imaging. The methods of the invention are advantageous for the treatment of various clinical presentations of stroke subjects. A subject having a stroke may present with one or more of the following symptoms: paralysis, weakness, decreased sensation and/or vision, numbness, tingling, aphasia (e.g., inability to speak or slurred speech, difficulty reading or writing), agnosia (i.e., inability to recognize or identify sensory stimuli), loss of memory, coordination difficulties, lethargy, sleepiness or unconsciousness, lack of bladder or bowel control and cognitive decline (e.g., dementia, limited attention span, inability to concentrate). Using medical imaging techniques, it may be possible to identify a subject having a stroke as one having an infarct or one having hemorrhage in the brain.

An important embodiment of the invention is treatment of a subject with an abnormally elevated risk of an ischemic stroke. As used herein, subjects having an abnormally elevated risk of an ischemic stroke are a category determined according to conventional medical practice (see earlier discussion); such subjects may also be identified in conventional medical practice as having known risk factors for stroke or having increased risk of cerebrovascular events. This category includes, for example, subjects which are having elected vascular surgery. Typically, the risk factors associated with cardiac disease are the same as are associated with stroke. The primary risk factors include hypertension, hypercholesterolemia, and smoking. Atrial fibrillation or recent myocardial infarction are also important risk factors. In addition, modified levels of expression of a nucleic acid molecule selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1, or an expression product thereof, are also, according to the present invention, important risk factors.

As used herein, subjects having an abnormally elevated risk of an ischemic stroke also include individuals undergoing surgical or diagnostic procedures which risk release of emboli, lowering of blood pressure or decrease in blood flow to the brain, such as carotid endarterectomy, brain angiography, neurosurgical procedures in which blood vessels are compressed or occluded, cardiac catheterization, angioplasty, including balloon angioplasty, coronary by-pass surgery, or similar procedures. Subjects having an abnormally elevated risk of an ischemic stroke also include individuals having any cardiac condition that may lead to decreased blood flow to the brain, such as atrial fibrillation, ventricular tachycardia, dilated cardiomyopathy and other cardiac conditions requiring anticoagulation. Subjects having an abnormally elevated risk of an ischemic stroke also include individuals having conditions

including arteriopathy or brain vasculitis, such as that caused by lupus, congenital diseases of blood vessels, such as CADASIL syndrome, or migraine, especially prolonged episodes.

The treatment of stroke can be for patients who have experienced a stroke or can be a prophylactic treatment. Short term prophylactic treatment is indicated for subjects having surgical or diagnostic procedures which risk release of emboli, lowering of blood pressure or decrease in blood flow to the brain, to reduce the injury due to any ischemic event that occurs as a consequence of the procedure. Longer term or chronic prophylactic treatment is indicated for subjects having cardiac conditions that may lead to decreased blood flow to the brain, or conditions directly affecting brain vasculature. If prophylactic, then the treatment is for subjects having an abnormally elevated risk of an ischemic stroke, as described above. If the subject has experienced a stroke, then the treatment can include acute treatment. Acute treatment for stroke subjects means administration of an agent of the invention at the onset of symptoms of the condition or within 48 hours of the onset, preferably within 24 hours, more preferably within 12 hours, more preferably within 6 hours, and even more preferably within 3 hours of the onset of symptoms of the condition.

Criteria for defining hypercholesterolemic and/or hypertriglyceridemic subjects are well known in the art (see, e.g., "Harrison's"). Hypercholesterolemic subjects and hypertriglyceridemic subjects are associated with increased incidence of premature coronary heart disease. A hypercholesterolemic subject has an LDL level of  $>160$  mg/dL or  $>130$  mg/dL and at least two risk factors selected from the group consisting of male gender, family history of premature coronary heart disease, cigarette smoking (more than 10 per day), hypertension, low HDL ( $<35$  mg/dL), diabetes mellitus, hyperinsulinemia, abdominal obesity, high lipoprotein (a), and personal history of cerebrovascular disease or occlusive peripheral vascular disease. A hypertriglyceridemic subject has a triglyceride (TG) level of  $>250$  mg/dL. Thus, a hyperlipidemic subject is defined as one whose cholesterol and triglyceride levels equal or exceed the limits set as described above for both the hypercholesterolemic and hypertriglyceridemic subjects.

"Myocardial infarction" is a focus of necrosis resulting from inadequate perfusion of the cardiac tissue. Myocardial infarction generally occurs with the abrupt decrease in coronary blood flow that follows a thrombotic occlusion of a coronary artery previously narrowed by atherosclerosis. Generally, infarction occurs when an atherosclerotic plaque fissures, ruptures, or ulcerates, and a mural thrombus forms leading to coronary artery occlusion.



The diagnosis of myocardial infarction in a subject determines the need for treating the subject according to the methods of the invention. A number of laboratory tests, well known in the art, are described, for example, in Harrison's. Generally, the tests may be divided into four main categories: (1) nonspecific indexes of tissue necrosis and inflammation, (2) electrocardiograms, (3) serum enzyme changes (e.g., creatine phosphokinase levels), and (4) cardiac imaging. A person of ordinary skill in the art could easily apply any of the foregoing tests to determine when a subject is at risk, is suffering, or has suffered, a myocardial infarction. In addition, decreased levels of expression of a nucleic acid molecule selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1, or an expression product thereof, are also, according to the present invention, important risk factors. A positively identified subject would thus benefit from a method of treatment of the invention.

According to the invention, the method involves administering to a subject having a myocardial infarction any of the foregoing molecules (Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1) in an amount effective to treat the cardiovascular disorder in the subject. By "having a myocardial infarction" it is meant that the subject is at risk of developing, is currently having, or has suffered a myocardial infarction. It is believed that immediate administration of the molecule would greatly benefit the subject by inhibiting apoptotic cell-death of cardiomyocytes (the cells mostly affected by the infarct) prior to, or following the infarct. By "immediate" it is meant that administration occurs before (if it is diagnosed in time), or within 48 hours from the myocardial infarct, although administration up to 14 days after the episode may also be beneficial to the subject.

Another important embodiment of the invention is the treatment of ischemic injury resulting from arteriosclerosis. Arteriosclerosis is a term used to describe a thickening and hardening of the arterial wall. It is believed to be responsible for the majority of deaths in the United States and in most westernized societies. Atherosclerosis is one type of arteriosclerosis that is believed to be the cause of most coronary artery disease, aortic aneurysm and arterial disease of the lower extremities (including peripheral vascular arteriopathy), as well as contributing to cerebrovascular disease. Atherosclerosis is the leading cause of death in the United States.

A normal artery typically is lined on its inner-side only by a single layer of endothelial cells, the intima. The intima overlays the media, which contains only a single cell type, the smooth muscle cell. The outer-most layer of the artery is the adventitia. With aging, there is a continuous increase in the thickness of the intima, believed to result in part from migration and

proliferation of smooth muscle cells from the media. A similar increase in the thickness of the intima also occurs as a result of various traumatic events or interventions, such as occurs when, for example, a balloon dilatation procedure causes injury to the vessel wall. The invention is used in connection with treating ischemic injury resulting from arteriosclerotic conditions. An  
5 arteriosclerotic condition as used herein means classical atherosclerosis, accelerated atherosclerosis, atherosclerosis lesions and any other arteriosclerotic conditions characterized by undesirable endothelial and/or vascular smooth muscle cell proliferation, including vascular complications of diabetes.

Another important embodiment of the invention is the treatment of heart failure. Heart  
10 failure is a clinical syndrome of diverse etiologies linked by the common denominator of impaired heart pumping and is characterized by the failure of the heart to pump blood commensurate with the requirements of the metabolizing tissues, or to do so only from an elevating filling pressure.

Another important embodiment of the invention is the treatment of cardiac hypertrophy.  
15 This condition is typically characterized by left ventricular hypertrophy, usually of a nondilated chamber, without obvious antecedent cause. Current methods of diagnosis include the electrocardiogram and the echocardiogram. Many patients, however, are asymptomatic and may be relatives of patients with known disease. Unfortunately, the first manifestation of the disease may be sudden death, frequently occurring in children and young adults, often during  
20 or after physical exertion.

Agents for reducing the risk of or treating a cardiovascular disorder include those selected from the group consisting of anti-inflammatory agents, anti-thrombotic agents, anti-platelet agents, fibrinolytic agents, lipid reducing agents, direct thrombin inhibitors, glycoprotein IIb/IIIa receptor inhibitors, agents that bind to cellular adhesion molecules and  
25 inhibit the ability of white blood cells to attach to such molecules (e.g. anti-cellular adhesion molecule antibodies), calcium channel blockers, beta-adrenergic receptor blockers, cyclooxygenase-2 inhibitors, angiotensin system inhibitors, and/or any combinations thereof. One preferred agent is aspirin.

The mode of administration and dosage of a therapeutic agent of the invention will vary  
30 with the particular stage of the condition being treated, the age and physical condition of the subject being treated, the duration of the treatment, the nature of the concurrent therapy (if any), the specific route of administration, and the like factors within the knowledge and expertise of the health practitioner.

As described herein, the agents of the invention are administered in effective amounts to treat any of the foregoing cardiovascular disorders. In general, an effective amount is any amount that can cause a beneficial change in a desired tissue of a subject. Preferably, an effective amount is that amount sufficient to cause a favorable phenotypic change in a particular condition such as a lessening, alleviation or elimination of a symptom or of a condition as a whole.

In general, an effective amount is that amount of a pharmaceutical preparation that alone, or together with further doses, produces the desired response. This may involve only slowing the progression of the condition temporarily, although more preferably, it involves halting the progression of the condition permanently or delaying the onset of or preventing the condition from occurring. This can be monitored by routine methods. Generally, doses of active compounds would be from about 0.01 mg/kg per day to 1000 mg/kg per day. It is expected that doses ranging from 50-500 mg/kg will be suitable, preferably orally and in one or several administrations per day.

Such amounts will depend, of course, on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. Lower doses will result from certain forms of administration, such as intravenous administration. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of compounds. It is preferred generally that a maximum dose be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.

The agents of the invention may be combined, optionally, with a pharmaceutically-acceptable carrier to form a pharmaceutical preparation. The term "pharmaceutically-acceptable carrier," as used herein, means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the

pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy. In some aspects, the pharmaceutical preparations comprise an agent of the invention in an amount effective to treat  
5 a disorder.

The pharmaceutical preparations may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; or phosphoric acid in a salt. The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens or thimerosal.

10 A variety of administration routes are available. The particular mode selected will depend, of course, upon the particular drug selected, the severity of the condition being treated and the dosage required for therapeutic efficacy. The methods of the invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing  
15 clinically unacceptable adverse effects. Such modes of administration include oral, rectal, topical, nasal, intradermal, transdermal, or parenteral routes. The term "parenteral" includes subcutaneous, intravenous, intramuscular, or infusion. Intravenous or intramuscular routes are not particularly suitable for long-term therapy and prophylaxis. As an example, pharmaceutical compositions for the acute treatment of subjects having a migraine headache may be  
20 formulated in a variety of different ways and for a variety of administration modes including tablets, capsules, powders, suppositories, injections and nasal sprays.

The pharmaceutical preparations may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes  
25 one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound.  
30 Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, elixir or an emulsion.

Compositions suitable for parenteral administration conveniently comprise a sterile aqueous preparation of an agent of the invention, which is preferably isotonic with the blood of

the recipient. This aqueous preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable  
5 vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Formulations suitable for oral, subcutaneous, intravenous,  
10 intramuscular, etc. administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.

The term "permit entry" of a molecule into a cell according to the invention has the following meanings depending upon the nature of the molecule. For an isolated nucleic acid it is meant to describe entry of the nucleic acid through the cell membrane and into the cell  
15 nucleus, where upon the "nucleic acid transgene" can utilize the cell machinery to produce functional polypeptides encoded by the nucleic acid. By "nucleic acid transgene" it is meant to describe all of the nucleic acids of the invention with or without the associated vectors. For a polypeptide, it is meant to describe entry of the polypeptide through the cell membrane and into the cell cytoplasm, and if necessary, utilization of the cell cytoplasmic machinery to  
20 functionally modify the polypeptide (e.g., to an active form).

Various techniques may be employed for introducing nucleic acids of the invention into cells, depending on whether the nucleic acids are introduced *in vitro* or *in vivo* in a host. Such techniques include transfection of nucleic acid-CaPO<sub>4</sub> precipitates, transfection of nucleic acids associated with DEAE, transfection with a retrovirus including the nucleic acid of interest,  
25 liposome mediated transfection, and the like. For certain uses, it is preferred to target the nucleic acid to particular cells. In such instances, a vehicle used for delivering a nucleic acid of the invention into a cell (e.g., a liposome, a retrovirus, or other virus) can have a targeting molecule attached thereto. For example, a molecule such as an antibody specific for a surface membrane protein on the target cell or a ligand for a receptor on the target cell can be bound to  
30 or incorporated within the nucleic acid delivery vehicle. For example, where liposomes are employed to deliver the nucleic acids of the invention, proteins which bind to a surface membrane protein associated with endocytosis may be incorporated into the liposome formulation for targeting and/or to facilitate uptake. Such proteins include capsid proteins or

fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half life, and the like. Polymeric delivery systems also have been used successfully to deliver nucleic acids into cells, as is known by those skilled in the art. Such systems even permit oral  
5 delivery of nucleic acids.

Other delivery systems can include time release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of an agent of the present invention, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include  
10 polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides. Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S. Patent No. 5,075,109. Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as  
15 mono-, di-, and tri-glycerides; hydrogel release systems; slyastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like. Specific examples include, but are not limited to: (a) erosional systems in which an agent of the invention is contained in a form within a matrix such as those described in U.S. Patent Nos. 4,452,775; 4,675,189; and 5,736,152; and (b) diffusional systems  
20 in which an active component permeates at a controlled rate from a polymer such as described in U.S. Patent Nos. 3,854,480; 5,133,974; and 5,407,686. In addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation.

Use of a long-term sustained release implant may be desirable. Long-term release, as used herein, means that the implant is constructed and arranged to deliver therapeutic levels of  
25 the active ingredient for at least 30 days, and preferably 60 days. Long-term sustained release implants are well-known to those of ordinary skill in the art and include some of the release systems described above. Specific examples include, but are not limited to, long-term sustained release implants described in U.S. Patent No. 4,748,024, and Canadian Patent No. 1330939.

The invention also involves the administration, and in some embodiments co-  
30 administration, of agents other than the molecules of the invention (Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1, nucleic acids and polypeptides, and/or fragments thereof) that when administered in effective amounts can act cooperatively, additively or synergistically with a molecule of the invention to: (i) modulate cardiac cell anti-apoptotic activity, and (ii)

treat any of the conditions in which cardiac cell anti-apoptotic activity of a molecule of the invention is involved. Agents other than the molecules of the invention include anti-inflammatory agents, anti-thrombotic agents, anti-coagulants, anti-platelet agents, fibrinolytic agents, lipid reducing agents, direct thrombin inhibitors, glycoprotein IIb/IIIa receptor inhibitors, agents that bind to cellular adhesion molecules and inhibit the ability of white blood cells to attach to such molecules, calcium channel blockers, beta-adrenergic receptor blockers, cyclooxygenase-2 inhibitors, angiotensin system inhibitors, anti-hypertensive agents, and/or combinations thereof.

“Anti-inflammatory” agents include Alclofenac; Alclometasone Dipropionate;  
 10 Algestone Acetonide; Alpha Amylase; Amcinafal; Amcinafide; Amfenac Sodium; Amiprilose Hydrochloride; Anakinra; Aniolac; Anitrazafen; Apazone; Balsalazide Disodium; Bendazac; Benoxaprofen; Benzydamine Hydrochloride; Bromelains; Broperamole; Budesonide; Carprofen; Cicloprofen; Cintazone; Cliprofen; Clobetasol Propionate; Clobetasone Butyrate; Clopirac; Cloticasone Propionate; Cormethasone Acetate; Cortodoxone; Deflazacort;  
 15 Desonide; Desoximetasone; Dexamethasone Dipropionate; Diclofenac Potassium; Diclofenac Sodium; Diflorasone Diacetate; Diflumidone Sodium; Diflunisal; Difluprednate; Diftalone; Dimethyl Sulfoxide; Drocinnionide; Endrysone; Enlimomab; Enolicam Sodium; Epirizole; Etodolac; Etofenamate; Felbinac; Fenamole; Fenbufen; Fenclofenac; Fenclorac; Fendosal; Fenpipalone; Fentiazac; Flazalone; Fluazacort; Flufenamic Acid; Flumizole; Flunisolide  
 20 Acetate; Flunixin; Flunixin Meglumine; Fluocortin Butyl; Fluorometholone Acetate; Fluquazone; Flurbiprofen; Fluretofen; Fluticasone Propionate; Furaprofen; Furobufen; Halcinonide; Halobetasol Propionate; Halopredone Acetate; Ibufenac; Ibuprofen; Ibuprofen Aluminum; Ibuprofen Piconol; Ilonidap; Indomethacin; Indomethacin Sodium; Indoprofen; Indoxole; Intrazole; Isoflupredone Acetate; Isoxepac; Isoxicam; Ketoprofen; Lofemizole  
 25 Hydrochloride; Lornoxicam; Loteprednol Etabonate; Meclofenamate Sodium; Meclofenamic Acid; Meclorison Dibutyrate; Mefenamic Acid; Mesalamine; Meseclazone; Methylprednisolone Suleptanate; Morniflumate; Nabumetone; Naproxen; Naproxen Sodium; Naproxol; Nimazone; Olsalazine Sodium; Orgotein; Orpanoxin; Oxaprozin; Oxyphenbutazone; Paranyline Hydrochloride; Pentosan Polysulfate Sodium; Phenbutazone Sodium Glycerate;  
 30 Pirfenidone; Piroxicam; Piroxicam Cinnamate; Piroxicam Olamine; Pirprofen; Prednazate; Prifelone; Prodolic Acid; Proquazone; Proxazole; Proxazole Citrate; Rimexolone; Romazarit; Salcolex; Salnacedin; Salsalate; Salicylates; Sanguinarium Chloride; Seclazone; Sermetacin; Sudoxicam; Sulindac; Suprofen; Talmetacin; Talniflumate; Talosalate; Tebufelone; Tenidap;

Tenidap Sodium; Tenoxicam; Tesicam; Tesimide; Tetrydamine; Tiopinac; Tixocortol Pivalate; Tolmetin; Tolmetin Sodium; Triclonide; Triflumidate; Zidometacin; Glucocorticoids; and Zomepirac Sodium. One preferred anti-inflammatory agent is aspirin.

“Anti-thrombotic” and/or “fibrinolytic” agents include plasminogen (to plasmin via interactions of prekallikrein, kininogens, Factors XII, XIIIa, plasminogen proactivator, and tissue plasminogen activator[TPA]) Streptokinase; Urokinase: Anisoylated Plasminogen-Streptokinase Activator Complex; Pro-Urokinase; (Pro-UK); rTPA (alteplase or activase; “r” denotes recombinant); rPro-UK; Abbokinase; Eminase; Streptase Anagrelide Hydrochloride; Bivalirudin; Dalteparin Sodium; Danaparoid Sodium; Dazoxiben Hydrochloride; Efgatran Sulfate; Enoxaparin Sodium; Ifetroban; Ifetroban Sodium; Tinzaparin Sodium; Retaplast; Trifenagrel; Warfarin; and Dextran.

“Anti-platelet” agents include Clopidogrel; Sulfinpyrazone; Aspirin; Dipyridamole; Clofibrate; Pyridinol Carbamate; PGE; Glucagon; Antiserotonin drugs; Caffeine; Theophyllin; Pentoxifyllin; Ticlopidine; and Anagrelide.

“Lipid reducing” agents include gemfibrozil, cholestyramine, colestipol, nicotinic acid, probucol lovastatin, fluvastatin, simvastatin, atorvastatin, pravastatin, and cirivastatin.

“Direct thrombin inhibitors” include hirudin, hirugen, hirulog, agatroban, PPACK, and thrombin aptamers.

“Glycoprotein IIb/IIIa receptor inhibitors” embraces both antibodies and non-antibodies, and include, but are not limited, to ReoPro (abcixamab), lamifiban, and tirofiban.

“Calcium channel blockers” are a chemically diverse class of compounds having important therapeutic value in the control of a variety of diseases including several cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmias (Fleckenstein, *Cir. Res.* v. 52, (suppl. 1), p.13-16 (1983); Fleckenstein, *Experimental Facts and Therapeutic Prospects*, John Wiley, New York (1983); McCall, D., *Curr Pract Cardiol*, v. 10, p. 1-11 (1985)). Calcium channel blockers are a heterogeneous group of drugs that prevent or slow the entry of calcium into cells by regulating cellular calcium channels. (Remington, *The Science and Practice of Pharmacy*, Nineteenth Edition, Mack Publishing Company, Eaton, PA, p.963 (1995)). Most of the currently available calcium channel blockers, and useful according to the present invention, belong to one of three major chemical groups of drugs, the dihydropyridines, such as nifedipine, the phenyl alkyl amines, such as verapamil, and the benzothiazepines, such as diltiazem. Other calcium channel blockers useful according to the invention, include, but are not limited to, amrinone, amlodipine, bencyclane, felodipine, fendiline, flunarizine,



isradipine, nicardipine, nimodipine, perhexilene, gallopamil, tiapamil and tiapamil analogues (such as 1993RO-11-2933), phenytoin, barbiturates, and the peptides dynorphin, omega-conotoxin, and omega-agatoxin, and the like and/or pharmaceutically acceptable salts thereof.

“Beta-adrenergic receptor blocking agents” are a class of drugs that antagonize the cardiovascular effects of catecholamines in angina pectoris, hypertension, and cardiac arrhythmias. Beta-adrenergic receptor blockers include, but are not limited to, atenolol, acebutolol, alprenolol, befunolol, betaxolol, bunitrolol, carteolol, celiprolol, hedroxalol, indenolol, labetalol, levobunolol, mepindolol, methypranol, metindol, metoprolol, metrizoranolol, oxprenolol, pindolol, propranolol, practolol, practolol, sotalolnadolol, tiprenolol, tomalolol, timolol, bupranolol, penbutolol, trimepranol, 2-(3-(1,1-dimethylethyl)-amino-2-hydroxypropoxy)-3-pyridenecarbonitrilHCl, 1-butylamino-3-(2,5-dichlorophenoxy)-2-propanol, 1-isopropylamino-3-(4-(2-cyclopropylmethoxyethyl)phenoxy)-2-propanol, 3-isopropylamino-1-(7-methylindan-4-yloxy)-2-butanol, 2-(3-t-butylamino-2-hydroxy-propylthio)-4-(5-carbamoyl-2-thienyl)thiazol, 7-(2-hydroxy-3-t-butylaminpropoxy)phthalide.

The above-identified compounds can be used as isomeric mixtures, or in their respective levorotating or dextrorotating form.

Cyclooxygenase-2 (COX-2) is a recently identified form of a cyclooxygenase. “Cyclooxygenase” is an enzyme complex present in most tissues that produces various prostaglandins and thromboxanes from arachidonic acid. Non-steroidal, anti-inflammatory drugs exert most of their anti-inflammatory, analgesic and antipyretic activity and inhibit hormone-induced uterine contractions and certain types of cancer growth through inhibition of the cyclooxygenase (also known as prostaglandin G/H synthase and/or prostaglandin-endoperoxide synthase). Initially, only one form of cyclooxygenase was known, the “constitutive enzyme” or cyclooxygenase-1 (COX-1). It and was originally identified in bovine seminal vesicles.

Cyclooxygenase-2 (COX-2) has been cloned, sequenced and characterized initially from chicken, murine and human sources (see, e.g., U.S. Patent No. 5,543,297, issued August 6, 1996 to Cromlish *et al.*, and assigned to Merck Frosst Canada, Inc., Kirkland, CA, entitled: “Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity”). This enzyme is distinct from COX-1. COX-2 is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones, cytokines and growth factors. As prostaglandins have both physiological and pathological roles, the constitutive enzyme, COX-1, is responsible, in large part, for endogenous basal release of prostaglandins and hence is

important in their physiological functions such as the maintenance of gastrointestinal integrity and renal blood flow. By contrast, it is believed that the inducible form, COX-2, is mainly responsible for the pathological effects of prostaglandins where rapid induction of the enzyme would occur in response to such agents as inflammatory agents, hormones, growth factors, and cytokines. Therefore, it is believed that a selective inhibitor of COX-2 has similar anti-inflammatory, antipyretic and analgesic properties to a conventional non-steroidal anti-inflammatory drug, and in addition inhibits hormone-induced uterine contractions and also has potential anti-cancer effects, but with reduced side effects. In particular, such COX-2 inhibitors are believed to have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and possibly a decreased potential to induce asthma attacks in aspirin-sensitive asthmatic subjects, and are therefore useful according to the present invention.

A number of selective "COX-2 inhibitors" are known in the art. These include, but are not limited to, COX-2 inhibitors described in U.S. Patent No. 5,474,995 "Phenyl heterocycles as COX-2 inhibitors"; U.S. Patent No. 5,521,213 "Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2"; U.S. Patent No. 5,536,752 "Phenyl heterocycles as COX-2 inhibitors"; U.S. Patent No. 5,550,142 "Phenyl heterocycles as COX-2 inhibitors"; U.S. Patent No. 5,552,422 "Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents"; U.S. No. Patent 5,604,253 "N-Benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors"; U.S. No. Patent 5,604,260 "5-Methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2"; U.S. Patent No. 5,639,780 N-Benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors"; U.S. Patent No. 5,677,318 Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents"; U.S. Patent No. 5,691,374 "Diaryl-5-oxygenated-2-(5H)-furanones as COX-2 inhibitors"; U.S. Patent No. 5,698,584 "3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to COX-2 inhibitors"; U.S. Patent No. 5,710,140 "Phenyl heterocycles as COX-2 inhibitors"; U.S. Patent No. 5,733,909 "Diphenyl stilbenes as prodrugs to COX-2 inhibitors"; U.S. Patent No. 5,789,413 "Alkylated styrenes as prodrugs to COX-2 inhibitors"; U.S. Patent No. 5,817,700 "Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors"; U.S. Patent No. 5,849,943 "Stilbene derivatives useful as cyclooxygenase-2 inhibitors"; U.S. Patent No. 5,861,419 "Substituted pyridines as selective cyclooxygenase-2 inhibitors"; U.S. Patent No. 5,922,742 "Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors"; U.S. Patent No. 5,925,631 "Alkylated styrenes as prodrugs to COX-2 inhibitors"; all of which are commonly assigned to Merck Frosst Canada, Inc.

(Kirkland, CA or Merck & Co., Inc. (Rahway, NJ). Additional COX-2 inhibitors are also described in U.S. Patent No. 5,643,933, assigned to G. D. Searle & Co. (Skokie, IL), entitled: "Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors."

A number of the above-identified COX-2 inhibitors are prodrugs of selective COX-2 inhibitors, and exert their action by conversion *in vivo* to the active and selective COX-2 inhibitors. The active and selective COX-2 inhibitors formed from the above-identified COX-2 inhibitor prodrugs are described in detail in WO 95/00501, published January 5, 1995, WO 95/18799, published July 13, 1995 and U.S. Patent No. 5,474,995, issued December 12, 1995. Given the teachings of U.S. Patent No. 5,543,297, entitled: "Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity," a person of ordinary skill in the art would be able to determine whether an agent is a selective COX-2 inhibitor or a precursor of a COX-2 inhibitor, and therefore part of the present invention.

An "angiotensin system inhibitor" is an agent that interferes with the function, synthesis or catabolism of angiotensin II. These agents include, but are not limited to, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II antagonists, angiotensin II receptor antagonists, agents that activate the catabolism of angiotensin II, and agents that prevent the synthesis of angiotensin I from which angiotensin II is ultimately derived. The renin-angiotensin system is involved in the regulation of hemodynamics and water and electrolyte balance. Factors that lower blood volume, renal perfusion pressure, or the concentration of Na<sup>+</sup> in plasma tend to activate the system, while factors that increase these parameters tend to suppress its function.

Angiotensin I and angiotensin II are synthesized by the enzymatic renin-angiotensin pathway. The synthetic process is initiated when the enzyme renin acts on angiotensinogen, a pseudoglobulin in blood plasma, to produce the decapeptide angiotensin I. Angiotensin I is converted by angiotensin converting enzyme (ACE) to angiotensin II (angiotensin-[1-8] octapeptide). The latter is an active pressor substance which has been implicated as a causative agent in several forms of hypertension in various mammalian species, e.g., humans.

Angiotensin (renin-angiotensin) system inhibitors are compounds that act to interfere with the production of angiotensin II from angiotensinogen or angiotensin I or interfere with the activity of angiotensin II. Such inhibitors are well known to those of ordinary skill in the art and include compounds that act to inhibit the enzymes involved in the ultimate production of angiotensin II, including renin and ACE. They also include compounds that interfere with the activity of angiotensin II, once produced. Examples of classes of such compounds include

antibodies (e.g., to renin), amino acids and analogs thereof (including those conjugated to larger molecules), peptides (including peptide analogs of angiotensin and angiotensin I), pro-renin related analogs, etc. Among the most potent and useful renin-angiotensin system inhibitors are renin inhibitors, ACE inhibitors, and angiotensin II antagonists. In a preferred embodiment of the invention, the renin-angiotensin system inhibitors are renin inhibitors, ACE inhibitors, and angiotensin II antagonists.

"Angiotensin II antagonists" are compounds which interfere with the activity of angiotensin II by binding to angiotensin II receptors and interfering with its activity.

Angiotensin II antagonists are well known and include peptide compounds and non-peptide compounds. Most angiotensin II antagonists are slightly modified congeners in which agonist activity is attenuated by replacement of phenylalanine in position 8 with some other amino acid; stability can be enhanced by other replacements that slow degeneration *in vivo*. Examples of angiotensin II antagonists include: peptidic compounds (e.g., saralasin, [(San<sup>1</sup>)(Val<sup>5</sup>)(Ala<sup>8</sup>)] angiotensin-(1-8) octapeptide and related analogs); N-substituted imidazole-2-one (U.S. Patent No. 5,087,634); imidazole acetate derivatives including 2-N-butyl-4-chloro-1-(2-chlorobenzile), imidazole-5-acetic acid (see Long *et al.*, *J. Pharmacol. Exp. Ther.* 247(1), 1-7 (1988)); 4, 5, 6, 7-tetrahydro-1H-imidazo [4, 5-c] pyridine-6-carboxylic acid and analog derivatives (US Patent No. 4,816,463); N2-tetrazole beta-glucuronide analogs (US Patent No. 5,085,992); substituted pyrroles, pyrazoles, and tryazoles (US Patent No. 5,081,127); phenol and heterocyclic derivatives such as 1, 3-imidazoles (US Patent No. 5,073,566); imidazo-fused 7-member ring heterocycles (US Patent No. 5,064,825); peptides (e.g., US Patent No. 4,772,684); antibodies to angiotensin II (e.g., US Patent No. 4,302,386); and aralkyl imidazole compounds such as biphenyl-methyl substituted imidazoles (e.g., EP Number 253,310, January 20, 1988); ES8891 (N-morpholinoacetyl-(-1-naphthyl)-L-alanyl-(4, thiazolyl)-L-alanyl (35, 45)-4-amino-3-hydroxy-5-cyclo-hexapentanoyl-N-hexylamide, Sankyo Company, Ltd., Tokyo, Japan); SKF108566 (E-alpha-2-[2-butyl-1-(carboxyphenyl)methyl] 1H-imidazole-5-yl[methylane]-2-thiophenepropanoic acid, Smith Kline Beecham Pharmaceuticals, PA); Losartan (DUP753/MK954, DuPont Merck Pharmaceutical Company); Remikirin (RO42-5892, F. Hoffman LaRoche AG); A<sub>2</sub> agonists (Marion Merrill Dow) and certain non-peptide heterocycles (G.D.Searle and Company).

"Angiotensin converting enzyme," (ACE), is an enzyme which catalyzes the conversion of angiotensin I to angiotensin II. ACE inhibitors include amino acids and derivatives thereof, peptides, including di- and tripeptides and antibodies to ACE which intervene in the renin-

angiotensin system by inhibiting the activity of ACE thereby reducing or eliminating the formation of pressor substance angiotensin II. ACE inhibitors have been used medically to treat hypertension, congestive heart failure, myocardial infarction and renal disease. Classes of compounds known to be useful as ACE inhibitors include acylmercapto and mercaptoalkanoyl prolines such as captopril (US Patent No. 4,105,776) and zofenopril (US Patent Number 4,316,906), carboxyalkyl dipeptides such as enalapril (US Patent No. 4,374,829), lisinopril (US Patent No. 4,374,829), quinapril (US Patent No. 4,344,949), ramipril (US Patent No. 4,587,258), and perindopril (US Patent No. 4,508,729), carboxyalkyl dipeptide mimics such as cilazapril (US Patent No. 4,512,924) and benazapril (US Patent No. 4,410,520), phosphinylalkanoyl prolines such as fosinopril (US Patent No. 4,337,201) and trandolopril.

“Renin inhibitors” are compounds which interfere with the activity of renin. Renin inhibitors include amino acids and derivatives thereof, peptides and derivatives thereof, and antibodies to renin. Examples of renin inhibitors that are the subject of United States patents are as follows: urea derivatives of peptides (US Patent No. 5,116,835); amino acids connected by nonpeptide bonds (US Patent No. 5,114,937); di- and tri- peptide derivatives (US Patent No. 5,106,835); amino acids and derivatives thereof (US Patent Nos. 5,104,869 and 5,095,119); diol sulfonamides and sulfinyls (US Patent No. 5,098,924); modified peptides (US Patent No. 5,095,006); peptidyl beta-aminoacyl aminodiols carbamates (US Patent No. 5,089,471); pyroimidazolones (US Patent No. 5,075,451); fluorine and chlorine statine or statone containing peptides (US Patent No. 5,066,643); peptidyl amino diols (US Patent Nos. 5,063,208 and 4,845,079); N-morpholino derivatives (US Patent No. 5,055,466); pepstatin derivatives (US Patent No. 4,980,283); N-heterocyclic alcohols (US Patent No. 4,885,292); monoclonal antibodies to renin (US Patent No. 4,780,401); and a variety of other peptides and analogs thereof (US Patent Nos. 5,071,837, 5,064,965, 5,063,207, 5,036,054, 5,036,053, 5,034,512, and 4,894,437).

Agents that bind to cellular adhesion molecules and inhibit the ability of white blood cells to attach to such molecules include polypeptide agents. Such polypeptides include polyclonal and monoclonal antibodies, prepared according to conventional methodology. Such antibodies already are known in the art and include anti-ICAM 1 antibodies as well as other such antibodies described above.

Anticoagulant agents include, but are not limited to, Ancrod; Anticoagulant Citrate Dextrose Solution; Anticoagulant Citrate Phosphate Dextrose Adenine Solution; Anticoagulant Citrate Phosphate Dextrose Solution; Anticoagulant Heparin Solution; Anticoagulant Sodium

Citrate Solution; Ardeparin Sodium; Bivalirudin; Bromindione; Dalteparin Sodium; Desirudin; Dicumarol; Heparin Calcium; Heparin Sodium; Lyapolate Sodium; Nafamostat Mesylate; Phenprocoumon; Tinzaparin Sodium; and Warfarin Sodium.

Heparin may stabilize symptoms in evolving stroke, but anticoagulants are useless (and possibly dangerous) in acute completed stroke, and are contraindicated in hypertensives because of the increased possibility of hemorrhage into the brain or other organs. Although the timing is controversial, anticoagulants may be started to prevent recurrent cardiogenic emboli. Clot lysing agents, including tissue plasminogen activator and streptokinase, are being evaluated for the very early treatment of acute stroke. Nimodipine has recently been shown to improve survival and clinical outcome after ischemic stroke.

Other than aspirin, ticlopidine is another antiplatelet agent that has been shown to be beneficial for stroke treatment. Endarterectomy may be indicated in patients with 70 to 99 percent narrowing of a symptomatic internal carotid artery. However, most authorities agree that carotid endarterectomy is not indicated in patients with TIAs that are referable to the basilar-vertebral system, in patients with significant deficits from prior strokes, or in patients in whom a stroke is evolving.

HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase is the microsomal enzyme that catalyzes the rate limiting reaction in cholesterol biosynthesis (HMG-CoA6Mevalonate). An HMG-CoA reductase inhibitor inhibits HMG-CoA reductase, and as a result inhibits the synthesis of cholesterol. A number of HMG-CoA reductase inhibitors has been used to treat individuals with hypercholesterolemia. More recently, HMG-CoA reductase inhibitors have been shown to be beneficial in the treatment of stroke (Endres M, *et al.*, *Proc Natl Acad Sci U S A*, 1998, 95:8880-5).

HMG-CoA reductase inhibitors useful for co-administration with the agents of the invention include, but are not limited to, simvastatin (U.S. Patent No. 4, 444,784); lovastatin (U.S. Patent No. 4,231,938); pravastatin sodium (U.S. Patent No. 4,346,227); fluvastatin (U.S. Patent No. 4,739,073); atorvastatin (U.S. Patent No. 5,273,995); cerivastatin, and numerous others described in U.S. Patent No. 5,622,985; U.S. Patent No. 5,135,935; U.S. Patent No. 5,356,896; U.S. Patent No. 4,920,109; U.S. Patent No. 5,286,895; U.S. Patent No. 5,262,435; U.S. Patent No. 5,260,332; U.S. Patent No. 5,317,031; U.S. Patent No. 5,283,256; U.S. Patent No. 5,256,689; U.S. Patent No. 5,182,298; U.S. Patent No. 5,369,125; U.S. Patent No. 5,302,604; U.S. Patent No. 5,166,171; U.S. Patent No. 5,202,327; U.S. Patent No. 5,276,021; U.S. Patent No. 5,196,440; U.S. Patent No. 5,091,386; U.S. Patent No. 5,091,378; U.S. Patent

No. 4,904,646; U.S. Patent No. 5,385,932; U.S. Patent No. 5,250,435; U.S. Patent No. 5,132,312; U.S. Patent No. 5,130,306; U.S. Patent No. 5,116,870; U.S. Patent No. 5,112,857; U.S. Patent No. 5,102,911; U.S. Patent No. 5,098,931; U.S. Patent No. 5,081,136; U.S. Patent No. 5,025,000; U.S. Patent No. 5,021,453; U.S. Patent No. 5,017,716; U.S. Patent No. 5,001,144; U.S. Patent No. 5,001,128; U.S. Patent No. 4,997,837; U.S. Patent No. 4,996,234; U.S. Patent No. 4,994,494; U.S. Patent No. 4,992,429; U.S. Patent No. 4,970,231; U.S. Patent No. 4,968,693; U.S. Patent No. 4,963,538; U.S. Patent No. 4,957,940; U.S. Patent No. 4,950,675; U.S. Patent No. 4,946,864; U.S. Patent No. 4,946,860; U.S. Patent No. 4,940,800; U.S. Patent No. 4,940,727; U.S. Patent No. 4,939,143; U.S. Patent No. 4,929,620; U.S. Patent No. 4,923,861; U.S. Patent No. 4,906,657” U.S. Patent No. 4,906,624; and U.S. Patent No. 4,897,402, the disclosures of which patents are incorporated herein by reference.

Nitric oxide (NO) has been recognized as a messenger molecule with many physiologic roles, in the cardiovascular, neurologic and immune systems (Griffith, TM *et al.*, *J Am Coll Cardiol*, 1988, 12:797-806). It mediates blood vessel relaxation, neurotransmission and pathogen suppression. NO is produced from the guanidino nitrogen of L-arginine by NO Synthase (Moncada, S and Higgs, EA, *Eur J Clin Invest*, 1991, 21:361-374). Agents that upregulate endothelial cell Nitric Oxide Synthase include, but are not limited to, L-arginine, *rho* GTPase function inhibitors (see International Application WO 99/47153, the disclosure of which is incorporated herein by reference), and agents that disrupt actin cytoskeletal organization (see International Application WO 00/03746, the disclosure of which is incorporated herein by reference).

“Co-administering,” as used herein, refers to administering simultaneously two or more compounds of the invention (e.g., a Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and/or Mrg-1, nucleic acid and/or polypeptide, and an agent known to be beneficial in the treatment of, for example, a cardiovascular condition, e.g., an anticoagulant-), as an admixture in a single composition, or sequentially, close enough in time so that the compounds may exert an additive or even synergistic effect, i.e., on reducing cardiomyocyte cell-death in a cardiovascular condition.

The invention also embraces solid-phase nucleic acid molecule arrays. The array consists essentially of a set of nucleic acid molecules, expression products thereof, or fragments (of either the nucleic acid or the polypeptide molecule) thereof, each nucleic acid molecule selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1, fixed to a solid substrate. In some embodiments, the solid-phase array

further comprises at least one control nucleic acid molecule. In certain embodiments, the set of nucleic acid molecules comprises at least one, at least two, at least three, at least four, or even at least five nucleic acid molecules, each selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1, provided that when only one nucleic acid molecule is present on the array, the nucleic acid molecule is not vacuolar ATPase. In preferred embodiments, the set of nucleic acid molecules comprises a maximum number of 100 different nucleic acid molecules. In important embodiments, the set of nucleic acid molecules comprises a maximum number of 10 different nucleic acid molecules.

According to the invention, standard hybridization techniques of microarray technology are utilized to assess patterns of nucleic acid expression and identify nucleic acid expression. Microarray technology, which is also known by other names including: DNA chip technology, gene chip technology, and solid-phase nucleic acid array technology, is well known to those of ordinary skill in the art and is based on, but not limited to, obtaining an array of identified nucleic acid probes (e.g., molecules described elsewhere herein such as Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and/or Mrg-1) on a fixed substrate, labeling target molecules with reporter molecules (e.g., radioactive, chemiluminescent, or fluorescent tags such as fluorescein, Cy3-dUTP, or Cy5-dUTP), hybridizing target nucleic acids to the probes, and evaluating target-probe hybridization. A probe with a nucleic acid sequence that perfectly matches the target sequence will, in general, result in detection of a stronger reporter-molecule signal than will probes with less perfect matches. Many components and techniques utilized in nucleic acid microarray technology are presented in Nature Genetics, Vol.21, Jan 1999, the entire contents of which is incorporated by reference herein.

According to the present invention, microarray substrates may include but are not limited to glass, silica, aluminosilicates, borosilicates, metal oxides such as alumina and nickel oxide, various clays, nitrocellulose, or nylon. In all embodiments a glass substrate is preferred. According to the invention, probes are selected from the group of nucleic acids including, but not limited to: DNA, genomic DNA, cDNA, and oligonucleotides; and may be natural or synthetic. Oligonucleotide probes preferably are 20 to 25-mer oligonucleotides and DNA/cDNA probes preferably are 500 to 5000 bases in length, although other lengths may be used. Appropriate probe length may be determined by one of ordinary skill in the art by following art-known procedures. In one embodiment, preferred probes are sets of two or more of the nucleic acid molecules set forth as SEQ ID NOs: 1, 3, 5, 7, 9, 11 and/or 12. Probes may



be purified to remove contaminants using standard methods known to those of ordinary skill in the art such as gel filtration or precipitation.

In one embodiment, the microarray substrate may be coated with a compound to enhance synthesis of the probe on the substrate. Such compounds include, but are not limited to, oligoethylene glycols. In another embodiment, coupling agents or groups on the substrate can be used to covalently link the first nucleotide or oligonucleotide to the substrate. These agents or groups may include, but are not limited to: amino, hydroxy, bromo, and carboxy groups. These reactive groups are preferably attached to the substrate through a hydrocarbyl radical such as an alkylene or phenylene divalent radical, one valence position occupied by the chain bonding and the remaining attached to the reactive groups. These hydrocarbyl groups may contain up to about ten carbon atoms, preferably up to about six carbon atoms. Alkylene radicals are usually preferred containing two to four carbon atoms in the principal chain. These and additional details of the process are disclosed, for example, in U.S. Patent No. 4,458,066, which is incorporated by reference in its entirety.

In one embodiment, probes are synthesized directly on the substrate in a predetermined grid pattern using methods such as light-directed chemical synthesis, photochemical deprotection, or delivery of nucleotide precursors to the substrate and subsequent probe production.

In another embodiment, the substrate may be coated with a compound to enhance binding of the probe to the substrate. Such compounds include, but are not limited to: polylysine, amino silanes, amino-reactive silanes (Nature Genetics, Vol.21, Jan 1999) or chromium (Gwynne and Page, 2000). In this embodiment, presynthesized probes are applied to the substrate in a precise, predetermined volume and grid pattern, utilizing a computer-controlled robot to apply probe to the substrate in a contact-printing manner or in a non-contact manner such as ink jet or piezo-electric delivery. Probes may be covalently linked to the substrate with methods that include, but are not limited to, UV-irradiation and heat.

Targets are nucleic acids selected from the group, including but not limited to, DNA, genomic DNA, cDNA, RNA, mRNA and may be natural or synthetic. In all embodiments, nucleic acid molecules from subjects suspected of developing or having a cardiovascular condition, are preferred. In certain embodiments of the invention, one or more control nucleic acid molecules are attached to the substrate. Preferably, control nucleic acid molecules allow determination of factors including but not limited to: nucleic acid quality and binding characteristics; reagent quality and effectiveness; hybridization success; and analysis thresholds

and success. Control nucleic acids may include, but are not limited to, expression products of genes such as housekeeping genes or fragments thereof.

To select a set of cardiovascular disease markers, the expression data generated by, for example, microarray analysis of gene expression, is preferably analyzed to determine which  
5 genes in different categories of patients (each category of patients being a different cardiovascular disorder), are significantly differentially expressed. The significance of gene expression can be determined using Permax computer software, although any standard statistical package that can discriminate significant differences in expression may be used. Permax performs permutation 2-sample t-tests on large arrays of data. For high dimensional  
10 vectors of observations, the Permax software computes t-statistics for each attribute, and assesses significance using the permutation distribution of the maximum and minimum overall attributes. The main use is to determine the attributes (genes) that are the most different between two groups (e.g., control healthy subject and a subject with a particular cardiovascular disorder), measuring “most different” using the value of the t-statistics, and their significance  
15 levels.

Expression of cardiovascular disease nucleic acid molecules can also be determined using protein measurement methods to determine expression of SEQ ID NOs: 2, 4, 6, 8, and/or 10, e.g., by determining the expression of polypeptides encoded by SEQ ID NOs: 1, 3, 5, 7, and/or 9, respectively. Preferred methods of specifically and quantitatively measuring proteins  
20 include, but are not limited to: mass spectroscopy-based methods such as surface enhanced laser desorption ionization (SELDI; e.g., Ciphergen ProteinChip System), non-mass spectroscopy-based methods, and immunohistochemistry-based methods such as 2-dimensional gel electrophoresis.

SELDI methodology may, through procedures known to those of ordinary skill in the  
25 art, be used to vaporize microscopic amounts of tumor protein and to create a “fingerprint” of individual proteins, thereby allowing simultaneous measurement of the abundance of many proteins in a single sample. Preferably SELDI-based assays may be utilized to characterize cardiovascular conditions as well as stages of such conditions. Such assays preferably include, but are not limited to the following examples. Gene products discovered by RNA microarrays  
30 may be selectively measured by specific (antibody mediated) capture to the SELDI protein disc (e.g., selective SELDI). Gene products discovered by protein screening (e.g., with 2-D gels), may be resolved by “total protein SELDI” optimized to visualize those particular markers of interest from among SEQ ID NOs: 1, 3, 5, 7, and/or 9. Predictive models of tumor

classification from SELDI measurement of multiple markers from among SEQ ID NOs: 1, 3, 5, 7, and/or 9 may be utilized for the SELDI strategies.

The use of any of the foregoing microarray methods to determine expression of cardiovascular disease nucleic acids can be done with routine methods known to those of ordinary skill in the art and the expression determined by protein measurement methods may be correlated to predetermined levels of a marker used as a prognostic method for selecting treatment strategies for cardiovascular disease patients.

The invention will be more fully understood by reference to the following examples. These examples, however, are merely intended to illustrate the embodiments of the invention and are not to be construed to limit the scope of the invention.

### Examples

#### EXAMPLE 1.

##### **Experimental Protocols: Materials and Methods**

##### **Mechanical Strain Device**

Experiments of mechanically overloading cardiomyocytes have generally been performed by stretching cells with no control of the cardiac cycle, an approach that does not allow distinction between mechanical overload in contraction versus relaxation. In the present study, we designed and constructed a unique experimental system that allows precisely controlled mechanical strains as well as electrical pacing in cultured cardiomyocytes, to investigate, *inter alia*, how cardiomyocyte mechanotransduction is regulated by the cardiac cycle, and identify genes that are involved in such regulation.

**The Pacing-Strain Device.** The approach to mechanical stimulation used an apparatus that has multiple platens that contact the underside of silicone elastomer membranes to apply a spatially isotropic biaxial strain profile to the membrane (Schaffer JL, *et al.*, *J Orthop Res*, 1993,12:709-719; and U.S. Provisional Patent application filed on July 16, 1999 entitled "AN APPARATUS FOR STUDYING MYOCARDIAL MECHANICAL OVERLOAD HYPERTROPHY AND USES THEREFOR, by Richard T. Lee, and bearing Attorney Docket no. 100038.130 and express mail no. EL110243781US). Six individual 78mm membranes can be stretched at once with varying amplitudes of strain by controlling displacement of each platen with a stepper motor. Measured Green strains are accurate to  $\sim \pm 0.25\%$  at strains from 1-14% (Cheng GC, *et al.*, *Circ Res*, 1997, 80:28-36; Brown TD, *J Biomechanics*, 2000, 33:3-14). Throughout this study, 8% biaxial strain was used.

To control the timing of mechanical strain relative to the cardiac cycle, the computer paced each dish electrically, and controlled: the phase between the mechanical strain and the electrical impulse, the electrical impulse duration, and the voltage of the impulse. In addition, the electrical impulses had alternating polarity to minimize electrochemical effects such as pH  
5 gradients at the electrodes. The two outputs were each connected to a single set of electrodes in each dish. The dishes were paced in parallel with a resistance of approximately 500 ohms per dish.

The positive and negative voltage sources were provided by two power supplies (6545A, Hewlett Packard Company, Palo Alto, CA). The control circuit was divided into two  
10 parts: a high voltage circuit and a low voltage or digital signal circuit. The high voltage circuit was a gate that switched the output based on the input signal. The low voltage circuit accepted two control signals from the computer and accepted the pulse width from a variable resistor, which controlled both the positive and negative voltage gates. The low voltage circuit allowed a voltage pulse between 0-120V DC amplitude and 2-37ms duration. Lights provided  
15 continuous monitoring of the pulses, and the timing of the circuits and calibration were validated by oscilloscope.

The electrodes for each dish were two arc-shaped  $\text{AgCl}_2$  wire electrodes at the base of the inner surface of the dish, just above the deformable membrane. The electrodes were pre-made, ethanol-sterilized, and placed into the dish just prior to each experiment to minimize  
20 potential toxicity from silver. Using this method no cellular death or detachment was observed in 24 hr experiments. Each arc was 120 degrees; we performed a two dimensional finite element analysis to estimate the uniformity of the potential field with this configuration. These calculations estimate a spatial variation in the potential field of  $\{\text{root mean square}\} = 29\%$ . Thus, this system provides highly uniform biaxial mechanical strain, with a relatively small  
25 variation in the voltage field.

**Mechanical stimulation protocols.** We imposed strain only during first third of the cardiac cycle by electrical stimulation for strain imposed during the “systolic phase”, and only during one third of the cardiac cycle in the relaxation phase for strain imposed during  
“diastolic phase,” respectively. Conditions used in this study were: (1) control; (2) strain, no  
30 pacing; (3) pacing, no strain; (4) strain imposed during systolic phase; and (5) strain imposed during diastolic phase.

Neonatal rat ventricular myocytes (NRVM) from 1-day old Sprague-Dawley rats were isolated by previously described methods (Springhorn JP, and Claycomb WC., *Biochem J*,

1989;258:73-78; Arstall MA, *et al.*, *J Mol Cell Cardiol*, 1998, 30:1019-25). NRVM were plated on the coated membrane dish at a density of 2,000,000 cells/dish in DMEM containing 7% FCS and incubated 24 h. Approximate cell confluence was 85-90%. NRVM were then made quiescent by washing with 10 ml of Hanks' balanced salt solution (HBSS, 138 mM NaCl, 5.3 mM KCl, 4.0 mM NaHCO<sub>3</sub>, 1.3 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub>, 0.4 mM MgSO<sub>4</sub>, 0.4 mM KH<sub>2</sub>PO<sub>4</sub>, 0.3 mM Na<sub>2</sub>HPO<sub>4</sub>, 5.6 mM glucose; Life Technologies, Inc., Rockville, MD) twice and incubating with 26 ml of DMEM containing 0.2% FCS for 48-72 hours.

In these cell culture conditions, cells beat at 40-60 beats/minute. At this rate, we have observed negligible competition when pacing at a rate of 70 beats/minute. We performed trial capture experiments; nine locations on each dish were sampled. Capture efficiency was similar at all locations, and maximal capture occurred at 60 V and above with 10 ms of pulse width. Therefore, a voltage of 70 V with 10 ms of impulse duration at a rate of 1.2 Hz (70 beats/minute) was selected. Under these conditions we did not observe partial cell detachment.

**Transcriptional Profiling.** The DNA microarray experiment was performed with rat neonatal cardiac myocytes cultured on fibronectin-coated membranes with serum-free medium for 48 hours. Cells were deformed with an 8% deformation imposed only during systole for a period of 30 minutes, and RNA was prepared after 6 hours of subsequent no strain conditions and no pacing conditions. This time point was based upon previous studies demonstrating that the gene tenascin (positive control for cardiomyocytes) is induced at this time period. The DNA microarray hybridization experiment was performed using the Affymatrix GeneChip RGU34A (Affymetrix, Inc., Santa Clara, CA). Data were analyzed using Affymatrix software.

**Northern Analyses.** The cDNA clones for differentially expressed genes were obtained by PCR using the GenBank sequences. Each clone was sequenced from both 5' and 3' ends to confirm identity. Positive elements in the DNA microarray were confirmed by Northern blot hybridization analysis in at least three independent experiments using three different sources of NRVMs. Total RNA was isolated by the guanidium thiocyanate and phenol chloroform method (Chomczynski, *et al.*, *Anal. Biochem.*, 1987, 162:156-159). For Northern blotting, 15 µg RNA was loaded on a 1.0% agarose-formaldehyde gel (2.0 mol/l), transferred to a nylon membrane (Amersham Pharmacia Biotech AB, Piscataway, NJ), and UV cross-linked with a UV Stratalinker (Stratagene, Inc., La Jolla, CA). Each probe was hybridized with ExpressHyb solution (Clontech Labs., Inc., Palo Alto, CA) at 68 °C for 1 hour. The membrane was washed with 2 x SSC, 0.05% SDS solution for 30 to 40 minutes and three times at room temperature and 0.1 x SSC, 0.1 % SDS solution with continuous shaking at 50 °C for 40

minutes. The membrane was exposed to film at -80 °C, and radiographs were scanned and analyzed with Optimas 5.0 software (Optimas Co./Media Cybernetics, Silver Springs, MD). Densitometric units were normalized to the ethidium-stained 28S ribosomal subunit on the membrane.

5       **Results.** Figure 1 shows the timecourse (early, left; late, right) of the induction of Fit-1 mRNA expression by 8% cyclic mechanical strain in neonatal cardiac myocytes in culture. Maximal induction occurs at 3 hours and is sustained for 15 hours.

Figure 2 shows the effects of 8% mechanical strain, angiotensin receptor blockade (ARB, CP-19116, 100 nM), angiotensin II (Ang II, 50 nM), interleukin-1 $\beta$  (IL-1 $\beta$ , 10 ng/ml),  
10       and phorbol ester (Pma, 200 nM) for 3 hours on the induction of Fit-1 mRNA expression in cultured neonatal rat cardiac myocytes. The induction of Fit-1 mRNA expression by strain was not blocked by angiotensin receptor blockade; furthermore, treatment with angiotensin II did not induce Fit-1 mRNA expression. Treatment with both IL-1 $\beta$  and PMA were associated with an induction of Fit-1 mRNA expression in the absence of mechanical strain.

15       Figure 3 shows the effects of 8% mechanical strain, hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>, 100  $\mu$ M) and the antioxidant, TIRON (10 mM) on the induction of Fit-1 mRNA expression. Unlike the mRNA expression of the mechanically induced Tenascin-C gene which is induced by H<sub>2</sub>O<sub>2</sub> in the absence of mechanical strain and blocked by TIRON, H<sub>2</sub>O<sub>2</sub> does not induce Fit-1 in the absence of strain and blocks the strain-induced induction of Fit-1. TIRON slightly attenuated  
20       the mRNA expression of Fit-1 in the absence and presence of strain.

Figure 4 shows the effects of actinomycin D (5  $\mu$ g/ml, left) and cyclohexamide (10  $\mu$ g/ml, right) on the induction of Fit-1 mRNA expression by 8% mechanical strain. Actinomycin D and cyclohexamide were applied during mechanical strain. Actinomycin D blocked the induction of Fit-1 mRNA expression at both 2 and 4 hours suggesting that the  
25       induction of Fit-1 in response to strain is due to increased transcription of Fit-1. The protein synthesis inhibitor, cyclohexamide blocked the induction of Fit-1 mRNA expression in response to strain suggesting that new protein synthesis is required for the induction of Fit-1 mRNA expression.

Figure 5 shows the effects of 8% mechanical strain alone and in combination with  
30       interleukin-1 $\beta$  (IL-1 $\beta$ , 10 ng/ml), and phorbol ester in the absence of strain (PMA, 100 ng/ml) on Fit-1 mRNA expression in cultured neonatal cardiac myocytes. Both IL-1 $\beta$  and mechanical strain alone induced Fit-1 mRNA expression but the induction of Fit-1 by mechanical strain in the presence of IL-1 $\beta$  was not further increased suggesting that mechanical strain and IL-1 $\beta$  do

not act in a synergistic or additive manner on the induction of Fit-1. The strongest induction of Fit-1 mRNA expression is seen with PMA. The rank order potency for the induction of Fit-1 mRNA expression is PMA>strain>IL-1 $\beta$ .

Figure 6 shows neonatal rat cardiac myocytes were exposed to 8% strain for 0, 1, 3, 6, 9, hours. Total RNA was isolated using RNeasy kit. Five  $\mu$ g of total RNA were size-separated on 1% agarose-formaldehyde gel and transferred to nylon membrane. After cross-linking with UV light, membrane was hybridized with  $^{32}$ P-labeled probe specific for V-ATPase B subunit. The membrane was then exposed to x-ray film for 3 hours at -80 °C with an intensifying screen.

## **EXAMPLE 2.**

### **Introduction:**

**Cytokines and Cardiac Injury.** Stress-activated cytokines participate in many forms of cardiac injury and pathophysiological conditions, the most characterized ones being tumor necrosis factor- $\alpha$ , interleukin-1 and interleukin-6. These molecules are not constitutively expressed in the normal heart but are rapidly induced during ischemia and reperfusion or upon hemodynamic overloading, suggesting that they play an important role in the initial myocardial response to stress, injury or growth stimuli (Mann DL, *Cytokine and Growth Factor Reviews*. 1996;7:341-354; St. John Sutton MG, et al. *Circulation*. 2000;101:2981-2988). However, cytokines have also been shown to be stably expressed in pathologic myocardial conditions including ischemic heart disease and heart failure and are associated with a poor prognosis (Pulkki KJ, et al.. *Annals of Medicine*. 1997; 29:339-343; Kubota T, et al *Proc Natl Acad Sci*. 1998;95:6930-6935; Aukrust P, et al. *Am J Cardiol* 1999;83:376-382; MacGowan GA, et al. *Am J Cardiol* 1997;79:1128-1132; Roig E, et al. *Am J Cardiol* 1998;688-690; Tsutamoto T, et al. *J Am Coll Cardiol* 1998;31:391-398; Prabhu SD, et al. *Circulation*. 2000;101:2103-2109; Murray DR, et al.. *Annu Rev Immunol*. 2000;18:451-494).

Interleukin-1 signaling through the interleukin-1 receptor is an early event in inflammatory cytokine signaling in many different systems (Trehu EG., *Clin Cancer Res*. 1996; 8:1341-51). In cardiac injury, interleukin-6 is produced by cardiac myocytes secondary to stimulation with interleukin-1, tumor necrosis factor- $\alpha$ , or lipopolysaccharide and has been detected in the post-ischemic lymph during reperfusion of ischemic myocardium (Gwechenberger M, et al. *Circulation* 1999;99:546-551). Recently recognized is the potential expression of counteracting anti-inflammatory cytokines in cardiac disease secondary to

interleukin-1 signaling. Interleukin-4 and interleukin-10 can suppress the synthesis of tumor necrosis factor- $\alpha$  and enhance the release of soluble tumor necrosis factor receptors, which are ligand sinks for tumor necrosis factor (Joyce DA., 1994; *Eur. J. Immunol.* 11:2699-705).

Interleukin-10 is increased in patients with heart failure (Yamaoka M, et al. *Jpn Circ J.*

5 1999;63:951-956) and interleukin-10 serum levels are increased when tumor necrosis factor- $\alpha$  serum levels are increased in patients with dilated cardiomyopathy (Ohtsuka T, et al. *J Am Coll Cardiol.* 2001;37:412-417).

**T1/ST2 (fit-1): A Novel Mechanically Induced Receptor.** We have identified a novel potential stress-activated signaling pathway in the heart: regulation of the induction of  
10 an interleukin-1 family member gene, T1/ST2. Little is known of the induction, signaling and function of T1/ST2 in *any* cell type and T1/ST2 was shown in separate areas of investigation to have two seemingly unrelated functions. One of these is growth regulation and the other is immune modulation. Both compensatory hypertrophic growth and immune/inflammatory modulation are involved in the pathophysiology of cardiovascular diseases.

15 **Growth.** The T1/ST2 gene was first identified by its induction following serum stimulation of resting mouse 3T3 fibroblasts, suggesting that the T1/ST2 gene participates in growth regulation (Tominaga S., *FEBS Letters* 1989;258:301-304). The same group later identified a longer transcript consisting of transmembrane and cytoplasmic domains homologous to the full-length interleukin-1 receptor (Yanagisawa K, et al. *FEBS Letters.*  
20 1993;318:83-87).

**Immunity.** T1/ST2 is expressed on T helper-2, but not T helper-1, cells of the adaptive immune system, which produce interleukin-4, interleukin-5 and interleukin-10 (Yanagisawa KI, et al. *J Biochem.* 1997;121:95-103; Coyle AJ, et al. *J Exp Med.* 1999;190:895-902). T helper-2 cells mediate beneficial responses to infection, but are detrimental in the development  
25 of allergy and asthma. There is a strong correlation between expression of T1/ST2 and interleukin-4 production on T helper-2 cells (Coyle AJ, et al. *J Exp Med.* 1999;190:895-902). T1/ST2 plays a *critical role in differentiation* to and activation of T helper-2 but not T helper-1 cells (O'Neill LAJ, et al. *Immunology Today.* 2000;21:206-209).

Inhibition of T1/ST2 signaling attenuated T helper 2-mediated induction of eosinophil  
30 inflammatory responses in lung and inhibited cytokine secretion from T helper-2 cells without modifying interferon-gamma secretion from T helper-1 cells (Coyle AJ, et al. *J Exp Med.* 1999;190:895-902). These studies indicate that expression of T1/ST2 can alter the cytokine profile in favor of expression of interleukin-4, interleukin-5 and interleukin-10. Interleukin-10



has recently been shown to have anti-inflammatory effects in the setting of cardiac injury (Ohtsuka T, et al. *J Am Coll Cardiol.* 2001;37:412-417). Similarly, the absence of T1/ST2 expression could result in a shift towards interferon-gamma expression, which may be deleterious following myocardial injury.

5 Taken together, the involvement of T1/ST2 in growth responses and immune function coupled with the clinical recognition of the role of cytokines in the inflammatory response to ischemia/reperfusion are suggestive that T1/ST2 activation is a growth- or stress-activated signaling pathway that contributes to myocardial growth and remodeling.

10 **Phenotype of T1/ST2 Null Mice.** (Townsend MJ, et al. *J Exp Med.* 2000;191:1069-1075). The absence of T1/ST2 in T1/ST2 null mice does not compromise their basal immune function in the absence of immune challenge. However, T1/ST2 null mice have an impaired ability to generate IL-4, IL-5, and IL-10, but not IFN- $\gamma$  (a Th1 cytokine) and to generate a T helper-2 inflammatory response during eosinophilic infiltration in the lung (a Th2 response).

15 We have begun to study the induction of T1/ST2 in cardiac myocytes and its involvement in survival/death signaling within the context of the myocyte signaling pathways. Preliminary studies presented below show that T1/ST2 is induced in cardiac myocytes in response to interleukin-1 and mechanical strain and that the induction of T1/ST2 by interleukin-1 may be dependent on NF- $\kappa$ B activation. T1/ST2 mRNA is also induced in *human*  
20 *adult* vascular smooth muscle cells in response to interleukin-1. T1/ST2 protein is expressed in the mouse heart early after myocardial ischemia in vivo as well as in human aorta tissue from patients with unstable plaque.

### Results:

25 **IN VITRO STUDIES.** The following studies demonstrate the induction of T1/ST2 by mechanical strain and interleukin-1, possibly through activation of NF- $\kappa$ B. Both transcripts of T1/ST2 (that is, Fit-1S and Fit-1M) are induced by strain in cardiac myocytes. T1/ST2 mRNA is induced by mechanical strain in cultured neonatal cardiac myocytes (Figure 8).

T1/ST2 mRNA is induced by mechanical strain in cultured neonatal cardiac myocytes. Neonatal rat ventricular myocytes were isolated by collagenase digestion, plated on  
30 fibronectin-coated silicone membrane dishes at a density of 3.5 million cells/dish in 13 ml media as previously described (Yamamoto K, et al. *J Biol Chem.* 1999;274:21840-21846). This technique yields cultures with  $\geq$  95% myocytes. Mechanical deformation was applied using a device that provides uniform biaxial cyclic strain as previously described (Yamamoto

K, et al. *J Biol Chem.* 1999;274:21840-21846). RNA was extracted (Qiagen) and Northern blotting was performed using as a probe a <sup>32</sup>P-labelled 600bp PCR fragment specific to rat T1/ST2. Maximal induction occurs at 3 hours, is sustained for 9 hours and declines by 15 hours.

5 Both interleukin-1 $\beta$  and mechanical strain each induce T1/ST2 RNA in cardiac myocytes (Figure 9). Shown is the induction of T1/ST2 by interleukin-1 and strain. We also found that the induction of T1/ST2 by mechanical strain in the presence of interleukin-1 $\beta$  was not further increased suggesting that interleukin-1 does not sensitize myocytes to the effects of mechanical strain (or vice versa) on the induction of T1/ST2. The 1hour time point was  
10 included in the event that induction by strain is saturated at 3 hours and therefore masks an additive effect of interleukin-1 $\beta$ . Shown in the two right lanes are the effects of phorbol ester (PMA) at 1 and 3 hours. The rank order potency for the induction of T1/ST2 mRNA expression is PMA>strain> interleukin-1 $\beta$ . Since interleukin-1 $\beta$  signals through NF- $\kappa$ B and PMA through PKC these results suggest that NF- $\kappa$ B and PKC activation both participate in the  
15 induction of T1/ST2.

T1/ST2 may be a NF- $\kappa$ B target gene in cardiac myocytes through interleukin-1/interleukin-1 receptor signaling (Figure 10). Previously reported by us (Yamamoto K, et al. *J Biol Chem.* 1999;274:21840-21846), mechanical strain of cardiac myocytes activates NF- $\kappa$ B. To investigate the role of NF- $\kappa$ B in interleukin-1 $\beta$  and strain induction of T1/ST2 RNA, we  
20 overexpressed I $\kappa$ B $\alpha$ , which decreases NF- $\kappa$ B DNA-binding activity. Cultured cardiac myocytes were infected with I $\kappa$ B $\alpha$  overexpression adenovirus vector or with  $\beta$ -galactosidase control vector and exposed for 4 hours to 8% cyclic mechanical strain or interleukin-1 (10ng/ml). RNA was analyzed by Northern blotting with <sup>32</sup>P-labeled T1/ST2 cDNA probe. Ectopic expression of I $\kappa$ B $\alpha$  blocked interleukin-1 $\beta$  induction of T1/ST2-1 mRNA and partially blocked  
25 strain induction of T1/ST2 mRNA expression when compared with T1/ST2 induction in cells treated with the  $\beta$ -galactosidase control vector. These results suggest that T1/ST2 is an early, NF- $\kappa$ B target gene through interleukin-1/interleukin-1 receptor signaling. In contrast, pathways in addition to NF- $\kappa$ B activation may be involved in the induction of T1/ST2 RNA by mechanical strain. T1/ST2 mRNA is also induced by interleukin-1 but not PMA or tumor  
30 necrosis factor (TNF) in human adult vascular smooth muscle cells.

In addition to the above-noted results, we have shown that T1/ST2 is induced secondary to NF- $\kappa$ B activation by interleukin-1 and NF- $\kappa$ B is linked to cardiac myocyte survival. Further

in vitro studies are performed to confirm that T1/ST2 activation is linked to cell growth and survival.

#### IN VIVO STUDIES. In vivo Expression of T1/ST2 Protein in Myocardial

- 5 **Infarction in Mice.** Figure 11 shows protein expression of T1/ST2 using immunohistochemistry in paraffin sections of mouse hearts 1 and 3 days post-infarction. T1/ST2 protein was visualized by DAB staining. This antibody (Morwell Diagnostics) does not distinguish between the two isoforms of T1/ST2. Positive staining (brownish color) is seen 1 day post-infarction (post-MI) in the normal, infarct and border zones but not at 3 days post-MI.
- 10 These results suggest that ST2 protein is rapidly expressed in response to myocardial injury during the early phase of post-infarction remodeling before the migration of macrophages into the infarct and border zones (see 3 days post-MI). *Magnification: 40X.*

- In addition to the above, we are generating an operational colony of T1/ST2 null mice.
- 15 Our in vivo studies indicate that T1/ST2 is expressed in the mouse heart following myocardial infarction. The in vivo studies confirm the hypothesis that local cardiac expression of T1/ST2 favorably modifies the process of LV remodeling following ischemia and left ventricular pressure overload. We have also generated adeno-associated viruses to express isoforms of these genes and their effects on null mice are determined.

- 20 More recently, we have obtained results which support the utility of the gene/protein called fit-1, or ST-2, as a diagnostic indicator of a cardiovascular condition in humans. We assayed serum levels on 69 patients who participated in the HEART study, a clinical trial of acute myocardial infarction patients. The assay employed a monoclonal assay for the human ST2 protein. The results show that the levels of ST2 correlated with serum creatine
- 25 phosphokinase levels, which is a standard way of looking at size of heart attack. Also, such levels rapidly decline after the infarct. The levels were: Day 1: 3.8 +/- 3.3 ng/ml; Day 14: 0.9 +/- 0.5; and Day 90: 0.8 +/- 0.5 and are highly statistically significant. These results also establish that the protein is secreted during heart attacks and can be easily measured, thereby supporting the asserted utility of the invention.

30

#### Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

All references disclosed herein are incorporated by reference in their entirety.

5

What is claimed is presented below and is followed by a Sequence Listing.

I claim:

### Claims

1. A method of diagnosing a cardiovascular condition characterized by aberrant expression of a nucleic acid molecule or an expression product thereof, said method comprising:

5 a) contacting a biological sample from a subject with an agent, wherein said agent specifically binds to said nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof; and

b) measuring the amount of bound agent and determining therefrom if the expression of said nucleic acid molecule or of an expression product thereof is aberrant,  
10 aberrant expression being diagnostic of the condition;

wherein the nucleic acid molecule is at least one nucleic acid molecule selected from the group consisting of Fit-1, CD44, Lot-1, AA892598, and Mrg-1.

2. The method of claim 1, wherein the nucleic acid molecule is at least two nucleic acid  
15 molecules, each selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1.

3. The method of claim 1, wherein the nucleic acid molecule is at least three nucleic acid molecules, each selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1,  
20 AA892598, and Mrg-1.

4. The method of claim 1, wherein the nucleic acid molecule is at least four nucleic acid molecules, each selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1.

25 5. The method of claim 1, wherein the nucleic acid molecule is at least five nucleic acid molecules, each selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1.

30 6. The method of claim 1, wherein the condition is a cardiovascular condition selected from the group consisting of myocardial infarction, stroke, arteriosclerosis, and heart failure.

7. The method of claim 1, wherein the condition is cardiac hypertrophy.

8. A method for determining the stage of a cardiovascular condition in a subject characterized by aberrant expression of a nucleic acid molecule or an expression product thereof, comprising:

monitoring a sample from a patient, for a parameter selected from the group consisting of

- (i) a nucleic acid molecule selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1,
- (ii) a polypeptide encoded by the nucleic acid,
- (iii) a peptide derived from the polypeptide, and
- (iv) an antibody which selectively binds the polypeptide or peptide,

as a determination of the stage of said vascular condition in the subject.

9. The method of claim 8, wherein the sample is a biological fluid or a tissue.

10. The method of claim 8, wherein the step of monitoring comprises contacting the sample with a detectable agent selected from the group consisting of:

- (a) an isolated nucleic acid molecule which selectively hybridizes under stringent conditions to the nucleic acid molecule of (i),
- (b) an antibody which selectively binds the polypeptide of (ii), or the peptide of (iii), and
- (c) a polypeptide or peptide which binds the antibody of (iv).

11. The method of claim 10, wherein the antibody, the polypeptide, the peptide or the nucleic acid is labeled with a radioactive label or an enzyme.

12. The method of claim 10, comprising assaying the sample for the peptide.

13. A kit, comprising a package containing:

an agent that selectively binds to an isolated nucleic acid molecule selected from the group consisting of Fit-1, CD44, Lot-1, AA892598, and Mrg-1, or an expression product thereof, and

a control for comparing to a measured value of binding of said agent to said  
5 isolated nucleic acid or expression product thereof.

14. The kit of claim 13, wherein the control has a predetermined value for comparing to the measured value.

10 15. The kit of claim 13, wherein the control comprises an epitope of the expression product of an isolated nucleic acid molecule selected from the group consisting of Fit-1, CD44, Lot-1, AA892598, and Mrg-1.

16. A method for treating a cardiovascular condition, comprising:  
15 administering to a subject in need of such treatment an agent that modulates expression of a molecule selected from the group consisting of Fit-1, CD44, Lot-1, AA892598, and Mrg-1, in an amount effective to treat the cardiovascular condition.

17. The method of claim 16, further comprising co-administering an agent selected from  
20 the group consisting of an anti-inflammatory agent, an anti-thrombotic agent, an anti-platelet agent, a fibrinolytic agent, a lipid reducing agent, a direct thrombin inhibitor, a glycoprotein IIb/IIIa receptor inhibitor, an agent that binds to cellular adhesion molecules and inhibits the ability of white blood cells to attach to such molecules, a calcium channel blocker, a beta-adrenergic receptor blocker, a cyclooxygenase-2 inhibitor, and an angiotensin system inhibitor.

25 18. The method of claim 16, wherein the cardiovascular condition is selected from the group consisting of cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.

30 19. A method for treating a subject to reduce the risk of a cardiovascular condition developing in the subject, comprising:

administering to a subject that expresses decreased levels of a molecule selected from the group consisting of Fit-1, CD44, Lot-1, AA892598, and Mrg-1, an agent for reducing

the risk of the cardiovascular disorder in an amount effective to lower the risk of the subject developing a future cardiovascular disorder,

wherein the agent is an anti-inflammatory agent, an anti-thrombotic agent, an anti-platelet agent, a fibrinolytic agent, a lipid reducing agent, a direct thrombin inhibitor, a glycoprotein IIb/IIIa receptor inhibitor, an agent that binds to cellular adhesion molecules and inhibits the ability of white blood cells to attach to such molecules, a calcium channel blocker, a beta-adrenergic receptor blocker, a cyclooxygenase-2 inhibitor, or an angiotensin system inhibitor, or an agent that modulates expression of a molecule selected from the group consisting of Fit-1, CD44, Lot-1, AA892598, and Mrg-1.

10

20. A method for identifying a candidate agent useful in the treatment of a cardiovascular condition, comprising:

determining expression of a set of nucleic acid molecules in a cardiac cell or tissue under conditions which, in the absence of a candidate agent, permit a first amount of expression of the set of nucleic acid molecules, wherein the set of nucleic acid molecules comprises at least one nucleic acid molecule selected from the group consisting of Fit-1, CD44, Lot-1, AA892598, and Mrg-1,

15

contacting the cardiac cell or tissue with the candidate agent, and

detecting a test amount of expression of the set of nucleic acid molecules, wherein an increase in the test amount of expression in the presence of the candidate agent relative to the first amount of expression indicates that the candidate agent is useful in the treatment of the cardiovascular condition.

20

21. The method of claim 20, wherein the cardiovascular condition is selected from the group consisting of cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.

25

22. The method of claim 20, wherein the set of nucleic acid molecules comprises at least two nucleic acid molecules, each selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1.

30



23. The method of claim 20, wherein the set of nucleic acid molecules comprises at least three nucleic acid molecules, each selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1.

5 24. The method of claim 20, wherein the set of nucleic acid molecules comprises at least four nucleic acid molecules, each selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1.

10 25. The method of claim 20, wherein the set of nucleic acid molecules comprises at least five nucleic acid molecules, each selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1.

26. A pharmaceutical composition, comprising:  
an agent comprising an isolated nucleic acid molecule selected from the group  
15 consisting of Fit-1, CD44, Lot-1, AA892598, and Mrg-1, or an expression product thereof, in a pharmaceutically effective amount to treat a cardiovascular condition, and  
a pharmaceutically acceptable carrier.


27. The pharmaceutical composition of claim 26, wherein the agent is an expression product of the isolated nucleic acid molecule selected from the group consisting of Fit-1,  
20 CD44, Lot-1, AA892598, and Mrg-1.

28. The pharmaceutical composition of claim 26, wherein the cardiovascular condition is selected from the group consisting of cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.

25 29. A solid-phase nucleic acid molecule array consisting essentially of a set of at least two nucleic acid molecules, expression products thereof, or fragments thereof, are fixed to a solid substrate, wherein each nucleic acid molecule is selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1.

30 30. The solid-phase nucleic acid molecule array of claim 29, further comprising at least one control nucleic acid molecule.

31. The solid-phase nucleic acid molecule array of claim 29, wherein the set of nucleic acid molecules comprises at least three nucleic acid molecules, each selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1.
- 5 32. The solid-phase nucleic acid molecule array of claim 29, wherein the set of nucleic acid molecules comprises at least four nucleic acid molecules, each selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1.
- 10 33. The solid-phase nucleic acid molecule array of claim 29, wherein the set of nucleic acid molecules comprises at least 5 nucleic acid molecules, each selected from the group consisting of Fit-1, vacuolar ATPase, CD44, Lot-1, AA892598, and Mrg-1.
- 15 34. The solid-phase nucleic acid molecule array of claim 29, wherein the solid substrate comprises a material selected from the group consisting of glass, silica, aluminosilicates, borosilicates, metal oxides, clays, nitrocellulose, or nylon.
35. The solid-phase nucleic acid molecule array of claim 29, wherein the solid substrate is glass.
- 20 36. The solid-phase nucleic acid molecule array of claim 29, wherein each of the nucleic acid molecules are fixed to the solid substrate by covalent bonding.






Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11



-1-

## SEQUENCE LISTING

<110> The Brigham and Women's Hospital, Inc.  
Lee, Richard T.

<120> CARDIOVASCULAR DISEASE DIAGNOSTIC AND THERAPEUTIC TARGETS

<130> B0801/7231WO/ERP/KA

<150> US 60/247,457

<151> 2000-11-09

<160> 33

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 2586

<212> DNA

<213> Rattus norvegicus

<220>

<221> mRNA

<222> (1)... (2586)

<223> Fit-1S

<400> 1

gggtagtctg	aagagaccag	aggaaggagc	accaagtagc	ctcagggccc	tggggtttatt	60
cttcccagcc	cttcatctgg	gctacactga	tttctctttt	ggacctaca	tcagacagca	120
cacatcaacc	gcctagtggg	ctcacogtta	ccttcctgtg	ccattgccat	cggagagatc	180
tgggccatca	atcactagca	catgattggc	aaatggagaa	tggggccttg	ggctttggca	240
attctgacag	ttcccatgta	tttcatagt	acagagggca	gaaaaacatc	ctgggggtcta	300
gaaaacgagg	ctttaattgt	cagatgcccc	caaagaggag	gtgcgattaa	ccctgtggaa	360
tgggtattatt	caaatacaaa	tgaaagaatt	cctactcaaa	agagaaatcg	gatcttcgtc	420
tcaagagatc	gtctgaagtt	tctaccagcc	aaagtggag	actctgggat	ttatacgtgt	480
gttatcagaa	gccctgaatc	gattaagacc	ggatctttga	atgtcaccat	atataaaaga	540
ccaccaaact	gcaaaatccc	tgattacatg	atgtactcga	cagtagatgg	atcagataaa	600
aattccaaga	taacatgtcc	aacaattgcc	ttgtataatt	ggacagcgcc	tgttcagtgg	660
tttaagaact	gcaaagctct	ccaagggcca	agggttcagg	cacacatgtc	ctatttgttc	720
attgacaaag	tgagtcatgt	tgatgaaggt	gactacacat	gtcgattcac	tcacacggag	780
aacggaacca	attacattgt	gactgccacc	agatcattca	cagttgaaga	aaaaggcttc	840
tctacatttc	cagtaattac	aaaocctcca	cacaactaca	cagtgggaagt	ggaaatagga	900
aaaacagcaa	acattgcctg	ctcagcttgc	tttggcacag	cctctcagtt	cgttgctgtc	960
ctgtggcaga	ttaacaaaac	gagaattgga	tcttttggca	aagcaagaat	tcaagaagag	1020
aaaggcccaa	ataaaagtcc	cagcaatggc	atgatttgct	taacctcact	gttaaggata	1080
actggtgtga	cogacaagga	cttctcctcg	aaatatgact	gtgtggccat	gaaccatcac	1140
ggagtgataa	ggcaccocgt	aagactgaga	aggaaacaac	caagtaagga	gtgtctctca	1200
caaattgctt	gacaaaattg	gctgaatttg	ctgcaaacca	caatcctttt	tctcagagga	1260
ctgtgtgtta	tagcttgggtc	ccaggggatt	catcatgata	gtgggattag	ttggccagtt	1320
toctcaaatg	tgtttttcat	gttgagaaag	ctccttaaat	ctgggtctgtc	cagaatgttt	1380
ctgtcttcta	gaaggactct	ctgtcattgt	atctttcctc	tctctgtttc	cccttgtcct	1440
tgttctcctc	acggtcctcc	ccatcccttc	accttccttc	acgttctctc	tactcttctt	1500
cccttatctc	tgggctcctt	ctcacctgtt	agtggcttct	tcagtcaccc	tttgcacatg	1560
ctacaaggga	cattgggtgtt	gatactgggt	tgggaagcagt	aataacccta	ctgtgtttct	1620
ccctttgtga	ctcttgtaac	agaaaacaac	ttacacatta	ggtggatgac	caacttgatc	1680
ccattttaaa	agagttagaga	aaacatgata	tttttacctt	taacactctc	ttatgatact	1740
aacctctgcc	tcaatggcaa	tacaactaat	gtaaaaacat	tatttttaact	tctttcaaat	1800
atcaagaggg	tgtggaagg	agagagacac	tgactctaag	ctcatagtga	tatgtggggc	1860
atttattggg	attaagatat	tgattaaatg	attagggtgg	gggtacctat	tggataccat	1920
caagctgtgt	cactgcctga	agtggtagtt	gggatttttt	tttggttctg	tttgtcttct	1980
ttggtttggt	ttaactatag	agaccattct	gctcttgaac	tcctagagtt	ccacctggct	2040

-2-

```

ttgcctctca ggtcctggga ttaaagccat atgtcacctt acccagccag gatgtttctt 2100
gttttggttt caattttaga gcctctggct tgtaagattt ttataaagta gagtttgatt 2160
cataggtggc cagagttgtg actcatagat gggttttagt gaggtcttag gcatccaccc 2220
cttataatgc tgttaccag ggtgactgtg gaccacagca ctgtgttatg agatggtgga 2280
ggtcatggca cattctatag gaaaagagaa gccaagcccc tagtctcacc aggcacaacc 2340
ttgagtcctc actgctctcc tctgccaaca ggaccttttg tccagatttc tgagtattct 2400
ctagttacat ttgtatttga actatatattg tgttatctgt aattctgtat ttgttttggt 2460
tgtgtgtggt tttgtatttt ccagattatt ttttaattcac ctgttgctat tcaaataaat 2520
gtatctgtac tgcttcatca acacagcctg ttaaataaaa gtcgtgtctg ttgttggtga 2580
atgata 2586

```

```

<210> 2
<211> 336
<212> PRT
<213> Rattus norvegicus

```

```

<220>
<221> PEPTIDE
<222> (1)...(336)
<223> Fit-1S

```

```

<400> 2
Met Ile Gly Lys Trp Arg Met Gly Leu Trp Ala Leu Ala Ile Leu Thr
1 5 10 15
Val Pro Met Tyr Phe Ile Val Thr Glu Gly Arg Lys Thr Ser Trp Gly
20 25 30
Leu Glu Asn Glu Ala Leu Ile Val Arg Cys Pro Gln Arg Gly Gly Ala
35 40 45
Ile Asn Pro Val Glu Trp Tyr Tyr Ser Asn Thr Asn Glu Arg Ile Pro
50 55 60
Thr Gln Lys Arg Asn Arg Ile Phe Val Ser Arg Asp Arg Leu Lys Phe
65 70 75 80
Leu Pro Ala Lys Val Glu Asp Ser Gly Ile Tyr Thr Cys Val Ile Arg
85 90 95
Ser Pro Glu Ser Ile Lys Thr Gly Ser Leu Asn Val Thr Ile Tyr Lys
100 105 110
Arg Pro Pro Asn Cys Lys Ile Pro Asp Tyr Met Met Tyr Ser Thr Val
115 120 125
Asp Gly Ser Asp Lys Asn Ser Lys Ile Thr Cys Pro Thr Ile Ala Leu
130 135 140
Tyr Asn Trp Thr Ala Pro Val Gln Trp Phe Lys Asn Cys Lys Ala Leu
145 150 155 160
Gln Gly Pro Arg Phe Arg Ala His Met Ser Tyr Leu Phe Ile Asp Lys
165 170 175
Val Ser His Val Asp Glu Gly Asp Tyr Thr Cys Arg Phe Thr His Thr
180 185 190
Glu Asn Gly Thr Asn Tyr Ile Val Thr Ala Thr Arg Ser Phe Thr Val
195 200 205
Glu Glu Lys Gly Phe Ser Thr Phe Pro Val Ile Thr Asn Pro Pro His
210 215 220
Asn Tyr Thr Val Glu Val Glu Ile Gly Lys Thr Ala Asn Ile Ala Cys
225 230 235 240
Ser Ala Cys Phe Gly Thr Ala Ser Gln Phe Val Ala Val Leu Trp Gln
245 250 255
Ile Asn Lys Thr Arg Ile Gly Ser Phe Gly Lys Ala Arg Ile Gln Glu
260 265 270
Glu Lys Gly Pro Asn Lys Ser Ser Asn Gly Met Ile Cys Leu Thr
275 280 285
Ser Leu Leu Arg Ile Thr Gly Val Thr Asp Lys Asp Phe Ser Leu Lys
290 295 300
Tyr Asp Cys Val Ala Met Asn His His Gly Val Ile Arg His Pro Val

```

-3-

305		310		315		320
Arg	Leu	Arg	Arg	Lys	Gln	Pro
				Ser	Lys	Glu
				Cys	Leu	Ser
				Gln	Ile	Ala
		325		330		335

<210> 3  
 <211> 2065  
 <212> DNA  
 <213> Rattus norvegicus

<220>  
 <221> mRNA  
 <222> (1)... (2065)  
 <223> Fit-1M

<400> 3

aggagaaaaag	actgggatat	gctagcttgc	tagctccagc	aagcggcggt	atgcgcggtc	60
tttaaaatag	acagacatag	aggctttggg	ggagaggaag	aagtgcctgg	gatgaagaag	120
agatgcacct	acccggcagg	ggtgaaatcc	caagctacac	tgattttctct	tttggaccct	180
acatcagaca	gcacacatca	accgcctagt	ggactcaccg	ttaccttcct	gtgccattgc	240
catcggagag	atctcggcca	tcaatcacta	gcacatgatt	ggcaaatgga	gaatggggct	300
ttgggctttg	gcaattctga	cagttcccat	gtatttcata	gtgacagagg	gcagaaaaac	360
atcctggggg	ctagaaaaacg	aggctttaat	tgctcagatgc	cccaaagag	gaggtgcgat	420
taaccctgtg	gaatggtatt	attcaaatac	aaatgaaaga	attcctactc	aaaagagaaa	480
tcggatcttc	gtctcaagag	atcgtctgaa	gtttctacca	gccaaagtgg	aagactctgg	540
gattttatag	tgtgttatca	gaagccctga	atcgattaag	accggatctt	tgaatgtcac	600
catatataaa	agaccaccaa	actgcaaaat	ccctgattac	atgatgtact	cgacagtaga	660
tggatcagat	aaaaattcca	agataacatg	tccaacaatt	gccttgtata	attggacagc	720
gcctgttcag	tgggttaaga	actgcaaagc	tctccaaggg	ccaagggttca	gggcacacat	780
gtcctatttg	ttcattgaca	aagtgagtca	tggtgatgaa	ggtgactaca	catgtcgtat	840
cactcacacg	gagaacggaa	ccaattacat	tgtagactgcc	accagatcat	tcacagttga	900
agaaaaaggc	ttctctacat	ttccagtaat	tacaaaccct	ccacacaact	acacagtggg	960
agtggaaata	ggaaaaacag	caaacattgc	ctgctcagct	tgctttggca	cagcctctca	1020
gttcgttgct	gtcctgtggc	agattaacaa	aacgagaatt	ggatcttttg	gcaaagcaag	1080
aattcaagaa	gagaaaggcc	caaataaaaag	ttccagcaat	ggcatgatgt	gcttaacctc	1140
actgttaagg	ataactgggtg	tgaccgacaa	ggacttctcc	ctgaaatatg	actgtgtggc	1200
catgaacct	cacggagtga	taaggcacc	cgtaagactg	agaaggaaac	aaccaattga	1260
ccaccaaagc	acctactaca	tagttgccgg	atgtagttaa	ttgctaattg	ttatcaatgt	1320
cttggtgata	gtcttaaaaag	tgttctggat	tgagggttgc	ctgttctgga	gagatataat	1380
ggcaccttac	aaaaccacga	atgatggaaa	gctctatgat	gottacatca	tttaccctcg	1440
ggtcttccgg	ggcagcgag	cagggaccgg	ctctgtggag	tactttgttc	actacactct	1500
gcccgcggtt	ctcgaaaata	aatgtggcta	caagttgtgc	atttacggga	gagacctgct	1560
gcctgggcaa	gatgcggcca	ctgtggtgga	aagcagtatc	cagaatagta	gacggcaagt	1620
gtttgtcctg	gcccctcaca	tgatgcacag	caaagagttt	gcctatgagc	aggagatcgc	1680
cctgcacagc	gcccctcatcc	agaacaactc	caagggtgatt	ctgattgaaa	tggagcctat	1740
gggtgaggca	agccgactgc	agcttgggga	tctgcaagat	tctctccagc	atcttgtgaa	1800
aatgcagggg	accatcaagt	ggagggaaga	ccacgtggcc	gacaaacagt	ctctaagctc	1860
caaattcttg	aagcatgtga	gataccaaat	gccagtcccc	aaaagacccc	ccaagatggc	1920
atctgttgcc	gtccggttga	gtggcaagg	gtgcttgac	ctgaaacact	tttgagtcgt	1980
ggacttgcc	actcagagct	ggggaatccc	agcagtaggc	cccagaagt	aaggtgtgaa	2040
gacttgaat	gccaaagggtg	gggcc				2065

<210> 4  
 <211> 566  
 <212> PRT  
 <213> Rattus norvegicus

<220>  
 <221> PEPTIDE  
 <222> (1)... (566)  
 <223> Fit-1M

-4-

	<400> 4														
Met 1	Ile	Gly	Lys	Trp 5	Arg	Met	Gly	Leu	Trp 10	Ala	Leu	Ala	Ile	Leu 15	Thr
Val	Pro	Met	Tyr 20	Phe	Ile	Val	Thr	Glu 25	Gly	Arg	Lys	Thr	Ser 30	Trp	Gly
Leu	Glu	Asn 35	Glu	Ala	Leu	Ile	Val 40	Arg	Cys	Pro	Gln	Arg 45	Gly	Gly	Ala
Ile	Asn 50	Pro	Val	Glu	Trp 55	Tyr	Tyr	Ser	Asn	Thr	Asn 60	Glu	Arg	Ile	Pro
Thr 65	Gln	Lys	Arg	Asn 70	Arg	Ile	Phe	Val	Ser 75	Asp	Arg	Leu	Lys	Phe 80	
Leu	Pro	Ala	Lys 85	Val	Glu	Asp	Ser	Gly 90	Ile	Tyr	Thr	Cys	Val 95	Ile	Arg
Ser	Pro	Glu	Ser 100	Ile	Lys	Thr	Gly	Ser 105	Leu	Asn	Val	Thr 110	Ile	Tyr	Lys
Arg	Pro	Pro 115	Asn	Cys	Lys	Ile	Pro 120	Asp	Tyr	Met	Met	Tyr 125	Ser	Thr	Val
Asp	Gly 130	Ser	Asp	Lys	Asn	Ser 135	Lys	Ile	Thr	Cys	Pro 140	Thr	Ile	Ala	Leu
Tyr 145	Asn	Trp	Thr	Ala 150	Pro	Val	Gln	Trp	Phe	Lys 155	Asn	Cys	Lys	Ala	Leu 160
Gln	Gly	Pro	Arg	Phe 165	Arg	Ala	His	Met	Ser 170	Tyr	Leu	Phe	Ile 175	Asp	Lys
Val	Ser	His	Val 180	Asp	Glu	Gly	Asp	Tyr 185	Thr	Cys	Arg	Phe	Thr 190	His	Thr
Glu	Asn 195	Gly	Thr	Asn	Tyr	Ile	Val 200	Thr	Ala	Thr	Arg	Ser 205	Phe	Thr	Val
Glu	Glu 210	Lys	Gly	Phe	Ser	Thr 215	Phe	Pro	Val	Ile	Thr 220	Asn	Pro	Pro	His
Asn 225	Tyr	Thr	Val	Glu 230	Val	Glu	Ile	Gly	Lys	Thr 235	Ala	Asn	Ile	Ala	Cys 240
Ser	Ala	Cys	Phe 245	Gly	Thr	Ala	Ser	Gln	Phe 250	Val	Ala	Val	Leu	Trp 255	Gln
Ile	Asn	Lys	Thr 260	Arg	Ile	Gly	Ser	Phe 265	Gly	Lys	Ala	Arg	Ile 270	Gln	Glu
Glu	Lys 275	Gly	Pro	Asn	Lys	Ser	Ser 280	Ser	Asn	Gly	Met	Ile 285	Cys	Leu	Thr
Ser	Leu 290	Leu	Arg	Ile	Thr	Gly 295	Val	Thr	Asp	Lys	Asp 300	Phe	Ser	Leu	Lys
Tyr 305	Asp	Cys	Val	Ala 310	Met	Asn	His	His	Gly	Val 315	Ile	Arg	His	Pro	Val 320
Arg	Leu	Arg	Arg 325	Lys	Gln	Pro	Ile	Asp	His 330	Gln	Ser	Thr	Tyr 335	Tyr	Ile
Val	Ala	Gly	Cys 340	Ser	Leu	Leu	Leu 345	Met	Phe	Ile	Asn	Val	Leu 350	Val	Ile
Val	Leu 355	Lys	Val	Phe	Trp	Ile	Glu 360	Val	Ala	Leu	Phe	Trp 365	Arg	Asp	Ile
Met	Ala 370	Pro	Tyr	Lys	Thr	Gln 375	Asn	Asp	Gly	Lys	Leu 380	Tyr	Asp	Ala	Tyr
Ile 385	Ile	Tyr	Pro	Arg 390	Val	Phe	Arg	Gly	Ser	Ala 395	Ala	Gly	Thr	Gly	Ser 400
Val	Glu	Tyr	Phe 405	Val	His	Tyr	Thr	Leu	Pro 410	Asp	Val	Leu	Glu	Asn 415	Lys
Cys	Gly	Tyr	Lys 420	Leu	Cys	Ile	Tyr	Gly 425	Arg	Asp	Leu	Leu	Pro 430	Gly	Gln
Asp	Ala 435	Ala	Thr	Val	Val	Glu	Ser 440	Ser	Ile	Gln	Asn	Ser 445	Arg	Arg	Gln
Val	Phe 450	Val	Leu	Ala	Pro	His 455	Met	Met	His	Ser	Lys 460	Glu	Phe	Ala	Tyr
Glu 465	Gln	Glu	Ile	Ala 470	Leu	His	Ser	Ala	Leu 475	Ile	Gln	Asn	Asn	Ser	Lys 480

-5-

Val Ile Leu Ile Glu Met Glu Pro Met Gly Glu Ala Ser Arg Leu Gln  
 485 490 495  
 Leu Gly Asp Leu Gln Asp Ser Leu Gln His Leu Val Lys Met Gln Gly  
 500 505 510  
 Thr Ile Lys Trp Arg Glu Asp His Val Ala Asp Lys Gln Ser Leu Ser  
 515 520 525  
 Ser Lys Phe Trp Lys His Val Arg Tyr Gln Met Pro Val Pro Lys Arg  
 530 535 540  
 Pro Pro Lys Met Ala Ser Val Ala Ala Pro Leu Ser Gly Lys Val Cys  
 545 550 555 560  
 Leu Asp Leu Lys His Phe  
 565

<210> 5  
 <211> 1614  
 <212> DNA  
 <213> Rattus norvegicus

<220>  
 <221> mRNA  
 <222> (1)...(1614)  
 <223> vacuolar ATPase

<400> 5  
 cggggccagca caagatggcg ttgcgagcga tgcggggaat cgtgaacggg gccgcgcccg 60  
 agctgcccgt gccaccggg gggccgatgg ccggagctcg ggagcaggcg ctggcggtga 120  
 gccggaacta cctctcccag cctcgtctca cctacaagac tgtctctgga gtgaatggtc 180  
 cactagtgat cttagatcat gtaaagtttc ccagatatgc tgagattgtc cacttgacat 240  
 taccagatgg cacaaaaaga agtgggcaag ttctagaagt tagtggctcc aaagctgtgg 300  
 ttccaggtatt tgaaggaaca tccggcatag atgccaagaa aacatcctgt gagtttactg 360  
 gagatattct ccgcacacca gtgtctgagg atatgcttgg tcgagtattc aatggatcag 420  
 gaaaacccat tgaccgaggt cctgtggtgt tggccgaaga cttccttgac atcatgggtc 480  
 agccaatcaa ccctcagtgt cgcattacc cagaagagat gattcagacg ggcatttctg 540  
 ccatcgacgg catgaacagt attgcgaggg gacagaaaat ccccatcttt tctgtgcgcg 600  
 gggtaccaca caacgagatt gcagctcaga tctgtcgcca ggctggtttg gtaaagaaat 660  
 ccaaagacgt ggtagactac agtgaagaaa actttgccat tgtgtttgct gctatgggag 720  
 taaacatgga aacagcccgg ttcttcaaat ctgactttga agaaaatggc tcaatggaca 780  
 atgtctgctt ttctttgaat ctggctaatt acccaactat cgagaggatc atcactctc 840  
 gcctggctct gaccacgct gagtttctgg cttaccagt tgagaagcat gtcctgggtca 900  
 tctgacaga tatgattct tacgctgaag cacttcgaga ggtttcagct gccagggaag 960  
 aggttctctg tgcggcaggc ttccccggct acatgtatac ggatttagcc accatctatg 1020  
 aacgcgctgg gcgagtggaa ggtagaaatg gctctattac ccaaaccct attctcacca 1080  
 tgcccaatga tgatatcact catcctatcc ctgacttgac tgggtatatt actgagggcc 1140  
 agatctatgt ggacagacag ctgcacaaca gacagattta ccctcctatt aatgtgctgc 1200  
 cctcactctc tcggttaatg aagtcagcta ttggagaagg aatgaccagg aaggatcatg 1260  
 ctgatgtgtc taaccagttg tacgcatgct atgctatcgg taaggatgtg caagccatga 1320  
 aagctgtggt gggagaagaa gccctgacct cagatgacct cctttacttg gaatttctgc 1380  
 agaagtttga gaaaaacttc attactcagg gtccctatga aaatcgaact gtctatgaga 1440  
 ctttgacat tggtggcag ttgcttcgaa tcttccccc aaagatgctg aagaggatcc 1500  
 ctcagagtac cctgagcgaa ttttacccct gagactctgc aaagcactag ctgctgctgc 1560  
 ttgtgcggct cgaccctctt gtgaagtgtt ggttctgttt cctgattcct tttg 1614

<210> 6  
 <211> 511  
 <212> PRT  
 <213> Rattus norvegicus

<220>  
 <221> PEPTIDE  
 <222> (1)...(511)  
 <223> vacuolar ATPase

-6-

<400> 6

Met	Ala	Leu	Arg	Ala	Met	Arg	Gly	Ile	Val	Asn	Gly	Ala	Ala	Pro	Glu	1	5	10	15
Leu	Pro	Val	Pro	Thr	Gly	Gly	Pro	Met	Ala	Gly	Ala	Arg	Glu	Gln	Ala	20	25	30	
Leu	Ala	Val	Ser	Arg	Asn	Tyr	Leu	Ser	Gln	Pro	Arg	Leu	Thr	Tyr	Lys	35	40	45	
Thr	Val	Ser	Gly	Val	Asn	Gly	Pro	Leu	Val	Ile	Leu	Asp	His	Val	Lys	50	55	60	
Phe	Pro	Arg	Tyr	Ala	Glu	Ile	Val	His	Leu	Thr	Leu	Pro	Asp	Gly	Thr	65	70	75	80
Lys	Arg	Ser	Gly	Gln	Val	Leu	Glu	Val	Ser	Gly	Ser	Lys	Ala	Val	Val	85	90	95	
Gln	Val	Phe	Glu	Gly	Thr	Ser	Gly	Ile	Asp	Ala	Lys	Lys	Thr	Ser	Cys	100	105	110	
Glu	Phe	Thr	Gly	Asp	Ile	Leu	Arg	Thr	Pro	Val	Ser	Glu	Asp	Met	Leu	115	120	125	
Gly	Arg	Val	Phe	Asn	Gly	Ser	Gly	Lys	Pro	Ile	Asp	Arg	Gly	Pro	Val	130	135	140	
Val	Leu	Ala	Glu	Asp	Phe	Leu	Asp	Ile	Met	Gly	Gln	Pro	Ile	Asn	Pro	145	150	155	160
Gln	Cys	Arg	Ile	Tyr	Pro	Glu	Glu	Met	Ile	Gln	Thr	Gly	Ile	Ser	Ala	165	170	175	
Ile	Asp	Gly	Met	Asn	Ser	Ile	Ala	Arg	Gly	Gln	Lys	Ile	Pro	Ile	Phe	180	185	190	
Ser	Ala	Ala	Gly	Leu	Pro	His	Asn	Glu	Ile	Ala	Ala	Gln	Ile	Cys	Arg	195	200	205	
Gln	Ala	Gly	Leu	Val	Lys	Lys	Ser	Lys	Asp	Val	Val	Asp	Tyr	Ser	Glu	210	215	220	
Glu	Asn	Phe	Ala	Ile	Val	Phe	Ala	Ala	Met	Gly	Val	Asn	Met	Glu	Thr	225	230	235	240
Ala	Arg	Phe	Phe	Lys	Ser	Asp	Phe	Glu	Glu	Asn	Gly	Ser	Met	Asp	Asn	245	250	255	
Val	Cys	Leu	Phe	Leu	Asn	Leu	Ala	Asn	Asp	Pro	Thr	Ile	Glu	Arg	Ile	260	265	270	
Ile	Thr	Pro	Arg	Leu	Ala	Leu	Thr	Thr	Ala	Glu	Phe	Leu	Ala	Tyr	Gln	275	280	285	
Cys	Glu	Lys	His	Val	Leu	Val	Ile	Leu	Thr	Asp	Met	Ser	Ser	Tyr	Ala	290	295	300	
Glu	Ala	Leu	Arg	Glu	Val	Ser	Ala	Ala	Arg	Glu	Glu	Val	Pro	Gly	Arg	305	310	315	320
Arg	Gly	Phe	Pro	Gly	Tyr	Met	Tyr	Thr	Asp	Leu	Ala	Thr	Ile	Tyr	Glu	325	330	335	
Arg	Ala	Gly	Arg	Val	Glu	Gly	Arg	Asn	Gly	Ser	Ile	Thr	Gln	Ile	Pro	340	345	350	
Ile	Leu	Thr	Met	Pro	Asn	Asp	Asp	Ile	Thr	His	Pro	Ile	Pro	Asp	Leu	355	360	365	
Thr	Gly	Tyr	Ile	Thr	Glu	Gly	Gln	Ile	Tyr	Val	Asp	Arg	Gln	Leu	His	370	375	380	
Asn	Arg	Gln	Ile	Tyr	Pro	Pro	Ile	Asn	Val	Leu	Pro	Ser	Leu	Ser	Arg	385	390	395	400
Leu	Met	Lys	Ser	Ala	Ile	Gly	Glu	Gly	Met	Thr	Arg	Lys	Asp	His	Ala	405	410	415	
Asp	Val	Ser	Asn	Gln	Leu	Tyr	Ala	Cys	Tyr	Ala	Ile	Gly	Lys	Asp	Val	420	425	430	
Gln	Ala	Met	Lys	Ala	Val	Val	Gly	Glu	Glu	Ala	Leu	Thr	Ser	Asp	Asp	435	440	445	
Leu	Leu	Tyr	Leu	Glu	Phe	Leu	Gln	Lys	Phe	Glu	Lys	Asn	Phe	Ile	Thr	450	455	460	
Gln	Gly	Pro	Tyr	Glu	Asn	Arg	Thr	Val	Tyr	Glu	Thr	Leu	Asp	Ile	Gly				

-7-

465		470		475		480									
Trp	Gln	Leu	Leu	Arg	Ile	Phe	Pro	Lys	Glu	Met	Leu	Lys	Arg	Ile	Pro
			485						490					495	
Gln	Ser	Thr	Leu	Ser	Glu	Phe	Tyr	Pro	Arg	Asp	Ser	Ala	Lys	His	
			500					505					510		

<210> 7  
 <211> 2747  
 <212> DNA  
 <213> Rattus norvegicus

<220>  
 <221> mRNA  
 <222> (1)... (2747)  
 <223> glycoprotein CD44

<400> 7

ctcattgccc	agcagccccc	agccagtgac	aggttccatt	caccctcttt	gccccttccc	60
ccgcgacct	tttccagagg	ctactagatc	ctttggtttc	atcctgcaca	tcatggacaa	120
ggtttggtgg	cacacagctt	ggggactact	ttgcctctta	cagttgagcc	tggcacagca	180
gcagatcgat	ttgaatataa	cctgccgtta	cgcagggtga	ttccatgtgg	agaaaaatgg	240
ccgctacagt	atctccagga	ctgaagcagc	tgacctctgc	gaggctttca	acaccacctt	300
gcccaccatg	gtcagatgg	agttagccct	gagaaagggg	tttgaaacat	gcaggatggt	360
gttcatagaa	ggacacgtgg	taatcccgag	gatccacccc	aacgctatct	gtgcagccaa	420
caacacagga	gtgtatatcc	tcctcgcatc	caacacctcc	cactatgaca	catattgctt	480
caatgcctca	gtcctcttg	aagaagactg	tacatcagtc	acagacctac	ccaattcctt	540
cgatggacca	gttaccataa	ctattgtcaa	ccgtgatggc	acccgctaca	gcaagaaggg	600
cgagtataga	acacaccaag	aagacatcga	tgccctcaaac	attatagatg	aggatgtcag	660
cagtggatcc	accattgaga	agagcacccc	agaaggctac	atittgcaca	ccgaccttcc	720
cacttcacag	cctactggag	accgggatga	cgccctcttt	attgggagca	ccctggccac	780
cagtgatgga	gactcatcca	tggaccccag	gggtggtttc	gacactgtga	ctcatggatc	840
cgaattagct	ggacactcaa	gtgggaatca	agacagtggg	gtgaccacaa	cttctgggtcc	900
tgcgaggaga	cctcagattc	cagagtggct	tatcatcttg	gcatccctcc	tggcgctggc	960
tctgattctt	gccgtctgca	ttgctgtcaa	cagtaggaga	agggtgtggc	agaagaagaa	1020
gctggtgatc	aacagtggca	atggaacagt	ggaagacagg	aaaccaagtg	aactcaacgg	1080
ggaggccagc	aagtctcagg	aaatgggtga	tttggtgaa	aaggaacca	cagagactcc	1140
ggaccagttt	atgacagctg	atgagaccg	gaatctgcag	agtgtggata	tgaagattgg	1200
ggtgtagtgc	ctatgccact	aacttgaaaa	gacacaacaa	ttggagacat	gtcattactg	1260
ggagctggga	cccttaacag	atgcaatgtg	ctactgatta	ttttttattg	ggattatttt	1320
gggcataaaa	tttccctttt	tttgtttttt	aaaagtgtgt	tttccaattt	atgaaaatag	1380
cattgctttc	tgaatgagg	gtctcttcca	gttccctcct	agaggccttg	cattaccagg	1440
gtatgctacc	ataggcttct	accaaataaa	tactcttggt	cccgattgaa	cccaaagtcc	1500
caggtaacat	ccaccagcta	aggatttccc	cagaacttag	agagattggt	ctctgggagg	1560
aaatttgaat	gggtccatat	tgcctcccag	cagtccaatc	tgtaggcatt	gctttgcagt	1620
ggatgggaga	tcaggtgtac	tggttacaca	ctctctttat	agactccctt	ctgctggaaa	1680
atttccacat	gcttctgaga	gattccccaa	agggtgacgt	atttatcttt	agtaagctat	1740
ttatctttgt	ttttgaaata	tcaaaccctg	gaggtccctt	tttcagtatg	acttttttta	1800
ttttgttttt	ttttattttg	tttttttaggt	tactttgtca	gaagcataac	agggtataag	1860
ttgattcata	ataaatacct	gtccatcttc	catcttgacc	tgttgtgctg	tgatccttca	1920
gtttctaaa	cagcaaggtc	tgagtctttg	tagcacatca	atgtgacctt	agtatggtcc	1980
tctgaaactc	atggttagagc	atccgtgccc	tgcttgggtt	taccagctg	aatctcagaa	2040
gagcaaggac	aggagcactg	ttttcattct	aggactatca	aaggggtttc	tctcctgttc	2100
aagaatctga	attgggagta	ggagagcttc	tgtccctttt	atgtttcgat	aaccacctat	2160
ttctctttct	taaagggcac	attaagtgtt	tatatcttac	aacattcgcg	gtcctgtttc	2220
atagacactg	atcttattgg	cactttcaca	aaacagtgtg	gaggggactt	ctgacacctt	2280
atagtaaaag	gagaagccaa	cagaaatgaa	agtgtggaca	gagagcagta	gattggcatg	2340
aggaggcatg	atgtacaacc	cccagaccac	tctttccatc	accacatttg	ttgatgcttt	2400
cgcaagccag	ttggtactta	gaatcagttc	cccagggaat	ccttcaaaaa	gccataagaa	2460
tgcccacccc	tggaaatctta	ccaccaccag	atgagcaggt	ttatgggttt	gcaaaaggag	2520
aatgctgtca	ccctctgacc	tcatagtttt	cacatactgg	gcaagtgttc	atctgccagg	2580
atgccccatt	gtccttaggt	cttcccagggt	accttgtaga	agaacttaaa	tctataaaat	2640

-8-

aaggcttttct ctaaaatgga acttcctttc taaggctccc atttttactg ttgactaaat 2700  
 ttatatgtttt aatagttttt tttcaataaa aaacaaacac aaaaagg 2747

<210> 8  
 <211> 364  
 <212> PRT  
 <213> Rattus norvegicus

<220>  
 <221> PEPTIDE  
 <222> (1)...(364)  
 <223> glycoprotein CD44

<400> 8  
 Met Asp Lys Val Trp Trp His Thr Ala Trp Gly Leu Leu Cys Leu Leu  
 1 5 10 15  
 Gln Leu Ser Leu Ala Gln Gln Gln Ile Asp Leu Asn Ile Thr Cys Arg  
 20 25 30  
 Tyr Ala Gly Val Phe His Val Glu Lys Asn Gly Arg Tyr Ser Ile Ser  
 35 40 45  
 Arg Thr Glu Ala Ala Asp Leu Cys Glu Ala Phe Asn Thr Thr Leu Pro  
 50 55 60  
 Thr Met Ala Gln Met Glu Leu Ala Leu Arg Lys Gly Phe Glu Thr Cys  
 65 70 75 80  
 Arg Tyr Gly Phe Ile Glu Gly His Val Val Ile Pro Arg Ile His Pro  
 85 90 95  
 Asn Ala Ile Cys Ala Ala Asn Asn Thr Gly Val Tyr Ile Leu Leu Ala  
 100 105 110  
 Ser Asn Thr Ser His Tyr Asp Thr Tyr Cys Phe Asn Ala Ser Ala Pro  
 115 120 125  
 Leu Glu Glu Asp Cys Thr Ser Val Thr Asp Leu Pro Asn Ser Phe Asp  
 130 135 140  
 Gly Pro Val Thr Ile Thr Ile Val Asn Arg Asp Gly Thr Arg Tyr Ser  
 145 150 155 160  
 Lys Lys Gly Glu Tyr Arg Thr His Gln Glu Asp Ile Asp Ala Ser Asn  
 165 170 175  
 Ile Ile Asp Glu Asp Val Ser Ser Gly Ser Thr Ile Glu Lys Ser Thr  
 180 185 190  
 Pro Glu Gly Tyr Ile Leu His Thr Asp Leu Pro Thr Ser Gln Pro Thr  
 195 200 205  
 Gly Asp Arg Asp Asp Ala Phe Phe Ile Gly Ser Thr Leu Ala Thr Ser  
 210 215 220  
 Asp Gly Asp Ser Ser Met Asp Pro Arg Gly Gly Phe Asp Thr Val Thr  
 225 230 235 240  
 His Gly Ser Glu Leu Ala Gly His Ser Ser Gly Asn Gln Asp Ser Gly  
 245 250 255  
 Val Thr Thr Thr Ser Gly Pro Ala Arg Arg Pro Gln Ile Pro Glu Trp  
 260 265 270  
 Leu Ile Ile Leu Ala Ser Leu Leu Ala Leu Ala Leu Ile Leu Ala Val  
 275 280 285  
 Cys Ile Ala Val Asn Ser Arg Arg Arg Cys Gly Gln Lys Lys Lys Leu  
 290 295 300  
 Val Ile Asn Ser Gly Asn Gly Thr Val Glu Asp Arg Lys Pro Ser Glu  
 305 310 315 320  
 Leu Asn Gly Glu Ala Ser Lys Ser Gln Glu Met Val His Leu Val Asn  
 325 330 335  
 Lys Glu Pro Thr Glu Thr Pro Asp Gln Phe Met Thr Ala Asp Glu Thr  
 340 345 350  
 Arg Asn Leu Gln Ser Val Asp Met Lys Ile Gly Val  
 355 360



-9-

<210> 9  
 <211> 5028  
 <212> DNA  
 <213> *Rattus norvegicus*

<220>  
 <221> mRNA  
 <222> (1)...(5028)  
 <223> Lot-1

<400> 9

gcctggcagg	cgggagaacg	ctccggagtt	gtggccgtgg	gcaccgggct	cgcggaaga	60
ggagcggaga	gcgggcatct	cctgagcgcc	gtcatggctg	cttaggctgc	gcctgccagc	120
ggaccgacgg	tgctgcccga	atccggctcg	gataggtctg	gttggaagtct	gtgcctgctt	180
gcttggcgtg	tggttggtcc	tgcttgattg	gcacggtgcc	attggcttcg	tatttgggaa	240
tcggaggagt	taatcttgtc	tcttctcaca	ggttcgagtc	ctcagacctt	ctgcaggact	300
ccatccatat	ctgcctcgca	gctgactctc	ctgctcacac	agaagacggc	catcctagat	360
ccccagctat	tgtgctgacc	atccccctcc	tgctccggat	ctcgcctggc	tgctaggctg	420
tggtgctgcc	ttttcagagt	caggctgtag	cgactccccg	ccttcgtccc	ggctgggctt	480
aggtggaaca	gtggttcctc	tcctctcctc	agcacttctg	aagaagaaag	tgtgagaagc	540
agaggccatg	gctccttttc	gctgtcaaaa	atgcggaag	tccttctcga	ccctggagaa	600
gttcaccatc	cacaattatt	cccacaccag	ggagcgccca	ttcaagtgtc	ccaagactga	660
gtgtggcaaa	gccttcgtct	ccaagtataa	gctgatgaga	cacatggcta	cgcactctcc	720
ccagaagacg	caccagtga	ctcattgtga	aaagactttc	aaccggaagg	atcatctgaa	780
gaatcacctc	cagacccaag	atcccaacaa	gatgatctac	gcctgcgaag	attgtggcaa	840
gaaataccac	accatgctgg	gctacaagag	gcacatggcc	ctgcattcgg	ccagcagcgg	900
cgatctcacc	tgcggcgtct	gcaccctgga	gctggggagc	accgaggtcc	tgctggacca	960
cctcaagtct	cacgcggaag	aaaaggccca	ccacgcgccc	agggagaaga	aacaccagtg	1020
cgaccactgc	gagagatgct	tctacacccg	gaaggatgtg	cgctcgccacc	tggtggtcca	1080
cacaggatgc	aaggacttcc	tgtgtcagtt	ctgcgcccag	agatttgggc	gcaaagacca	1140
cctcactcgt	cacaccaaga	agacccactc	ccaggagctg	atgcaagaga	gcctgcaagc	1200
aggagaatac	cagggcgggt	accaacccat	tgcgccctccg	ttccagatca	aggctgatcc	1260
catgcctcct	ttccagttag	aatgcccccc	cgagagcggg	cttgatgggg	gcttgccctc	1320
tgagattcat	ggtctagtgc	ttgcttcccc	agaggaggtt	ccccagccta	tgctgtctat	1380
gccgccaatg	cagccaatgc	cagagcagcc	tttcaactctg	caccctgggg	tagttccctc	1440
ctctcctccc	ccgatcattc	ttcaggagca	taagtacagc	ccagttccta	cctcttttgc	1500
ccggttcgta	agcatgccga	tgaaagcaga	tctcaagggc	ttttgcaaca	tggtgtctct	1560
tgaggaattt	cctctgcaag	agtgtcagtc	gctgtcgaag	ttcagtcagt	gctttgagat	1620
ggctaaggaa	gggtttggga	aagtcaccct	gcccaagag	ctgctggtag	atgctgtaaa	1680
tatagccatt	cctggtctct	tggagatttc	ctctctcttg	gggttctggc	agctgcccc	1740
tcctcctccc	cagaatggct	tcatgaatgg	caccatccct	gtgggggccc	gggagccgct	1800
gccccatagg	ataacttgct	tggcacagca	gcagccacca	cctctgctac	ctccgcccgc	1860
gccgctgccg	ctgccagagc	cgctgccaca	gccacagctg	ccgccacagt	ttcagttgca	1920
gctccagccc	cagccccaga	tgagccccca	gatgcagctg	cagcctctac	agctgcagct	1980
gccccagctg	ctgccccagc	tgagccccga	gcctgagcca	gagccagagc	cagaggaaga	2040
agaggaagaa	gaagaagaga	tagaagaaga	agaagagatc	gaagaagaag	aagaagccga	2100
accagaagca	gaagaagaag	aggaggcaga	agacgaagag	gaggcagagg	aagaggaaga	2160
agagccacag	ccagaagaag	cccaaatagc	aatgagcgct	gtgaatatgg	gccagccccc	2220
gctacccccg	acccctcatg	ttttcacagc	tggcaccaac	actgctatcc	tgccccattt	2280
ccaccacgcg	ttcagataaa	ttggtttttt	aagagggtgc	ttctcttctg	gaagatgttt	2340
caaacaccag	ttccagttcc	agacatcagt	tacagtttga	agagaagcgt	tgaaaaaaca	2400
ggaatggggg	ttctagctta	ttgcatgag	tagattgaga	aaaagaactc	tcttaactgc	2460
atgcactgtg	ccaatatata	tatatatata	tatatatata	tatatatgta	tatatatata	2520
tatatatata	atccttagta	ttcatgcttt	gtaccaaact	tagtgagtgc	gggcgttctc	2580
cgtaatcgaa	ctgcaagtag	tatcatatta	ttaccctgat	attgttagtc	tcatattatt	2640
agccttgat	tattctcata	taatcaaaac	caagatccaa	aacatgagct	gctaatttgt	2700
aaatatcgctg	ttgagtgtta	gccgtcgtag	tgatgttagc	tgcgtagttg	cgtgttagca	2760
ctgcctagga	agggcacgag	ggccaagtgg	ggcttctccc	acttggaaga	tgttttgaag	2820
agaagggggg	gatctccgta	gggcgtccgt	aactaggccg	tgtgttcttt	tcagggaccc	2880
gtctaccttc	aggattggat	gtagtttagt	cgctcttctt	cttagctcgc	tttgtagttt	2940
gtccttctg	tagcctactg	tgtgtgtctg	tgtgtagctt	tataggaaag	ttccgtgtga	3000

-10-

```

agctgtcggt gtcttcgttt tcaaaagtga attttaaatg tatttttcaa tatttttcat 3060
gtgatgttgt accaatgtga attatgactt cgtttatctt aaagacaaaa ctgggtgtca 3120
gtcatatctg acaggaagaa agaaatccct gtgggtaggc aagtcaagtg gccaaactaat 3180
gagaagaagc atcaatcgaa agtggtggct gactgggaca ctcattgattc tcacaggact 3240
ttgagaaacg tactggaatt aaaaaaaaaa aagcttaagt acattagata agaattttct 3300
ttgcctagct taacctacta cttagcctc ttaagttctg aagtattgtg atcaaccaat 3360
aggaaaatgt atctgtagtt gatgaatttc agtccttggt actttgtatc ccaagaggtt 3420
tgtgttttgg gaatgtaacc gtacttgtaa tctcagttgg tatcttgcta atcgatttga 3480
aagtgtaaaa cctaaccctt gaagactctg tatttccttt tttgagactg tatttcccag 3540
catgtatacc ctaacccttg gagactctgt attctgtttt tgagactttc cccccgcccc 3600
ccagcatatg taccocgacc cttgaagact gtatttcggt tttgagagcg tatttcccag 3660
catatatata ctaacccttg aagactctgt atttcctttt ttgagactgt atttcccagc 3720
atatatacac taacccttga agactctgta tttccttttt tgagactgta tttcccagca 3780
tatatacact aacctttgaa gactctgtat tctgtttttg agaccccccc ccagcatatg 3840
taccctaacc cttgaagact gtatttcggt tttgagaacg tatttcccag catatatata 3900
ctaacccttg gaagactctg tatttcattt ttgagactgt gtttcttagt atacataccc 3960
taacctttga aagactccat ttttgagact tccccccccc cagcatttgt gccctaacc 4020
ttggaggctt tgtatttttt ttttgagact tttccgccag catatatata ctaacccttg 4080
aagactctgt atttcatttt tgagactttt tttcccagca tatataccgt aacctttgaa 4140
gactctgtat tccgtttttg agattttttt cctcagcat atatacccca acctttgaag 4200
actctgtatt tcaatttttg gactttttcc cagcatatat accctaacct ttgaagactc 4260
tgtattccat ttttgagatt ttttccctca gcatatatac cctaaccttt gaagactctg 4320
tatttcgttt ttgagatttt tttccccagc atataaacac taacctttga agactctgta 4380
tttcattttt gagacttttt tcccagcata tataccctaa cccttgaaga ctctgtaatc 4440
tgtttttttt tttttttgag actttttccc ccagcatata tacactaacc tttgaagact 4500
ctgtattcca ttttttgaga cttttttccc cagcatatat accctaacct ttgaagactc 4560
tgtatttcatt ttttgagact ttttcccag catataacc ctaacctttg aagactctgt 4620
attccgtttt tgagaccccc cccccggcat gaatacccta atctttgaag actctgggtat 4680
ttcatttttg agattttttt cccctcagca tatatacact aacctttgta gactctgtat 4740
tccgtttttg agactttccc cccccagcat gtatacccta acctttgaag actctgtatt 4800
tccagcattt gtaccctacc cttgaagact ctgtatttcc cagcatttgt accctaacc 4860
ttgaagaccc tgtatttctg ttgtaagact tttcccagc atatatatcc tacatataat 4920
aaacgctaag catctagcaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4980
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa 5028

```

<210> 10  
 <211> 583  
 <212> PRT  
 <213> *Rattus norvegicus*

<220>  
 <221> PEPTIDE  
 <222> (1)...(583)  
 <223> Lot-1

```

<400> 10
Met Ala Pro Phe Arg Cys Gln Lys Cys Gly Lys Ser Phe Leu Thr Leu
 1          5          10          15
Glu Lys Phe Thr Ile His Asn Tyr Ser His Thr Arg Glu Arg Pro Phe
 20          25          30
Lys Cys Ser Lys Thr Glu Cys Gly Lys Ala Phe Val Ser Lys Tyr Lys
 35          40          45
Leu Met Arg His Met Ala Thr His Ser Pro Gln Lys Thr His Gln Cys
 50          55          60
Thr His Cys Glu Lys Thr Phe Asn Arg Lys Asp His Leu Lys Asn His
 65          70          75          80
Leu Gln Thr His Asp Pro Asn Lys Met Ile Tyr Ala Cys Glu Asp Cys
 85          90          95
Gly Lys Lys Tyr His Thr Met Leu Gly Tyr Lys Arg His Met Ala Leu
100          105          110
His Ser Ala Ser Ser Gly Asp Leu Thr Cys Gly Val Cys Thr Leu Glu

```

-11-

		115					120					125				
Leu	Gly	Ser	Thr	Glu	Val	Leu	Leu	Asp	His	Leu	Lys	Ser	His	Ala	Glu	
	130					135					140					
Glu	Lys	Ala	His	His	Ala	Pro	Arg	Glu	Lys	Lys	His	Gln	Cys	Asp	His	
145					150					155					160	
Cys	Glu	Arg	Cys	Phe	Tyr	Thr	Arg	Lys	Asp	Val	Arg	Arg	His	Leu	Val	
				165					170					175		
Val	His	Thr	Gly	Cys	Lys	Asp	Phe	Leu	Cys	Gln	Phe	Cys	Ala	Gln	Arg	
			180					185					190			
Phe	Gly	Arg	Lys	Asp	His	Leu	Thr	Arg	His	Thr	Lys	Lys	Thr	His	Ser	
		195				200						205				
Gln	Glu	Leu	Met	Gln	Glu	Ser	Leu	Gln	Ala	Gly	Glu	Tyr	Gln	Gly	Gly	
	210					215					220					
Tyr	Gln	Pro	Ile	Ala	Pro	Phe	Gln	Ile	Lys	Lys	Ala	Asp	Pro	Met	Pro	
225					230				235						240	
Pro	Phe	Gln	Leu	Glu	Met	Pro	Pro	Glu	Ser	Gly	Leu	Asp	Gly	Gly	Leu	
				245					250					255		
Pro	Pro	Glu	Ile	His	Gly	Leu	Val	Leu	Ala	Ser	Pro	Glu	Glu	Val	Pro	
			260					265					270			
Gln	Pro	Met	Leu	Ser	Met	Pro	Pro	Met	Gln	Pro	Met	Pro	Glu	Gln	Pro	
		275						280				285				
Phe	Thr	Leu	His	Pro	Gly	Val	Val	Pro	Ser	Ser	Pro	Pro	Pro	Ile	Ile	
	290					295					300					
Leu	Gln	Glu	His	Lys	Tyr	Ser	Pro	Val	Pro	Thr	Ser	Phe	Ala	Pro	Phe	
305					310					315					320	
Val	Ser	Met	Pro	Met	Lys	Ala	Asp	Leu	Lys	Gly	Phe	Cys	Asn	Met	Gly	
				325					330					335		
Leu	Phe	Glu	Glu	Phe	Pro	Leu	Gln	Glu	Cys	Gln	Ser	Pro	Val	Lys	Phe	
			340					345					350			
Ser	Gln	Cys	Phe	Glu	Met	Ala	Lys	Glu	Gly	Phe	Gly	Lys	Val	Thr	Leu	
		355					360					365				
Pro	Lys	Glu	Leu	Leu	Val	Asp	Ala	Val	Asn	Ile	Ala	Ile	Pro	Gly	Ser	
	370					375					380					
Leu	Glu	Ile	Ser	Ser	Leu	Leu	Gly	Phe	Trp	Gln	Leu	Pro	Pro	Pro	Pro	
385					390					395					400	
Pro	Gln	Asn	Gly	Phe	Met	Asn	Gly	Thr	Ile	Pro	Val	Gly	Ala	Gly	Glu	
				405					410					415		
Pro	Leu	Pro	His	Arg	Ile	Thr	Cys	Leu	Ala	Gln	Gln	Gln	Pro	Pro	Pro	
			420					425					430			
Leu	Leu	Pro	Pro	Pro	Pro	Pro	Leu	Pro	Leu	Pro	Glu	Pro	Leu	Pro	Gln	
		435					440					445				
Pro	Gln	Leu	Pro	Pro	Gln	Phe	Gln	Leu	Gln	Leu	Gln	Pro	Gln	Pro	Gln	
	450					455					460					
Met	Gln	Pro	Gln	Met	Gln	Leu	Gln	Pro	Leu	Gln	Leu	Gln	Leu	Pro	Gln	
465					470					475						

-12-

<211> 658  
 <212> DNA  
 <213> Rattus norvegicus

<220>  
 <221> mRNA  
 <222> (1)...(658)  
 <223> AA892598 (EST196401)

<400> 11  
 acaaacactt tttattttgt ttttaattta gaacatgata catattcaca agatttacac 60  
 tttatatcat accaaagcaa tctagaaaca ctgtacagag cacacttgaa catttagaag 120  
 gctatatata atctgtggta aagtcatagg catcgtcttc ttcactcatt ttatccaaga 180  
 taaaggatct gtcagatggt ttacttgctg ttgattgccc aggtgacatc tccctgggtct 240  
 cttctacagg agtcacatct gagatctctg catTTTTTt accagtaaca tgttcttgat 300  
 catcaccatc ctgttgggtct tctgtctggt ttggtgactc ttcggggatg tccttttctt 360  
 ctagtattcc atttgtcagg cccgaagacc ggaaaaggat tttattagtt aaatgagggc 420  
 ccttgaggac ttgtatgctg tgtgcattat tcttttctag ttcttctaga ttaaagcccc 480  
 tcttcatgat tgctgtaata ttctcattaa aatgaggaga atgattccag gatgcagggg 540  
 gatggcagta gtaacctaata gaggcacctg tccactcaga ccatagcagc ttagcagcac 600  
 ttctgacatt tgggcttcca cctttttggt gcagacctct tctctgagca agtttagt 658

<210> 12  
 <211> 480  
 <212> DNA  
 <213> Rattus norvegicus

<220>  
 <221> mRNA  
 <222> (1)...(480)  
 <223> AA900476 (Mrg-1)

<400> 12  
 tttttttttt tttttttggt tggttttgat tttttttaat tcacaccgaa gaagttgggg 60  
 gtggggggcag ggaggggtgat ttctttcagc cgcgagggtta accgagtcaa cagctgactc 120  
 tgctgggctg ctgtttgcac acgaagtccg tcataaaaatc aaactcattt tggcccagcc 180  
 agagttcttg cagctccttg atgcgggtcca aaccatctc taccactaag gacataagca 240  
 cttcctcgtc gatgaaatca gtgtctatga cattggggcg cagcattgcc gcggggacgt 300  
 gagccaccga ggcgggcatg gtgctgccac cgccactgcc gcccgcgctg ctgccacccg 360  
 cgccgcccga ggtgccgccc gagccgcccg ggggtgcgct gccaccgccc ccgccagggg 420  
 tgctgctgcc tccactgtgc ttgggggtgc aatctcgaa gtgctggttt gtcccgttca 480

<210> 13  
 <211> 2646  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> mRNA  
 <222> (1)...(2646)  
 <223> ST2

<400> 13  
 gcagaaatga gacgaaggag cgccaagtag cctcacggct ctgagcttat tctctccagc 60  
 ccttcatctg ggtatctaca gtgatttctc ttctggacct tacctcagag agcactgtc 120  
 aaccgcctag tgaacacacc attactatcc tgtgccattg ccatagagag acctcagcca 180  
 tcaatcacta gcacatgatt gacagacaga gaatgggact ttgggctttg gcaattctga 240  
 cacttcccat gtatttgaca gttacggagg gcagtaaate gtcctggggg ctggaaaatg 300  
 aggccttaat tgtgagatgc ccccaaagag gacgctcgac ttatcctgtg gaatggtatt 360  
 actcagatac aaatgaaagt attcctactc aaaaaagaaa tcggatcttt gtctcaagag 420  
 atcgtctgaa gtttctacca gccagagtgg aagactctgg gatttatgct tgtgttatca 480

-13-

gaagcccca	cttgaataag	actggatact	tgaatgtcac	catacataaa	aagccgcca	540
gctgcaatat	ccctgattat	ttgatgtact	cgacagtacg	tggatcagat	aaaaatttca	600
agataacgtg	tccaacaatt	gacctgtata	attggacagc	acctgttcag	tggtttaaga	660
actgcaaagc	tctccaagag	ccaaggttca	gggcacacag	gtcctacttg	ttcattgaca	720
acgtgactca	tgatgatgaa	ggtgactaca	cttgtcaatt	cacacacgcg	gagaatggaa	780
ccaactacat	cgtgacggcc	accagatcat	tcacagttga	agaaaaaggc	ttttctatgt	840
ttccagtaat	tacaaatcct	ccatacaacc	acacaatgga	agtggaaata	ggaaaaccag	900
caagtattgc	ctgttcagct	tgttttggca	aaggctctca	cttcttggct	gatgtcctgt	960
ggcagattaa	caaaacagta	gttggaaatt	ttggtgaagc	aagaattcaa	gaagaggaag	1020
gtcgaaatga	aagttccagc	aatgacatgg	attgtttaac	ctcagtgtta	aggataactg	1080
gtgtgacaga	aaaggacctg	tccctggaat	atgactgtct	ggccctgaac	cttcatggca	1140
tgataaggca	caccataagg	ctgagaagga	aacaaccaag	taaggagtgt	ccctcacaca	1200
ttgcttgaat	aaattggctg	aatcagctgt	gcactgcata	cgttttctcc	gaggactgtg	1260
tgtttagct	tggtcccagg	gaatccatca	tgatcaaggg	aatagttggc	ctgtttcatc	1320
aagtgttctt	ctcacgttga	ggaagctcct	taaatctggg	ctttccagaa	tgtttctgtc	1380
ttccaacagg	aatctctgtc	attgtatcct	tccccctctc	gtgtccccctc	ctccttggtc	1440
tcccggcagt	cctccccatc	tctcacctc	ccttaatgtg	ttcttgacct	ccttctctct	1500
tttcttctc	tctgagctcc	ttctcaccca	atagtggctt	ttgcagtcac	cctttgtacc	1560
gactacaagg	gacattggta	ttggtagtgg	gttcagagca	gtaataactc	tgctgtgtct	1620
ctttgtataa	ccttgtcatg	gaaaacaact	tacaaacttt	cattctgagc	agttattaat	1680
tcccttgctt	ggtccttggg	ttgacagggtg	cagccatcat	gatagataga	tgaccaacct	1740
gatccgattt	taaaagagta	aacatctttt	ttacccttat	cactctctta	tgatactgac	1800
cactgcctta	ctggcaatac	aactaatatg	aaaacatttt	taatttcttt	caaatatcaa	1860
gagggcatgg	gagggagaga	gacactaact	ctaagatcat	agcaatatgt	ggggcattta	1920
tttgatgaa	tatatgtatt	aaaagggtag	ggtggaggta	cctattagat	tcagtcatgc	1980
tgtgtctctg	cctgaagtgg	tatttgggat	ttttgttgat	tctgtttgtc	ttcttttgtt	2040
tgtttttact	atagaaacta	ttctgccctt	gtactcctag	agtcacctgt	ctttgcctcc	2100
agttactggg	actaaagcta	tgtgtcacct	tactgagcca	gggtgtttct	tgttttgggt	2160
ttgatttttag	agcctctggc	ttgtaacatt	tttataaaac	agaattttga	ttcctagggtg	2220
gccagagtgg	tgactcatag	agggattttt	gtgctgttgt	gatcagtggg	gtcctggggga	2280
tctgcccttg	ataatgggtg	tactccgggt	gactgtggac	cacagcactg	tgttcccaga	2340
tggtgggtgg	cactgcacat	tctgcaggaa	aagagaatcc	aaacccctat	tctaccccag	2400
tttgaccttg	attccacaat	gccttctctc	gtaacaggat	cttttgtcta	gatttctgag	2460
tgtacttttag	ttcacgtttg	tattagaatt	atatttttta	atcagtaatt	ttgtatttgt	2520
tttgtttgtg	tgtgatttct	ttgttttcca	gtttattttt	aattcacttg	ttgtatttca	2580
aatcaatgtg	ttcatactgt	ttgaacaaca	cagcgtatta	aataaaattc	gtgtctattg	2640
ttcttg						2646

&lt;210&gt; 14

&lt;211&gt; 4989

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;220&gt;

&lt;221&gt; mRNA

&lt;222&gt; (1) ... (4989)

&lt;223&gt; ST2L

&lt;400&gt; 14

tgccattgcc	atagagagac	ctcagccatc	aatcactagc	acatgattga	cagacagaga	60
atgggacttt	gggcttttggc	aattctgaca	cttcccatgt	atttgacagt	tacggagggc	120
agtaaatcgt	cctgggggtct	ggaaaatgag	gctttaattg	tgagatgcc	ccaaagagga	180
cgctcgactt	atcctgtgga	atggtattac	tcagatacaa	atgaaagtat	tcctactcaa	240
aaaagaaatc	ggatctttgt	ctcaagagat	cgtctgaagt	ttctaccagc	cagagtggaa	300
gactctggga	tttatgcttg	tgttatcaga	agccccaact	tgaataagac	tggtacttg	360
aatgtcacca	tacataaaaa	gccgccaagc	tgcaatatcc	ctgattattt	gatgtactcg	420
acagtacgtg	gatcagataa	aaatttcaag	ataacgtgtc	caacaattga	cctgtataat	480
tggaacagc	ctgttcagtg	gtttaagaac	tgcaaaagtc	tccaagagcc	aaggttcagg	540
gcacacaggt	cctacttggt	cattgacaac	gtgactcatg	atgatgaagg	tgactacact	600
tgtcaattca	cacacgcgga	gaatggaacc	aactacatcg	tgacggccac	cagatcattc	660
acagttgaag	aaaaaggctt	ttctatgttt	ccagtaatta	caaactctcc	atacaaccac	720

-14-

acaatggaag	tggaaatagg	aaaaccagca	agtattgcct	gttcagcttg	ctttggcaaa	780
ggctctcact	tcttggctga	tgtcctgtgg	cagattaaca	aaacagtagt	tggaaatctt	840
ggtgaagcaa	gaattcaaga	agaggaaggt	cgaatgaaa	gttccagcaa	tgacatggat	900
tgtttaacct	cagtgttaag	gataactggt	gtgacagaaa	aggacctgtc	cctggaatat	960
gactgtctgg	ccctgaacct	tcatggcatg	ataaggcaca	ccataaggct	gagaaggaaa	1020
caaccaattg	atcacccaag	catctactac	atagttgctg	gatgtagttt	attgctaattg	1080
tttatcaatg	tcttggatg	agtcttaaaa	gtgttctgga	ttgaggttgc	tctgttctgg	1140
agagatatag	tgacacctta	caaaacccgg	aacgatggca	agctctacga	tgcgtagatc	1200
atctaccctc	gggtcttccg	gggcagcgcg	gogggaaccc	actctgtgga	gtactttgtt	1260
caccacactc	tgcccgacgt	tcttgaaaat	aaatgtggct	acaaattgtg	catttatggg	1320
agagacctgt	tacctgggca	agatgcagcc	acogtgggtg	aaagcagtat	ccagaatagc	1380
agaagacagg	tgtttgttct	ggccctcac	atgatgcaca	gcaagggaatt	tgccacagag	1440
caggagattg	ctctgcacag	cgccctcatc	cagaacaact	ccaagggtgat	tcttattgaa	1500
atggagcctc	tgggtgaggg	aagccgacta	cagggtgggg	acctgcaaga	ttctctccag	1560
catcttgtga	aaattcaggg	gaccatcaag	tggaggggaag	atcatgtggc	cgacaagcag	1620
tctctaagtt	ccaaattctg	gaagcatgtg	aggtaccaa	tgccagtggc	agaaagagcc	1680
tccaagacgg	catctgttgc	ggctccgttg	agtggcaagg	catgcttaga	cctgaaacac	1740
ttttgagttg	agagctgcgg	agtccagca	gtaggcaccg	gagtgcaggt	gtgcagactt	1800
gaaatgccaa	gggtgggggc	cccaagtctc	agctaaagag	caactctagt	ttattttcct	1860
ggttatggta	ggagccaccc	atcgtttgtt	tccggtttcc	ttttcctact	tcactcttgt	1920
ggcacaagat	caacctgag	ctttttcctt	ttcttttatt	tctctttttg	ttccttcttt	1980
taaaagcttt	ttaaaattga	ttatcttatt	tatctacctt	tcaaagggtta	tcccccttcc	2040
cgttgccccc	tctacaaatc	cccatcctgc	ttccctcctc	cctgcttcta	tgagggtgcc	2100
ccccacctg	cccatccact	ccagccttac	aggccttgtg	ttcccttatg	ctggggcatc	2160
gagcctccat	aagacctccc	ctctcattca	tcaattatct	acattctgaa	tatcaagccg	2220
acacttttgt	ttttgttttt	gattttttga	gacagggttt	ctctgtgtag	ccctggctgt	2280
cttgaaactc	acattgtaga	ccaggctggc	ctcgaactca	gaaatcagcc	tgccctgcc	2340
tccccgagtg	ctgggattaa	aggcgtgcgc	caccacgcgc	ggctaagcct	acactttcag	2400
aataaagttc	tgattcacct	caaagagcag	tctcattccc	agaggcagag	agccggaaaag	2460
agcctccaat	gtgcttgtcc	aggcagagct	gacctatttt	gcttaccagt	cacaggtaaa	2520
caaagcgttt	ctccgtgttg	cctcttgtag	acatccctgt	aatagattag	gaagggaatg	2580
agccgtccta	ctgaccagtt	tgtgaattgt	ggtagaaaaa	gcgttgacgt	ttgttaaata	2640
cttgtagca	atgtaaacct	cattcctaac	acaccagaat	ttcttacttt	ttattcgtca	2700
attaccgagt	tttgtcaagt	cagtattaac	agatttggtc	gaatacctta	cccaaattgc	2760
cattacagtc	gagcatgttt	tcagttctaa	atgcctttta	tatatttttt	attcttctta	2820
gaaatacttc	ctcactttaa	aagtaatgta	aagatgtgtt	agaaaacata	aggtgtaaga	2880
gaaagtatga	taaaatataa	aaaataatag	aaaggaaagg	aaatataatg	aaaatcataa	2940
ctcttaagat	taattttggg	aggtctgtat	tttaaaatat	aattaaattt	tataccgata	3000
acttttatag	ctgagattgt	acactacaga	ctaggcagct	tttcttattt	accaccataa	3060
tgaaaactgg	tggctgattt	ctttaacatt	cacagaagtt	ccaaatgtct	catttttagac	3120
tgtgctgcag	acttggtcgt	aagcagccag	aatgagaaac	aggtctgcca	tgtcacatcg	3180
ggacattttc	ctacttactg	aaatgtatct	gtcactgtgc	gacagctaac	ttttgtgata	3240
ctcctatgaa	atgtgtaggg	aatttggaca	gaacagaatc	aatctatagt	cagaggctct	3300
ctggacagtc	ttttccagga	gcacacacag	accgtgaggt	cctaggcacc	caggaaacgg	3360
atccagagcc	caggcaagtg	tcttacaggt	accttgaatt	ttgccaatag	atatgagccc	3420
tgccctagct	gagttgctca	gtcgggtgat	ggactccagg	ctgagggtgac	aatgaacaca	3480
gaatttggga	gactcttgaa	aggaggggaa	tgttgaactc	acggccaaca	tatgaggctg	3540
cagagaagcc	gtatgcagaa	gtgtgtgtag	aggatctaga	gtagcccgtt	tctctgggga	3600
cagtgtgctc	ttagtctgta	cccttaggct	gggttgccag	gtaaacattt	gctagtgttc	3660
agttcaaagg	ctgaagcttg	agctgagggg	gatgaggaat	tcaaacttcc	cctcgcatgc	3720
atccaccctg	tggttgcctg	gtttgtctaa	tccacctgct	ctgctgtagt	agaaggtttt	3780
gatcttctgc	agcttcatct	acttcttagt	gagttgccaa	aactgaccac	tgaaaagcat	3840
gctgtgtaca	taactgtctc	atgtcccaga	acgtgcaatc	aggaggaagt	cctcactccc	3900
gataacggaa	tccttgctct	gtggctgtga	ggacgtccct	tagcaacctc	agatagtaat	3960
ttttcttagg	ttgatggaa	catagtaacg	tgtctgattc	tttgctaact	gaaaatagaa	4020
gtattcggat	ttcagaaaaga	actggataaa	tattaatgtt	ggtgattatg	aaatctcatt	4080
gtgagccgtg	tgagtttgag	tgtgtattcc	atgattgtgc	tgaatgaaga	cctctaaaaa	4140
tgaaattctc	tccaatctca	tccctgggaa	tagttgcttc	ctcatgcctg	ctgctccatc	4200
catggaaaat	gactaaagag	aattattatt	tgttcccag	attcttctga	taagtctaaa	4260
ctatttgcac	gtaattgagc	tgggcagcat	ggcacacttg	ggaggcagag	gcagggtgat	4320
ctctgtgagt	ttgaggccag	cctgctctac	agagttagtt	ccaggacacc	agagctacaa	4380

-15-

aaagaaaacc	tgtcctaaca	acaacagcaa	cagctgcagc	agcaacaaca	acaacaaaga	4440
aaaagaagag	gaggaggagg	aaaggaaaga	aggaagaagg	aagaagaaag	ggaagaaata	4500
atagattttt	ctgtaatgaa	cacacatatg	ctttgatgct	tttgctaaac	tcaaaatatt	4560
agttttttt	tactgttttg	aaaggttcaa	agcatgatcc	atgtaaaaat	gtcttctgtg	4620
gggctttctc	ccatttctac	ttttgttccc	ctcatttctt	caaagtgcct	gtccaggcag	4680
agctgacctt	atttgcttac	cagttacagg	taaacaaagc	gtttcctcgt	gttgccctctt	4740
gtagccatct	ctgtattaga	ttaggaaggg	aaggagccgt	cctactgtcc	agtttgtgag	4800
ttctggtaga	aagagtgttg	aagtttgtaa	aatgcttggt	ttccatgtat	caaaatgtta	4860
tgcttttctt	atttattatt	gtatgacaaa	ttatttttca	ctgggcaaaa	ataattgtgc	4920
cattgactcc	ttgtgtgttt	tcttcattgt	tgtttgaaga	gttctaagctt	attaaaaaaa	4980
aaaatctag						4989

<210> 15  
 <211> 2681  
 <212> DNA  
 <213> Bos taurus

<220>  
 <221> mRNA  
 <222> (1)... (2681)  
 <223> Bovine vacuolar H<sup>+</sup>-ATPase

<400> 15						
gaattcggcc	gcgaggagac	aagatggcgc	tgcgggcgat	gcgggggac	gtgaacgggg	60
ccgcgcctga	gctaccagta	cccaccagcg	ggctggcggg	gtctcgagag	caggcgctgg	120
cagtgcgccc	aaactacctc	tcccagcctc	gtctcaccta	caagactgtc	tctggagtga	180
atggctccact	agtgatctta	gatcatgtaa	agtttcccag	atatgctgag	attgtccact	240
tgacattacc	agatggcaca	aaaagaagtg	ggcaagttct	agaagttagt	ggctccaaag	300
ctgtggttca	ggtatttgaa	ggaacatccg	gcatagatgc	caagaaaaca	tcctgtgagt	360
ttactggaga	tattctccgc	acaccagtgt	ctgaggatat	gcttgggtcga	gtattcaatg	420
gatcaggaaa	acccattgac	cgaggtcctg	tggtgttggc	cgaagacttc	cttgacatca	480
tgggtcagcc	aatcaaccct	cattttcgca	tctaccaga	agagatgatt	cagactggca	540
tttctgccat	cgacggcatg	aacagtattg	cgaggggaca	gaaaatcccc	atcttttctg	600
ctgccgggtt	accacacaac	gagattgcag	ctcagatctg	tcgccaggct	ggtttggtaa	660
agaaatccaa	agacgtggta	gactacagtg	aagaaaactt	tgccattgtg	tttgcgtcta	720
tgggagtaaa	catggaaaca	gcccggttct	tcaaatctga	ctttgaagaa	aatggctcaa	780
tggacaatgt	ctgccttttc	ttgaatctgg	ctaattgacc	aactatcgag	aggatcatca	840
ctcctgcctt	ggctctgacc	accgctgagt	ttctggctta	ccagtgtgag	aagcatgtcc	900
tggctcatct	gacagatatg	agttcttacg	ctgaagcact	tcgagagggt	tcagctgcca	960
gggaagagg	tccctggtcg	cgaggcttcc	ccggctacat	gtatacggat	ttagccacca	1020
tctatgaacg	cgctgggcga	gtggaaggta	gaaatggctc	tattacccaa	atccctattc	1080
tcaccatgcc	caatgatgat	atcactcatc	ctatccctga	cttgactggg	tatattactg	1140
agggccagat	ctatgtggac	agacagctgc	acaacagaca	gatttaccct	cctattaatg	1200
tgctgccctc	actctctcgg	ttaatgaagt	cagctattgg	agaaggaatg	accaggaagg	1260
atcatgctga	tgtgtctaac	cagttgtacg	catgctatgc	tatcggttaag	gatgtgcaag	1320
ccatgaaagc	tgtggtggga	gaagaagccc	tgacctcaga	tgacctcctt	tacttggaa	1380
ttctgcagaa	gtttgagaaa	aacttcatta	ctcagggctc	ctatgaaaat	cgaactgtct	1440
atgagacttt	ggacattggc	tggcagttgc	ttcgaatctt	cccaaagaa	atgctgaaga	1500
ggatccctca	gagtaccctg	agcgaatttt	accctcgaga	ctctgcaaag	cactagctgc	1560
tgctgccttg	gcggtctcgac	cctcttgtca	agtgtgtgtt	ctgtttgtct	attccttttg	1620
cactcctcca	tccacctgtg	tgtgggagtt	cacctgttac	cctgtaatta	aagacaaagg	1680
ctaggtaact	gttgtgccag	tgttcagcgt	ttaaactgct	aaccgattga	gagatccccg	1740
ctcagaacct	caccttctgt	gctgtcttta	aagtggcgga	ggtgaggctt	gcttaccggt	1800
gtatctattt	gtacatagtg	gagagctagt	tgcgaataat	gtcttgtttg	ggtctcccaa	1860
accctacctc	tcaactccct	taagagtatc	aactgttttg	aagttaaaat	gcttcagtct	1920
caaatttagg	ggcaagggtg	agactggaag	aattctcctt	tcagaagaac	catgaggctc	1980
gtggctgagc	tccctctgga	gtactagtgt	acctgtgggt	ctgtcctctg	ctctgtgcag	2040
atgggtttta	ctgtctgctt	gagttttctt	aggaaaagag	ttctgttctg	ccagtgtgc	2100
gagttgggat	tcctgtgtgg	ccatctttct	ctttgaggcc	taaagagtca	gcaccactgt	2160
gcagcggcat	tctcctgcag	gggtggcgtg	ccttgtgtct	atgacccac	tgggctgcag	2220
tcataggaga	actgagactt	ggaaaatgct	ggggcacagt	taagaaaacc	tacatccac	2280

-16-

cctcatcttg	tgtttatggt	ggcttaggtc	tctgcattgc	cctccagatc	ctgagggtggg	2340
gcatggagat	gacttgccct	aggtttgtgg	atgctttaaa	ctctgctcag	tcctcaagct	2400
ttctgactca	gctctccctt	ttctggttga	tcttgtggca	cgtgtagcaa	tgtttctttc	2460
attcctgccc	cttcctggct	tgagctctta	gctgtattct	gtgtgcctct	gccgtgtctg	2520
ctgtttgggt	ctctgtgctg	tgtgttctca	ggtgcagcca	taacttcccc	actccgagca	2580
ttccaccttc	cagttgtttt	tctctgaggg	gatggggggg	cggtcagcat	gattatatatt	2640
taatgtagaa	aatgtgacat	ctcgttataa	atgcggaatt	c		2681

&lt;210&gt; 16

&lt;211&gt; 2594

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; mRNA

&lt;222&gt; (1)...(2594)

<223> human vacuolar H<sup>+</sup>-ATPase

&lt;400&gt; 16

gaattccggg	gacagaggag	acaagatggc	gctgcggggc	atgcggggga	ttgtcaacgg	60
ggccgcaccc	gagctaccgc	tccccaccgg	tgggcccggc	gtgggatctc	gggagcaggc	120
gctggcagtc	agtcggaact	acctctccca	gcctcgccctc	acatacaaga	cagtatctgg	180
agtcaatggt	ccactagtga	tcttagatca	tgtttaagttt	cccaggatg	ctgaaattgt	240
ccatttgacc	ttaccggatg	gcacaaagag	aagtgggcaa	gttctggaag	ttagtggttc	300
caaggcagta	gttcagggtat	ttgaagggac	ttcagggtata	gatgctaaga	aaacgtcctg	360
tgagtttact	ggggatatct	tccgaacacc	gggtgcttag	gatatgcttg	gtcgggtatt	420
caatggatcg	ggaaaaccca	ttgacagagg	tcctgtttgta	ctggccgaag	acttccttga	480
tatcatgggt	gacccaatca	acctcaatg	tcgaatctac	ccagaggaaa	tgattcagac	540
tggcatttgc	gccatcgatg	ggatgaacag	tattgctagg	gggcagaaaa	ttcctatctt	600
ctctgctgct	gggctaccac	acaatgagat	tgacgctcag	atctgtcgcc	aggctggttt	660
ggtaaagaaa	tccaaagatg	tagtagacta	cagtggaggaa	aattttgcaa	ttgtatttgc	720
tgctatgggt	gtaaacatgg	aaactgcccg	gttcttcaaa	tctgactttg	aagaaaatgg	780
ctcaatggac	aatgtctgcc	tctttttgaa	cttggctaata	gacccaacca	ttgagcgaat	840
tatcactcct	cgcttggtc	taaccacagc	tgaatttctg	gcgtaccaat	gtgagaaaca	900
tgtattgggt	attctaacag	acatgagttc	ttatgctgaa	gcacttcgag	aggtttcagc	960
agccagggaa	gaggtagctg	gtcgacgagg	ttttccagg	tacatgtata	cagatttagc	1020
cacgatata	gaacgcgctg	ggcgagtggg	agggagaaa	ggctcgatta	ctcaaatccc	1080
tattctaacc	atgcctaata	atgatatac	tcaccccatc	ccagacttga	ctggctacat	1140
tacagagggg	cagatctatg	tggacagaca	gctgcacaac	agacagattt	atccacctat	1200
caatgtgctg	ccctcactat	cacggttaat	gaagtctgtc	attggagaag	ggatgaccag	1260
gaaggatcat	cccgatgtat	ctaaccagct	atatcgctgc	tatgctattg	gaaaggatgt	1320
gcaagccatg	aaagctgtcg	ttggagaaga	agcccttacc	tcagatgatc	ttctctactt	1380
ggaattttctg	cagaagtttg	agaggaaactt	cattgctcag	ggtccttacg	aaaatcgcac	1440
tgtctttgag	actttggaca	ttggctggca	gctactccga	atcttcccca	aagaaatgct	1500
gaagagaatc	cctcagagca	ccctcagcga	attttaccct	cgagactctg	caaagcatta	1560
gctgctgctt	ctgcattgct	ccgcgctctt	gtgaaatact	ggttctgttt	tctttattcc	1620
ttttgcactc	toggttccca	cctttgtgtt	ggagtttacc	atgttaccct	gtaattaaaa	1680
acaaagaata	ggtaacatat	tgtgccagtg	ttgcaacggt	ttaaactgct	aacagacctt	1740
aaaatatccc	cctacctggg	tcctcagtcg	tatgtttaaa	gtgctgcagg	gatggagtgg	1800
cgttttctta	ttgctgtatg	tattgtacat	agtggagtag	ttagttacct	gataacagtc	1860
ttgttatttg	ggtctcttag	accttacctc	tcaactccct	caagagtacc	agtctctgaa	1920
gttataatgc	tttgggtctt	acattagggg	caagatccag	tctgagagaa	gtctcctttg	1980
agaagggcca	agaggctctt	tcctgagtgt	ttgctttcgg	tttggttgga	tgccgtgatt	2040
gctgggctgt	gctgctgctc	gaagcagatg	gttttgactg	tctttttgct	ctttcctata	2100
taatgaatag	atgagtga	ggagttttct	ttttctcttt	agtacttacg	tattgggatt	2160
cctgtgtctt	acagctctcc	ctctccaaat	aatacacaga	atcctgcaac	tttttgcaca	2220
gctgggtatc	ctctggtagc	agtgagaccc	cttgtcttgg	tgatccttac	tgggtttcca	2280
agcagaggag	tcacatgatt	acaattgccg	gttaggttgg	tggttggggg	acaagatgag	2340
aagaaagaaa	aacctacagc	ctttctacat	tctgacatgc	taacagtggg	tttaagttct	2400
aaagtgttta	ccagatgctg	aaggcaaggg	gagggagcag	aagcacttat	gtttacggat	2460
attttaaaact	ctgttagaga	gcagcctttg	aaaatcccca	atttggttct	gctttttgac	2520



-17-

ctctctctac cttttcaggg taatctttgt ggcacaaacg atagcatttc caagcttttag 2580  
agttttctga attc 2594

<210> 17  
<211> 1536  
<212> DNA  
<213> Mus musculus

<220>  
<221> mRNA  
<222> (1)...(1536)  
<223> mouse vacuolar H<sup>+</sup>-ATPase

<400> 17  
atggcggttgc gagegatgcg gggaatcgtg aacggggccg caccgaact gcccggtgcc 60  
accgcgtccgc cgatggccgg agctcgggag caggcgctgg cgggtgggccc gaactacctt 120  
tcccagcctc gtctcaccta caagactgtc tctgggggtga atgggtccact agtgatccta 180  
gatcatgtga agtttcccag atacgctgag attgtccact tgacattacc agatggcaca 240  
aagagaagtg gggcaagtct agaagttagt ggctccaaag cagtggttca ggtatttgaa 300  
gggacatctg gtatagacgc caagaaaaca tcctgtgagt ttactggaga tattctccga 360  
acaccagtgt ctgaggatat gottgggtcgg gtattcaacg gatcaggaaa acccattgac 420  
cgaggccctg tgggtgctggc tgaagacttc cttgacatca tgggtcagcc aatcaaccct 480  
cagtgtcggg tctatccaga agagatgatt cagacgggca tttccgccat cgatggcatg 540  
aacagtattg ctagggggaca gaaaatcccg atcttttctg ctgctggatt acccataac 600  
gagattgcag ctcatagctg tcgccaggct ggtttggtaa agaaatccaa agatgtagtg 660  
gactatagtg aagaaaattt tgccattgtg tttgctgcta tgggagtaaa catggaaaca 720  
gcccggttct ttaaattctga ctttgaagaa aatggctcaa tggacaatgt ctgcctgttt 780  
ttgatcttgc ctaatgacct aaccattgag cggatcatca ctccctgcct ggctctgacc 840  
acggccgagt ttctggcata tcagtgtgag aagcacgtgc tgggtgatcct gacggacacg 900  
agctcctatc ccgaagcgct tcgagagggt tcagctgcca ggaagagggt ccctggtcgg 960  
cgaggcttcc caggctacat gtataccgac ttagccacaa tctatgaacg tgccggtcga 1020  
gtggaaggta gaaacggctc tattacccaa atccctattc tcaccatgcc caatgacgat 1080  
atcactcatc ccatccctga cttgactggg tacattactg agggccagat ctatgtggac 1140  
agacagctgc acaacagaca gatttacctt cctattaatg tgctgccctc actctctcgg 1200  
ttaatgaagt cacctatcgg agaaggaatg accagaaagg atcacgctga tgtgtctaac 1260  
cagttgtatg cgtgctatgc catcggttaag gacgtgcaag ccatgaaagc cgtggtggga 1320  
gaggaagccc tgacctcgga tgatctgctt tacctggaat ttctgcagaa gtttgagaag 1380  
aacttcatta ctcagggtcc ctatgaaaac cgaactgttt atgagacttt ggacattggc 1440  
tggcagttgc ttcgaaattt ccccaaagaa atgctgaaga gaatccctca gagcaccctg 1500  
agcgaatttt accctcgaga ctctgcaaag cactag 1536

<210> 18  
<211> 2820  
<212> DNA  
<213> Homo Sapiens

<220>  
<221> mRNA  
<222> (1)...(2820)  
<223> human vacuolar H<sup>+</sup>-ATPase (56,000 subunit -H057)

<400> 18  
aagatggcgc tgcgggagat gcgggggatt gtcaacgggg ccgcacccga gctaccctg 60  
cccaccggtg ggccggcggt gggagctcgg gagcaggcgc tggcagtcag tcggaactac 120  
ctctcccagc ctgcctcac atacaagaca gtatctggag tcaatggtcc actagtgate 180  
ttagatcatg ttaagtttcc caggatgtct gaaattgtcc atttgacctt accggatggc 240  
acaaagagaa gtgggcaagt tctggaagt agtggttcca aggcagtagt tcaggatatt 300  
gaagggactt cagggtataga tgctaagaaa acgtcctgtg agtttactgg ggatattctc 360  
cgaacaccgg tgtctgagga tatgcttggt cgggtattca atggatcggg aaaaccatt 420  
gacagaggtc ctgttgtact ggccgaagac ttcttgata tcatgggtca gccaatcaac 480  
cctcaatgtc gaattctacc agaggaaatg attcagactg gcatttcggc catcgatggg 540

-18-

atgaacagta	ttgctagggg	gcagaaaatt	cctatcttct	ctgctgctgg	gctaccacac	600
aatgagattg	cagctcagat	ctgtcgccag	gctggtttgg	taaagaaatc	caaagatgta	660
gtagactaca	gtgaggaaaa	ttttgcaatt	gtatttgctg	ctatgggtgt	aaacatggaa	720
actgcccggt	tcttcaaata	tgactttgaa	gaaaatggct	caatggacaa	tgtctgcctc	780
tttttgaact	tggtaatga	cccaaccatt	gagcgaatta	tcactcctcg	cctggctcta	840
accacagctg	aattttctggc	gtaccaatgt	gagaaacatg	tattggttat	tctaacagac	900
atgagttctt	atgctgaagc	acttcgagag	gtttcagcag	ccaggggaaga	ggtacctggg	960
cgacgagggt	ttccagggtta	catgtatata	gatttagcca	cgatatatga	acgcgctggg	1020
cgagtggaag	ggagaaacgg	ctcgattact	caaatacccta	ttctaaccat	gcctaattgat	1080
gatatcactc	accccatccc	agacttgact	ggctacatta	cagaggggct	gatctatgtg	1140
gcagacagc	tgcacaacag	acagatttat	ccacctatca	atgtgctgcc	ctcactatca	1200
cggttaatga	agtctgctat	tggagaaggg	atgaccagga	aggatcatgc	cgatgtatct	1260
aaccagctat	atgctgtgta	tgtatttgga	aaggatgtgc	aagccatgaa	agctgtcgtt	1320
ggagaagaag	cccttacctc	agatgatctt	ctctacttgg	aattttctgca	gaagtttgag	1380
aggaacttca	ttgctcaggg	tccttacgaa	aatcgcactg	tctttgagac	tttgacatt	1440
ggctggcagc	tactccgaat	cttcccaaaa	gaaatgctga	agagaatccc	tcagagcacc	1500
ctcagcgaat	tttaccctcg	agactctgca	aagcattagc	tgctgcttct	gcattgctcc	1560
gcgctcttgt	gaaatactgg	ttctgttttc	tttattcctt	ttgcaactct	ggttcccacc	1620
tttgtgttgg	agttttaccat	gttaccctgt	aattaaaaac	aaagaatagg	taacatattg	1680
tgccagtgtt	gcaacgtttt	aaactgctaa	cagaccttaa	aatatccccc	tacctgggtc	1740
ctcagtgtta	tgtttaaagt	gctgcaggga	tggagtggcg	ttttcttatt	gctgtatgta	1800
ttgtacatag	tggagttagt	agttacctga	taacagtctt	gttatttggg	tctcttagac	1860
cttacctctc	aactccctca	agagtaccag	tctctgaagt	tataatgctt	tggtctctac	1920
attagggaca	agatccagtc	tgagagaagt	ctcctttgag	aagggccaaag	aggctctttc	1980
ctgagtgttt	cgtttcgggt	gttgggtatgc	ctgtattgct	gggctgtgct	gctgctcgaa	2040
gcagatgggt	ttgactgtct	ttttgctctt	tcctatataa	tgaatagatg	agtgaaggga	2100
gttttctttt	tctctttagt	acttacgtat	tgggattcct	gtgtcttaca	gctctccctc	2160
tccaaataat	acacagaatc	ctgcaacttt	ttgcacagct	ggtatctgtc	tggtagcagt	2220
gagaccctt	gtcttgggtga	tccttactgg	gtttccaagc	agaggagtca	catgattaca	2280
attgccagta	gagttgttgt	ttgggttaca	agatgagaag	aaagaaaaac	ctacagcctt	2340
tctacattct	gacatgctaa	cagtgggtta	agtttctaaa	gtgtttacca	gatgctgaag	2400
gcaaggggag	ggagcagaag	cacttatgtt	tacggatatt	ttaaactctg	ttagagagca	2460
gcctttgaaa	atccccaatt	tgggtctgct	ttttgacctc	tctctacctt	ttcagggtaa	2520
tctttgtggc	acaaacgata	gcatttccaa	gcttttagagt	tttctgaatt	cctgcgcctt	2580
cctgacgtga	gccctgagcg	atcttctatg	cagttctgcc	atgcgtcctg	ttggtctctc	2640
tgtgttcttt	gttacttggg	tgcaatagca	acttccctac	cccgtgcatt	ccatctttca	2700
tgttgtgtaa	agttcttcac	ttttttctct	gagggctggg	ggttggggga	gtcagcatga	2760
ttatatttta	atgtagaaaa	aatgtgacat	ctggatataa	aatgaaaata	aatgttaaat	2820

&lt;210&gt; 19

&lt;211&gt; 2457

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; mRNA

&lt;222&gt; (1)...(2457)

<223> human vacuolar H<sup>+</sup>-ATPase B subunit

&lt;400&gt; 19

gatgctaaga	aaacgtcctg	tgagtttact	ggggatatto	tccgaacacc	agtgtctgag	60
gatatgcttg	gtcgggtatt	caatggatcg	ggaaaaccca	ttgacagagg	tcctgtttgta	120
ctggctgaag	acttccttga	tatcatgggt	cagccaatca	acctcaatg	tcgaatctac	180
ccagaggaaa	tgattcagac	tggcatttca	gccatcgatg	gaatgaacag	tattgccagg	240
gggcagaaaa	ttcctatctt	ctctgctgct	gggctaccac	acaatgagat	tcgagctcag	300
atctgtcgcc	aggctgggtt	ggtaaagaaa	tccaagatg	tagtagacta	cagtagggaa	360
aattttgcaa	ttgtatttgc	tgctatgggt	gtaaactatg	aaaccgccc	attcttcaaa	420
tctgactttg	aagaaaaatg	ctcaatggac	aatgtctgcc	tctttttgaa	cttggcgaat	480
gaaccaacca	ttgagcgaat	tatcactcct	cgctggctc	taaccacagc	tgaatttctg	540
gcataccaat	gtgagaaaca	cgtaactggt	atcctcacag	acatgagttc	ttacgctgaa	600
gcacttcgag	aggtttcagc	agccagggaa	gaggttcctg	gtcgacgagg	cttcccagg	660

-19-

tacatgtata	cagatttagc	cacaatatat	gaacgcgctg	ggcgagtgga	agggagaaac	720
ggctcgatta	ctcaaatccc	tattcttacc	atgcctaattg	atgatatac	tcacccaatc	780
ccggacttga	ctggctacat	tacagagggg	cagatctatg	tggacagaca	gctacacaac	840
agacagattt	atccacctat	caatgtgcta	ccgtcactat	cacggttaat	gaagtctgct	900
attggagaag	ggatgaccag	gaaggatcat	gccgatgtat	ctaaccagct	gtatcgcgcg	960
tatgctattg	ggaaggatgt	acaagccgtg	aaagctgtcg	ttggagaaga	agcccttacc	1020
tcagatgac	ttctctactt	ggaatttctg	cagaagtttg	agaggaaactt	tattgctcag	1080
ggtccttacg	aaaatcgcac	tgtctttgag	actttggaca	ttggctggca	gctgctccga	1140
atcttcccca	aagaaatgct	gaagagaatc	cctcagagca	ccctcagcga	attttaccct	1200
cgagactctg	cgaacgatta	gctgccgctt	ctgcactgct	ccacactctt	gtgaaatact	1260
ggttctatatt	tctttattcc	ttttgcgctc	cccaatcccc	acctttgtgt	tggagtttac	1320
tgtgttacc	tgtaattaaa	aacaaagaat	aggtaacata	ttgtgccagt	gttgcaacgt	1380
tttaaactgc	taacagacct	taaaatattc	cgttcagaaa	acctgggtcc	tcagtgtctat	1440
gtttaaagta	gctgcaggga	tggagtggcg	ttttcctatt	gctgtatgta	ttgtacatag	1500
cggagtagtt	agttacctga	taacggtctc	attatttggg	cctcttagac	cttacctctc	1560
aactccctca	agagtaccag	tctctgaagt	tataatgctt	tggctctctac	attaggggca	1620
agatccggtc	taaaagaagt	ctcctttgag	aagggccaaag	aggtctttcc	tgagtgtatg	1680
ctttcgggtt	gttgggtatgc	ctgtgttgct	gggctgtact	gatactcgaa	gcagatgggt	1740
ttaactgtgt	acttactctt	actgtataat	gaatagatga	gtgaaagcag	ttttcttttt	1800
ctcttttagta	catatgtatt	gggattcctg	tgtcttacag	ctctccctct	cctaaataat	1860
acacagaatc	ctgcaacttt	tgacagcgg	tgtctgtcag	gtagcagtga	ggccccttgt	1920
cttggtgac	cttactggat	ttccaagcag	aggagtcacg	tgattaaaaat	cgctaataga	1980
gttgttgttt	gggggacaag	ataagaagaa	aggaaaaacc	tacagccttt	ctacattctg	2040
acataactaac	agtggtttca	gtttctaaag	cgtttaccag	atgcgaaggc	aagggtgggga	2100
gcaaacgcac	ttatgtttac	ggatatttta	aactctgtta	gagagcagcc	tttgaaaatc	2160
ccgaattttg	ttctactttt	tgacctctct	ctaccttttc	agggtaatct	ttgtggcaca	2220
aacaatagca	tttccaagct	ttagagttct	ctgaattcct	gcgccttcct	gaacgtgagc	2280
cctgagcgat	cttctatgca	gttctgccat	gtgtcctgtt	tggctctctct	gtgttctttg	2340
ttacttgtgc	aatagcgact	tccctactcc	gtgcattcca	tctttcatgt	tgtgtaaagt	2400
tcttcacttt	tttctttgag	ggggtggggg	tgggggggag	tcagcatgat	tatattt	2457

&lt;210&gt; 20

&lt;211&gt; 2676

&lt;212&gt; DNA

&lt;213&gt; Bos taurus

&lt;220&gt;

&lt;221&gt; mRNA

&lt;222&gt; (1)...(2676)

<223> bovine vacuolar H<sup>+</sup>-ATPase B subunit

&lt;400&gt; 20

aagatggcgc	tgcgggagat	gcgggggagc	gtgaacgggg	ccgcgcctga	gctaccagta	60
cccaccagcg	ggccctggc	ggggtctcga	gagcaggcgc	tggcagttag	ccggaactac	120
ctctcccage	ctcgtctcac	gtacaagaca	gtatcaggag	ttaatgggtcc	actagtgtac	180
ttagaccatg	ttaagtttcc	cagatatgct	gagattgtgc	acttaacact	acctgacggg	240
acgaagcgga	ctgggcaagt	tctagaagtt	agtggttcca	aagctgtggt	tcaggatattt	300
gaagggaactt	caggatatga	tgccaagaaa	acgtcctgtg	agtttactgg	ggatattctc	360
cgaacgccag	tgtctgagga	tatgcttggt	cgggtattca	atggatcagg	aaaacccatt	420
gacagaggtc	ctggtgtcct	ggctgaagac	ttccttgaca	tcatgggcca	gccaatcaac	480
cctcaatgtc	gaatctatcc	agaggagatg	attcagactg	gcatttcggc	catagatggc	540
atgaacagta	tgcctcgggg	gcagaagatt	cctatcttct	ctgctgctgg	cttaccgcac	600
aatgagattg	cagctcaaat	ctgtcgccag	gctggtttgg	taaaaaagtc	caaagatgta	660
gtggactaca	gtgaggaaaa	ttttgcgatt	gtatttgcgt	ctatgggtgt	aaacatggaa	720
actgcccggt	tcttcaaatc	tgactttgag	gaaaatggct	caatggacaa	tgtctgcctg	780
tttttgaact	tggctaata	cccaactatt	gagcgaatta	tcactcctcg	attggctcta	840
accacggcgc	agttcctggc	ctatcagtgt	gagaaacatg	tattggttat	cctaacagac	900
atgagttctt	atgctgaagc	acttcagagag	gtttcagcag	ccagggaaga	ggttcctggg	960
cgacgaggtt	tcccagggtta	catgtatata	gatttagcca	caatatatga	acgtgctggg	1020
cgagtggaa	gtcgaaatgg	ctctattact	caaattccta	ttctcaccat	gcctaacgat	1080
gatatactc	acccaatccc	tgacttgact	ggatatatta	cagaggggca	gatctatgtg	1140

-20-

gacagacagc	tacacaacag	acagatttat	ccaccaatta	atgtgctgcc	ctccttgtcg	1200
cggttgatga	agtctgctat	tggagaaggc	atgaccagaa	aggatcacgc	cgatgtgtct	1260
aaccagctgt	atgctgtcta	tgctattggg	aaggatgtac	aagccatgaa	agctgtcggt	1320
ggagaagaag	ctcttacctc	agatgatctt	ctttacttgg	aatttctgca	gaagtttgag	1380
aggaacttta	ttgctcaggg	tccttatgaa	aaccgcaactg	tgtatgagac	tttggacatt	1440
ggctggcaac	tgctccgaat	cttcccaaaa	gaaatgctga	agaggatccc	tcagagcacc	1500
ctgagcgaat	tctaccctcg	agactctgcg	aacagtttagc	tgctacttca	tcgctggctc	1560
gatgctcttg	tgaagtactg	gttctatttt	ctttattcct	ttttgcactc	ccccatcccc	1620
acctttgtgt	tggagtttac	tgtgttacct	tgtaattaaa	aacaaagact	aggtaacata	1680
ctgtgccagt	gttgcaatgt	tttaaaactgc	taacagactt	taaaatatcc	cctgtttaga	1740
aaaaccttgg	atccttccaa	cgctttcttc	aaagcagctg	agagttggag	gtggagtttt	1800
tcatcaatgt	gtgtatttgt	acatagtggg	gtaccttact	gcctagtgtc	ctcattattg	1860
gggtctctta	gcccttgcc	ctccaccctg	gcaatagtat	cactatctga	agttacagtg	1920
ttttgggtctc	cagctagggg	caagagaggg	gtctgaaagc	acttctcaga	gccaaagggc	1980
tttctgaggt	gctggtttta	gattttggta	tgctcaggg	tctgtgccgc	tgctctcacg	2040
agatggtttt	tactgccgc	ctgctctttc	ctgtctaata	gatagactag	aaaaggagtt	2100
ccatttctctc	tttgggtacg	attagcttca	acctccatgt	cttactgtct	ttcctcccta	2160
tgataacaca	gaatcatgcc	acttttgccc	tgctggcaat	cgctctgagc	agcaagatgc	2220
cctgtggtaa	tgatccttac	tgggtttcct	tgcaagaaga	tcattcattac	aataattaat	2280
agaactttgc	ttggaaagag	ttgggataca	attgtttaag	agttaaaaaa	aaaatccttt	2340
ctacacttgg	acgtgccaac	agtgttttta	agtttctaga	atgttgacca	gatgctagaa	2400
aggcaagtgg	ggaagagaaa	gcacttctgt	ttatggattt	tttaatttaa	tgtatggata	2460
ttttaaaactc	tgtagacag	tagcctttgg	gaaatcccca	ttgggtcctg	cttttcaacc	2520
tctttgtctt	tcagggtagt	tcttgtggca	caagtgcag	cattaaaagc	ttttagcctt	2580
tttaattcctc	ctccttctctg	ctgcgagccc	tgagctgtct	tctatgcact	tctgacgtgt	2640
ctcctgttgg	gtctctgtgt	tctttgttcc	ttgccg			2676

&lt;210&gt; 21

&lt;211&gt; 3035

&lt;212&gt; DNA

&lt;213&gt; Gallus gallus

&lt;220&gt;

&lt;221&gt; mRNA

&lt;222&gt; (1)... (3035)

<223> gallus vacuolar H<sup>+</sup>-ATPase

&lt;400&gt; 21

cgggcgatgg	tgaacggcgc	cgggcccgcc	ggggcgcgcg	agcaggcggc	ggcgctgacg	60
cgggactttc	tgtcccagcc	ggcctcact	tataaaaccg	tgtctggtgt	gaatggcccc	120
ctggttatct	tggatcaagt	gaagtttctt	aggtagcgcg	agattgtcca	cttgactctt	180
cctgatggca	ccagaagaag	tgggcaggtt	ctggaagtca	gtggctccaa	agctgtgggt	240
caggtatttg	agggcacttc	aggtattgat	gctaagaaaa	catcctgtga	gtttactggg	300
gacattcttc	gaacccctgt	ctctgaagat	atgcttggca	gagtatttaa	tggatcagga	360
aaacccatag	acagaggccc	cgctgttttg	gctgaagact	tcctggatat	aatgggtcag	420
ccaatcaatc	cccagtgtcg	aatctatcca	gaagagatga	ttcagactgg	catttctgca	480
atagacggta	tgaacagcat	tgccaggggg	cagaaaatcc	ccatattctc	tgctgtgggt	540
ttgccccaca	atgagattgc	agctcagatc	tgtcgccagg	ctggcttggg	gaagaaatcc	600
aaagatgtga	tggattacag	tgaagaaaat	tttgccatcg	tgtttgctgc	tatgggtgtg	660
aacatggaaa	ctgctcggtt	cttcaaatca	gactttgagg	aaaatgggtc	catggacaac	720
gtgtgtctgt	tcttgaattt	ggccaatgac	ccaaccattg	aacgcattat	cacacctcgt	780
ctggctctaa	caacggcaga	gttcttggca	tatcagtgtg	agaagcatgt	gctggtcatt	840
ctgacagata	tgagctccta	tgtggaagct	ctacgagagg	tctcagcagc	tagagaggag	900
gtacctggcc	gtcgtggttt	cccaggttac	atgtacactg	acttggctac	tatatatgaa	960
cgtgctgggc	gtgtggaagg	cagaaatggc	tcaattactc	agattcccat	tcttaccatg	1020
cccaatgatg	atattactca	tcctatccct	gacttgactg	gatacatcac	tgagggacaa	1080
atctatgttc	ataggcagct	gcacaacaga	cagatttacc	cacctattaa	tgtactgccc	1140
tccttgtctc	gactgatgaa	gtcagctatt	ggagagggga	tgaccaggaa	ggatcatgca	1200
gatgtatcca	accaactgta	tgccctgctat	gctattggga	aggacgtgca	ggccatgaag	1260
gctgtagtgt	gtgaggaagc	tcttacctca	gatgatcttc	tttatctgga	gtttctgcag	1320
aagtttgaga	agaacttcat	tgctcagggg	ccttatgaaa	atcgtactgt	ttacgagacc	1380

-21-

ttggacattg	gatggcagct	tttgcgaatc	ttccccaagg	agatgttgaa	gagaattccc	1440
caaacaacac	tggctgaatt	ctatcctcga	gattcgactg	caaaacacta	accacaactt	1500
cgtctccaac	cccttgctct	gtgaaatgct	gtttgttttc	cttttttcat	gtgttgatgt	1560
ttacttgctg	cccttacgat	taaaaccaag	aataggtgac	atttgtgcca	gtgttccaat	1620
gtacactgat	accagttctt	aaaatagccc	ttcttctaaa	gcctggatct	tcaggaagac	1680
ctttaggcca	gctcttacat	atgtgcaata	gctattgtta	agcttttctt	tttgtttgaa	1740
ctggaccttt	tataggcatt	tcaaatgaat	gtcagaggat	taccagaaac	tgcaaatctt	1800
taattccaaa	ccaggagcat	gtgggttaga	aagactaaat	gtgacttaat	gtccaaagca	1860
tctgctcatt	ttgatcacgt	gcagttgcct	tgctgctggt	agaacagatg	gctctctgct	1920
gtcctgctgc	tgtgcctgaa	gaccaggcta	acatgtgcaa	agtgtggtgc	acaatgtcat	1980
atctctaaaa	aatgcaagtc	actgatttaa	ctgtggttta	aaattcttaa	aggcgtgtat	2040
gaactaagga	cactagttag	catgctaagt	gcttttctgc	tagcaaggtc	tcagtgcaga	2100
ggcacaggc	cagtgggttg	cttacctgaa	ggcagcgtgt	tatggctcag	tggctgaatt	2160
aaaggtccaa	attgtacctt	gaagcttgca	aagaaagatt	cctacttaac	ttttcttttt	2220
cattgtggaa	atgccagaga	cgtgtgacag	cagctgaagc	gctctgagat	cagtagtgct	2280
agtaggttaa	gactggctaa	ttcaaggctc	catgctgcta	ttgaagggga	tgatatgaga	2340
tgtaaagaaa	acctctttat	gcgagacaca	attgtactgg	tgggagggtca	gcttttaaaa	2400
tgcgttggac	taaacaatgc	aacagcagaa	agcaacctaa	tgcatgaaag	gatattgaat	2460
tctgctacaa	agcgtgctgt	aggtggcget	gggtcctggg	tcgtgttcag	agctcttgctg	2520
gtttgcactc	caggcacaga	tttggctagc	caggagagct	cagcattccc	tatcactgcg	2580
aacttggcta	gcctcttcag	tgttatttct	tacttttaaac	tggttcagac	gaggctcaga	2640
gcccagtgtc	ggcaggcttg	ctggcctttt	tttttttccc	aggcttaatg	taatcttatc	2700
tctggtctag	ctcaccaaag	catgttgcac	ctctctgaac	gccttcagtg	cttgtctagg	2760
aaggtgctaa	cgtgactcaa	aggatagcgt	gctaattcca	gctttccctg	atgtttcctg	2820
tgtgcagttc	tatgggtttg	ttcagtgttc	tctgtaactt	ggacacaata	gtaactttat	2880
tccagtgcac	tccactctaa	agctgtgtca	agtctatttt	tttctcttga	ggtaggaatg	2940
ggaggctgca	agtgttggca	tgagaatact	ttaatgtaga	gaatatctaa	ataaattaaa	3000
tatgaaaggt	gttgaacaaa	aaaaaaaaaa	aaaaa			3035

&lt;210&gt; 22

&lt;211&gt; 1737

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; mRNA

&lt;222&gt; (1) ... (1737)

&lt;223&gt; human CD44R

&lt;400&gt; 22

ccagcctctg	ccaggttctg	tccgccatcc	togtcccgtc	ctccgcgggc	ccctgccccg	60
cgcccaggga	tcctccagct	cctttcgccc	gcgccctcgg	ttcgctccgg	acaccatgga	120
caagtttttg	tggcacgcag	cctggggact	ctgcctcgtg	ccgctgagcc	tggcgcagat	180
cgatttgaat	ataacctgcc	gctttgcagg	tgtattccac	gtggagaaaa	atggctcgcta	240
cagcatctct	cggacggagg	ccgctgacct	ctgcaaggct	ttcaatagca	ccttgcccac	300
aatggcccag	atggagaaag	ctctgagcat	oggatttgag	acctgcaggt	atgggttcat	360
agaagggcac	gtggtgatcc	cccggatcca	ccccaaactcc	atctgtgcag	caaacaacac	420
aggggtgtac	atcctcacat	ccaacacctc	ccagtatgac	acatattgct	tcaatgcttc	480
agctccacct	gaagaagatt	gtacatcagt	cacagacctg	cccaatgcct	ttgatggacc	540
aattaccata	actattgtta	accgtgatgg	cacccgctat	gtccagaaag	gagaatacag	600
aacgaatcct	gaagacatct	accccagcaa	cctactgat	gatgacgtga	gcagcggctc	660
ctccagtgaa	aggagcagca	cttcaggagg	ttacatcttt	tacacctttt	ctactgtaca	720
ccccatccca	gacgaagaca	gtccctggat	cacgcacagc	acagacagaa	tccctgctac	780
caatatggac	tccagtcata	gtacaacgct	tcagcctact	gcaaattccaa	acacaggttt	840
ggtggaagat	ttggacagga	caggacctct	ttcaatgaca	acgcagcaga	gtaattctca	900
gagcttctct	acatcacatg	aaggcttgga	agaagataaa	gaccatccaa	caacttctac	960
tctgacatca	agcaatagga	atgatgtcac	aggtggaaga	agagacccaa	atcattctga	1020
aggtccaact	actttactgg	aaggttatac	ctctcattac	ccacacacga	aggaaagcag	1080
gaccttcac	ccagtgaact	cagctaagac	tgggtccttt	ggagttactg	cagttactgt	1140
tggagattcc	aactctaattg	tcaatcgttc	cttatcagga	gaccaagaca	cattccaccc	1200
cagtgggggg	tcccatacca	ctcatggatc	tgaatcagat	ggacactcac	atgggagtc	1260

-22-

agaaggtgga	gcaaacacaa	cctctggtcc	tataaggaca	ccocaaattc	cagaatggct	1320
gatcatcttg	gcatccctct	tgcccttggc	tttgattctt	gcagtttgca	ttgcagtcaa	1380
cagtcgaaga	aggtgtgggc	agaagaaaa	gctagtgate	aacagtggca	atggagctgt	1440
ggaggacaga	aagccaagtg	gactcaacgg	agaggccagc	aagtctcagg	aaatgggtgca	1500
tttggtgaac	aaggagtctg	cagaaactcc	agaccagttt	atgacagctg	atgagacaag	1560
gaacctgcag	aatgtggaca	tgaagattgg	ggtgtaacac	ctacaccatt	atcttggaaa	1620
gaaacaaccg	ttggaaacat	aaccattaca	gggagctggg	acacttaaca	gatgcaatgt	1680
gctactgatt	gttttcattgc	gaatcttttt	tagcataaaa	ttttctactc	tttttaa	1737

<210> 23  
 <211> 1297  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> mRNA  
 <222> (1)...(1297)  
 <223> human CD44

<400> 23						
cctgccccgc	gcccagggat	cctccagctc	ctttcgcccc	cgccctccgt	tcgctccgga	60
caccatggac	aagtttttgt	ggcacgcagc	ctggggactc	tgccctcgtc	cgctgagcct	120
ggcgcatatc	gatttgaata	tgacctgccg	ctttgcaggt	gtattccacg	tgagagaaaa	180
tggtcgctac	agcatctctc	ggacggaggc	cgctgacctc	tgcaaggcct	tcaatagcac	240
cttgccccca	atggcccaga	tgagaaaagc	tctgagcatc	ggatttgaga	cctgcaggta	300
tgggttcata	gaagggcacg	tggtgattcc	cggatccac	cccaactcca	tctgtgcagc	360
aaacaacaca	ggggtgtaca	tcctcacatc	caacacctcc	cagtatgaca	catattgctt	420
caatgcttca	gctccacctg	aagaagattg	tacatcagtc	acagacctgc	ccaatgcctt	480
tgatggacca	attaccataa	ctattgttaa	ccgtgatggc	acccgctatg	tccagaaagg	540
agaatacaga	acgaatcctg	aagacatcta	ccccagcaac	cctactgatg	atgacgtgag	600
cagcggtctc	tccagtgaag	ggagcagcac	ttcaggaggt	tacatctttt	acaccttttc	660
tactgtacac	cccattcccag	acgaagacag	tccttggtatc	accgacagca	cagacagaat	720
ccctgctacc	agagaccaag	acacattcca	ccccagtggt	gggtcccata	ccactcatgg	780
atctgaatca	gatggacact	cacatgggag	tcaagaaggt	ggagcaaaca	caacctctgg	840
tcctataagg	acaccccaaa	ttccagaatg	gctgatcatc	ttggcatccc	tcttggcctt	900
ggctttgatt	cttgcagttt	gcattgcagt	caacagtcga	agaagggtgt	ggcagaagaa	960
aaagctagt	atcaacagtg	gcaatggagc	tgtggaggac	agaaagccaa	gtggactcaa	1020
cgagagggcc	agcaagtctc	aggaaatggt	gcatttggtg	aacaaggagt	cgtcagaaac	1080
tccagaccag	tttatgacag	ctgatgagac	aaggaacctg	cagaatgtgg	acatgaagat	1140
tggggtgtaa	cacctacacc	attatcttgg	aaagaaacaa	ccgttggaaa	cataaccatt	1200
acagggagct	gggacactta	acagatgcaa	tgtgctactg	attgtttcat	tgcaaatctt	1260
ttttagataa	aatttttact	ttaaaaaaa	aaaaaaa			1297

<210> 24  
 <211> 1177  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> mRNA  
 <222> (1)...(1177)  
 <223> mouse CD44

<400> 24						
gaattctg	ccctcggtt	gctccggacg	ccatggacaa	gttttggtgg	cacacagctt	60
ggggactttg	cctcttgca	ttgagcctgg	cacatcagca	gatcgatttg	aatgtaacct	120
gccgctacgc	aggtgtattc	catgtggaga	aaaatggccg	ctacagtatc	tcccggactg	180
aggcagctga	cctctgccag	gctttcaaca	gtaccttacc	caccatggac	caaataaggt	240
tggccctgag	caagggtttt	gaaacatgca	ggtatgggtt	catagaagga	aatgtggtaa	300
ttccgaggat	tcatcccaac	gctatctgtg	cagccaacca	cacaggagta	tatatcctcg	360
tcacgtccaa	cacctccac	tatgacacat	attgcttcaa	tgccctcagc	cctcctgaag	420

-23-

aagactgtac	atcagtcaca	gacctaccca	attccttcga	tggaccggtt	accataacta	480
ttgtcaaccg	tgatggtaact	cgctacagca	agaagggcga	gtatagaaca	caccaagaag	540
acatcgatgc	ttcaaacatt	atagatgacg	atgtcagcag	cggctccacc	atcgagaaga	600
gcaccccaga	aggctacatt	ttgcacacct	accttcctac	tgaacagcct	actggagatc	660
aggatgactc	cttctttatc	cggagcacct	tggccaccag	agatcgagac	tcatccaagg	720
actccagggg	gagttcccgc	actgtgactc	atggatccga	attagctgga	cactcaagtg	780
cgaaccagga	cagtggagtg	accacaactt	ctggtcctat	gaggagacct	cagattccag	840
aatggctcat	catcttggca	tctctcctgg	cactggctct	gattcttgcc	gtctgcatcg	900
cggtaaatag	taggagaagg	tgtgggcaga	agaaaaagct	ggtgatcaac	ggtggcaatg	960
ggacagtgga	agacaggaaa	cccagtgagc	tcaacgggga	ggccagcaag	tctcaggaaa	1020
tgggtgcattt	ggtgaacaag	gaaccatcag	agaccccaga	ccagtgtatg	acagctgacg	1080
agacccggaa	tctgcagagt	gtggacatga	agattggggg	gtagtgccta	cgccattaac	1140
ttgaaaagac	agcacgattg	gaaacgtcat	tgaattc			1177

<210> 25  
 <211> 1089  
 <212> DNA  
 <213> Cricetulus

<220>  
 <221> mRNA  
 <222> (1)...(1089)  
 <223> hamster CD44

atggacaagt	tttgggtggca	cgcagcttgg	ggactctgcc	tcttgccgct	gagcctggcg	60
cacgagcaga	tcgatttgaa	cataacctgc	cgctatgcag	gtgtattcca	cgtggagaaa	120
aatggccgct	acagcatctc	acggactgag	gcagctgacc	tctgccaagc	tttcaacagc	180
actctgccca	ccatggacca	gatgggtgatg	gccctgagca	agggctttga	aacatgcagg	240
tatgggttca	tagaaggcca	cgtgggtgatc	ccgaggatcc	agcccaatgc	catctgtgca	300
gccaaaccaca	ctgggggtgta	tatcctcaca	tccaacacat	ctcactacga	tacatattgc	360
ttcaatgcct	cagcaccctt	tgaagaagac	tgtacatctg	tcacagacct	gcccaattcc	420
ttcgaaggac	cagttaccat	aactattgtc	aaccgtgatg	gtacccgcta	cagcaagaag	480
ggcgagtata	gaacacacca	agaagacatt	gatgcctcaa	ataccacaga	tgatgatgtc	540
agcagcggat	cctccagtga	gaagagcacc	tcagggggct	atgttttcca	cacctacctt	600
cccataatac	aactcaactgc	agaccaggat	gatccctact	tcatcgggag	caccatggcc	660
accagagacc	aagactcatc	catggatccc	agggggaatt	ccctcactgt	gactgatgga	720
tccaaattaa	ctgaacactc	aagtgggaat	caagacagtg	ggcttaactc	aacttctcgt	780
cctggaggaa	aacctcgagt	tccagaatgg	ctcatcgtct	tggcatctct	cctggcgctg	840
gctctgattc	ttgctgtttg	cattgctgtc	aacagttaga	gaagggtgtg	acagaagaaa	900
aagctggtga	tcaacagtgg	caatggaaag	gtggaggaca	ggaagccaag	tgagctcaac	960
ggggaggcca	gcaagtctca	ggaaatggtg	catttgggtg	acaaggaacc	atcagagact	1020
cctgaccagt	ttatgacagc	tgatgagacc	cggaaatctgc	agaatgtgga	catgaagatt	1080
gggggtgtag						1089

<210> 26  
 <211> 4632  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> mRNA  
 <222> (1)...(4632)  
 <223> human LOT1

ccgtgctcac	agctcaacaa	cgcggggcct	tggcgcgcg	ggcgcttccc	cgggtcgccg	60
tcatggccgc	ggaggtggca	cgcccgagcg	gcctcgccctg	agctccgggg	gtcgctgccc	120
cgcagggatt	gctgtcacgt	ctaattgtggc	tgctgcctcg	tgtcacatct	gaaactcatc	180
tgtacctcac	ttanaaagtg	gttctgatta	gacaagactt	ttcggttgag	tcgacagaaa	240
cctaattggga	ccattgaaga	attccaaaaca	ggcaagtgac	aggaacatat	ttgcatgtta	300



gaagaatcag	cctggcagca	gcattgtgat	tagaatgaag	gggaaccgtc	caaaaacaga	360
ctggggaacc	aatatggatc	tgccctctagc	atgcggaaat	atctctctac	actgacctaa	420
ctgactcact	aagcttgttg	tttgtttaaa	ggaagccaca	tgaaaattga	gtttgggcca	480
atagagtga	ctcgttctcc	attctctagc	atccctcccc	atgcaaccac	cctatccctg	540
ccaagtttct	gggcaccaca	gattggaaag	tagcctcctg	taggtatttg	cccatgttaa	600
gtggtggggt	ctctttctgt	cttcccttct	tggtctcacc	tgtctgggtg	gacaaggga	660
gcatgtgcc	accaaggcta	gaccttgtg	agaccagagc	agccccactt	tcggtaaagc	720
aagcaacctc	tgcttacttg	cccaacacac	cctagcttcc	gtgttccttg	ccttgtgagt	780
tatcttcttg	ggtacaattt	aacacagcgt	tcccacctcc	ttataactaa	aatagctaga	840
gggggctttg	tgccctcaaac	cccaaggaga	ccatcttggc	aatctctgcc	tctgcaacag	900
ggcacttgct	ccctgggcaa	ctcctttccc	aggctcatctt	ctcccttgac	atgcccata	960
gatttaatat	tgtgcctatt	tggcagaaaa	atggggtccc	ttgggttgctg	attcttagga	1020
atgtgaggtt	ctccagacca	gagctctcag	cactaaaagt	tctagtctct	gcgtaatggc	1080
cggcatatct	ttggcgatc	taaaatcctc	ttcagtttcc	agcagggtct	ttataagctt	1140
cttctgaagg	tctcagacat	tcagccacgg	aactcaagtg	gaatttggtt	ggataacgtg	1200
actgatttca	aagcccggac	ccttagacgt	gcccatttgg	tgctgcaagt	actgaacatt	1260
actacaacat	cttacagtca	acaaatttga	cacattaaag	atttatatcc	tttcttttgg	1320
gttaggatct	tctctcccct	aaagcatctc	agtttccagc	atgcaatcat	ttccatctta	1380
tggaaatcag	ccatcccgtc	ccgtgccagc	atgctaccct	gggaggcaca	tccaggcttg	1440
ggaaacgggg	gtgtcctgga	tctcatgact	ccagcagcac	cagctgctct	ctttcctctt	1500
ccaagtagac	ttccgttccc	ccccacttg	ggtgtttttg	tttggttttag	caattcagag	1560
ctcaagataa	agaccttaaa	gataactttg	tgtgtctctc	cctttctagg	tatttgcata	1620
ggaatcagag	gagttaatct	tgtttgaact	ttcagacaaa	cctctgggag	gactcgggtc	1680
ctgcctcgca	gcagatgttt	ccctgtcact	cagtagccaa	tccgggggac	ccaggacatg	1740
ccccagctat	agtgatgcag	attaccttcc	tgctcctgaa	tcgcacctgt	gcctcagact	1800
ttctcccctc	agcttgagac	tgcatgtaaa	ctgggatgtg	tgaaagcagg	aagcaaagct	1860
agtgcacagct	gagaggtcca	tgtctgggta	gaaccaggcc	cacgatgctg	cctctcccgt	1920
gttctggagt	tcagctgcag	ggattctgct	gatgtgocca	gcaccatcgt	tctgtttgtg	1980
cttaaatggc	acagcatttg	gtcagcacat	ctgaaaagga	aggtgtgaga	agcaaagccc	2040
atggccacgt	tcccctgcc	gttatgtggc	aagacgttcc	tcaccctgga	gaagtccacg	2100
attcacaatt	attcccactc	caggagcgcg	ccgtacaagt	gtgtgcagcc	tgactgtggc	2160
aaagcctttg	ttccagata	taaattgatg	aggcatatgg	ctaccatttc	tccccagaaa	2220
tctcaccagt	gtgctcactg	tgagaagacg	ttcaaccgga	aagaccacct	gaaaaaccac	2280
ttccagaccc	acgaccccaa	caaaatggcc	tttgggtgtg	aggagtgtgg	gaagaagtac	2340
aacaccatgc	tgggctataa	gaggcacctg	gccctccatg	cggccagcag	tggggacctc	2400
acctgtgggg	tctgtgcctt	ggagctaggg	agcaccgagg	tgctactgga	ccacctcaaa	2460
gcccattgcg	aagagaagcc	ccctagcgga	accaaggaaa	agaagcacca	gtgcgaccac	2520
tgtgaaagat	gcttctacac	ccggaaggat	gtgcgacgcc	acctgggtgg	ccacacagga	2580
tgcaaggact	tcctgtgcca	gttctgtgcc	cagagatttg	ggcgcaagga	tcacctcacc	2640
cggcatacca	agaagaccca	ctcacaggag	ctgatgaaag	agagcttgca	gaccggagac	2700
cttctgagca	ccttccacac	catctcgctt	tcattccaac	tgaaggctgc	tgccctgcct	2760
cctttccctt	taggagcttc	tgcccagaac	gggcttgcaa	gtagcttgcc	agctgaggtc	2820
catagcctca	ccctcagtc	cccagaacaa	gccgcccagc	ctatgcagcc	gctgccagag	2880
tccctggcct	ccctccaccc	ctcggtatcc	cctggctctc	ctccgccacc	ccttcccaat	2940
cacaagtaca	acaccacttc	tacctatac	tccccacttg	caagcctgcc	cctcaaagca	3000
gataactaa	gtttttgcaa	tatcagtttg	tttgaggact	tgccctctga	agagcctcag	3060
tcacctcaaa	agctcaaccc	aggttttgat	ctggctaagg	gaaatgctgg	taaagtaa	3120
ctgcccgaag	agctgcctgc	agatgctgtg	aacctaaaca	tacctgcctc	tctggacctg	3180
tccccctgt	tgggcttctg	gcagctgcc	cctcctgcta	cccaaaatac	ctttgggaat	3240
agcactcttg	ccctggggcc	tggggaatct	ttgccccaca	ggttaagctg	tctggggcag	3300
cagcagcaag	aacccccact	tgccatgggc	actgtgagcc	tgggcccagct	ccccctgcc	3360
cccatccctc	atgtgttctc	agctggcact	ggctctgcca	tccctgcctca	tttccatcat	3420
gcatttcagat	taaagggtat	ttttcgtatt	ttttcgtatt	ctggaagatg	ttttaagaag	3480
catttttaaat	gtcagttaca	atatgagaaa	gatttgga	acgagactgg	gactatggct	3540
tattcagtga	tgactggctt	gagatgataa	gagaaattctc	gaactgcatg	tattgtgcca	3600
atctgtcctg	agtgttcagt	ctttgtacca	aatttaaatga	acgcgtgttc	tgtaataaaa	3660
ctgcaaata	tgtcataacc	aacatccaaa	atgacggctg	ctatatataa	gtgtttgtca	3720
tatggaattt	aatcgtaagc	catgatcata	atgttaacta	aataacttta	tgtggcactg	3780
cctagtaagg	gaactatgga	aaggtttgga	tttctccaaa	tctgggagaa	ttttcaaaat	3840
aagaaaataa	ccttttatatg	atatactatg	actaggctgt	gtatttcttt	tcagggattt	3900
ttctaccttc	agggttggat	gtagttagt	tactattacc	atagccaacc	tgtagtttta	3960



-25-

```

catatacatt ttcttgtgga gcaatagagt tctccatttt acagaagcat tttaaatgta 4020
gtttgaatat tttccacaag atgctgcaat gtgagttatc acttcattta tcttaaagaa 4080
agactaaact gggtgtcagt tacatctgac agaaaaaaaa aaaaaaatca ctgtgtaacc 4140
agggttaagt gggttaaaata atccagggcg tcagtcaaaag gcattttgct gactttaata 4200
ttgattatat ttttaacagg gaatttaagg aaaatattac cggggaatta aaaaatatat 4260
atatattaaa acaagaattt tcctttgccc ctgtccagcc taaacctacc tacctcaagg 4320
ctgcctaagt tcctaagtat tgtttgtaat caccacaataa ataagtgcac ttgtaattca 4380
tcagtcattha ttagctttta ttaaaagaag attacgtttt acaatgtaac tataatctct 4440
tgaattttggt atcttattaa tgagttttta agatgtaaaa cctaaccttt tttaaagctc 4500
cattgtctta tgtttttaga ggcttttccg taaacatata tcttacatat aataaacttt 4560
tcaaatcttg caaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4620
aaaaaaaaaa aa 4632

```

```

<210> 27
<211> 2828
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> mRNA
<222> (1)...(2828)
<223> human ZAC zinc finger protein

```

```

<400> 27
cggcattttg ggacaactgt ttttaacggt aataaatcac ttaggcgaga tataaattgg 60
ctttgttcca tagcagattt gcctttgtac tagttaagaa aatcctgaaa agctttccct 120
gtaagaggat cagttgggtg gaatagcctt ggttaggaaga agccaagttt gataattact 180
tggtgaacgg aaatgctggg ttccaaatgc tcatcagggg tcagtggcac aaagctggct 240
gtagacttgg ctctctgtaga tttggtaaaa acgtaaattc ctgggggtccc agtgatgctg 300
tttttagtctg tactgatttg ccctgtggcc acccaggaat ctgtattttt aaaagttttc 360
catgctgatt ctaatgcata gccagggtta gtaaccattt aattcagtat tcaacttaga 420
gacttcaacc ttcttgcact gcaaatttga taaatctttg tttatatgaa tctcctttgt 480
tgagtgccaa ctgggttattt gctgactttc tttcaattca gaatttggtt taggttctgt 540
tattgcatag atttgcatac ctgttttatg gtattttaat actggttggtt ttaaaaaata 600
ccatttcctc tgagtgtgtg tctgaatata ttagtgaagc aattttgtgt gttctttttt 660
ttccacttgc ataaagcagg ggaaaagttg agagtttttc ttaatccagt tgcaagtagg 720
acaaaggata tgagtgttta aagatcatct attaaaatgc atgaaaaaac actagaaaat 780
ctcctgtgca catcgccagt cgtgtgtgtg ctctagaagt gaagttcagg gggtaacata 840
atggaggaaat gttttcctag cttcattccc tgacgatgta caaggtctct tctcacaggt 900
ttgaatcttc agacaaactt ctgggaggac tcgggtccctg cctcgcagca gatgttccct 960
gtcactcagt agccaatccg ggggacccag gacatgcccc agctatagtg atgcagatta 1020
cctttctgct cctgaatcgc acctgtgcct cagactttct cccctcagct tgagactgca 1080
tgtaaactgg gatgtgtgaa agcaggaagc aaagctagtg acagctgaga ggtccatgtc 1140
tgggtagaac caggccacg atgctgcctc tcccgtgggtc tggagttcag ctgcagggac 1200
tctgctgatt ggcccagcac catcgttctg tttgtgctta aatggcacag catttggtca 1260
gcacatctga aaaggaaggt gtgagaagca aagcccattg ccacgttccc ctgccagtta 1320
tgtggcaaga cgttcctcac cctggagaag ttcacgattc acaattattc ccactccagg 1380
gagcggccgt acaagtgtgt gcagcctgac tgtggcaaag cctttgtttc cagatataaa 1440
ttgatgagga atattggctac ccattctccc cagaaatctc accagtgtgc tcaactgtgag 1500
aagacgttca accggaaaga ccacctgaaa aaccacctcc agaccacga cccaacaaa 1560
atggcctttg ggtgtgagga gtgtgggaag aagtacaaca ccatgctggg ctataagagg 1620
cacctggccc tccatgcggc cagcagtggtg gacctcacct gtgggggtctg tgccctggag 1680
ctaggagaca ccgaggtgct actggaccac ctcaaagccc atgcggaaga gaagccccct 1740
agcggaacca aggaaaagaa gcaccagtgc gaccactgtg aaagatgctt ctacaccggg 1800
aaggatgtgc gacgccacct ggtggtccac acaggatgca aggacttccct gtgccagttc 1860
tgtgcccgag gatttgggag caaggatcac ctacccggc ataccaagaa gaccactca 1920
caggagctga tgaaagagag cttgcagacc ggagaccttc tgagcacctt ccacaccatc 1980
tcgccttcat tccaactgaa ggctgctgcc ttgcctcctt tccctttagg agcttctgcc 2040
cagaacgggc ttgcaagtag ctgcccagct gaggtccata gcctcaccct cagtcccca 2100
gaacaagccg cccagcctat gcagccgctg ccagagtccc tggcctccct ccacccctcg 2160
gtatcccctg gctctcctcc gccaccctt cccaatcaca agtacaacac cacttctacc 2220

```

-26-

tcatactccc	cacttgcaag	cctgcccctc	aaagcagata	ctaaagggttt	ttgcaatatc	2280
agttttgtttg	aggacttgcc	tctgcaagag	cctcagtcac	ctcaaaagct	caaccaggt	2340
tttgatctgg	ctaaggga	tgctggtaaa	gtaaacctgc	ccaaggagct	gcctgcagat	2400
gctgtgaacc	taacaatacc	tgctctctctg	gacctgtccc	ccctgttggg	cttctggcag	2460
ctgccccctc	ctgctaccca	aaataccttt	gggaatagca	ctcttgccct	ggggcctggg	2520
gaatctttgc	cccacaggtt	aagctgtctg	gggcagcagc	agcaagaacc	cccacttgcc	2580
atgggcactg	tgagcctggg	ccagctcccc	ctgcccccca	tccctcatgt	gttctcagct	2640
ggcactggct	ctgccatcct	gcctcatttc	catcatgcat	tcagataatt	gattttttaa	2700
gtgtattttt	cgtattcttg	aagatgtttt	aagaagcatt	ttaaatgtca	gttacaatat	2760
gagaaagatt	tggaaaacga	gactgggact	atggcttatt	cagtgtatgac	tggcttgaga	2820
tgataaga						2828

&lt;210&gt; 28

&lt;211&gt; 3975

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;220&gt;

&lt;221&gt; mRNA

&lt;222&gt; (1)...(3975)

&lt;223&gt; mouse ZAC1 zinc finger protein

&lt;400&gt; 28

tgtctcttct	cacaggtttg	agtcttcaga	cttctacaga	actccataat	atctgcctca	60
cagctggctt	tcctgctctc	acagaagata	cccagctatt	gtgctctgga	tctctcctgg	120
ctgctaggct	gtagcgctgc	ctttctggag	tcaggctgta	gtgactcccc	accttcttct	180
tgtctgggct	taaatggcac	agcagttcct	cagcacatct	gaagaagaaa	gtgtgagaac	240
caaaggccat	ggctccattc	cgctgtcaaa	aatgtggcaa	gtccttcgtc	accctggaga	300
agttcaccat	tcacaattat	tccactcca	gggagcgccc	attcaagtgc	tcgaaggctg	360
agtgtggcaa	agccttcgtc	tccaagtata	agctgatgag	acacatggcc	acacactcgc	420
cacagaagat	tcaccagtgt	actcactgtg	agaagacatt	caaccggaag	gaccacctga	480
agaaccacct	ccagaccac	gatcccaaca	agatctccta	cgctgtgtac	gattgctggc	540
agaagtacca	caccatgctg	ggctacaaga	ggcacctggc	cctgcactcg	gcgagcaatg	600
gcgatctcac	ctgtgggggtg	tgcaccctgg	agctggggag	caccgagggtc	ctgctggacc	660
acctcaagtc	tcacgcggaa	gaaaaggcca	accaggcacc	cagggagaag	aaataccagt	720
gcgaccactg	tgatagatgc	ttctacaccc	ggaaagatgt	gcgtcgccac	ctggtggtcc	780
acacaggatg	caaggacttc	ctgtgtcagt	tctgtgccc	gagatttggg	cgcaaagacc	840
acctcactcg	tcacaccaag	aagaccact	cccaggagct	gatgcaagag	aatatgcagg	900
caggagatta	ccagagcaat	ttccaactca	ttgcgccttc	aacttcgttc	cagataaagg	960
ttgatcccat	gcctccttct	cagctaggag	cggctcccga	gaacgggctt	gatggtggct	1020
tgccaccoga	ggttcatggt	ctagtgtctg	ctgcccaga	agaagctccc	caaccctgct	1080
cgcccttggg	gcctttggag	cctttggagc	ctttggagcc	tttggagccg	atgcagtctt	1140
tggagccttt	gcagcctttg	gagccgatgc	agccttttga	gccaatgcag	cctttggagc	1200
cgatgcagcc	tttagagcct	ttggagcctc	tggagccgat	gcagcctttg	gagccgatgc	1260
agccttttga	gcctatgcag	ccaatgctgc	caatgcagcc	aatgcagcca	atgcagccaa	1320
tgcagccaat	gctgccaatg	cagccaatgc	tgccaatgca	gccaatgcag	ccaatgcagc	1380
caatgctgcc	aatgccagag	ccgtctttca	ctctgcaccc	tggcgtagtt	cccacctctc	1440
ctcccccaat	tattcttcag	gagcataagt	ataatcctgt	tcctacctca	tatgccccat	1500
ttgtaggcat	gcccgtcaaa	gcagatggca	aggccttttg	caacgtgggt	ttctttgagg	1560
aatttcctct	gcaagagcct	caggcgccctc	tcaagttcaa	cccatgtttt	gagatgccta	1620
tggaggggtt	tgggaaagtc	accctgtcca	aagagctgct	ggtagatgct	gtgaatatag	1680
ccattcctgc	ctctctggag	atttcctccc	tattgggggtt	ttggcagctc	ccccctccta	1740
ctccccagaa	tggctttgtg	aatagcacca	tccctgtggg	gcctggggag	ccactgcccc	1800
ataggataac	ctgtctggcg	cagcagcagc	caccgccact	gccgccgcca	ccaccgtgc	1860
cactgcccac	gccactgcca	gtgccacagc	cactaccaca	gccacagatg	cagccacagt	1920
ttcagttgca	gtaccagccc	cagatgcagc	cccagatgca	gctgcagcca	ctgcagctgc	1980
agctaccaca	gctgctgccc	caactgcaac	ctcagcagca	gcctgatcct	gagccagagc	2040
cagagccaga	gccagagcca	gagccagagc	cagagccgga	accggaaccg	gagccagagc	2100
cagagccaga	accagagcca	gaggaagaac	aggaagaggc	agaagaagag	gcagaggaag	2160
gagcagagga	aggagcagaa	ccagaggcac	aggcagaaga	agaggaagag	gaagaggaag	2220
cggaagagcc	acagccagaa	gaagcccaaa	tagcagttag	tgctgtgaat	ctgggccagc	2280

-27-

ccccctacc	cccaactccc	catattttca	cagctggctc	caacactgct	atcctgcccc	2340
atttccatca	cgcattttaga	taaatttggtt	tttaagaggg	tgcttctctt	gtgggagatg	2400
ttttaaacat	cagttacagt	ttgaggagaa	gcattggaaa	acaggaatgg	ggttttagct	2460
tatttgtcat	aagtagcttg	agaaaaagaa	ttctctaact	gcatgcgttg	tgccaatata	2520
tacccttagt	attcatgctt	cctaccaaat	ttagttagcg	tgtgtgcatt	ctgtaatcaa	2580
actgcaaata	ttatcatatt	atcctattat	tacccttgta	ttattaccct	catattatta	2640
ccctcatatt	atcctcatta	tcttataatc	acgtgattac	tgataaagat	ccaaaacatg	2700
agctgctatt	ttgtaaatat	cgtgttgagt	gtaagctgtt	gtagtgatgt	tagctatgta	2760
actgtgtgta	gcctaggaag	gggatgatgg	taaagtttgg	aattctccaa	cttggaaggt	2820
gtttttaaga	gaaggggata	atctttgtat	ggcgtttata	actaggctgt	gtgtttcttt	2880
tcagggaactc	gtctataaga	aatggacagt	ttagtctctc	ttcttgtag	cttactctgt	2940
agtttcttct	tcttggtgcc	cattgtgtag	ctttatagag	tgtgacgcta	ttgatgtctc	3000
catttttttaa	agtgaattta	aatgtactgt	tcaatatattt	tcatgtgatg	ttgttccaat	3060
gtgagttacg	acttcattta	tcttaaagac	aaaactgggt	gtcagtcata	tctgacagaa	3120
gaaagaaatc	actgtgtaac	caagtcaagt	ggccaactaa	ttgaagaaga	atcaatcaaa	3180
gtgtttgtgg	actgtgatac	tcattatgtt	tttaacagga	atttaagaaa	atgtactgga	3240
atttaaaaaa	agcataagta	tattagataa	gaattttctt	tgctagctt	aacctactac	3300
ttaagctgct	taagttctga	agtattgttt	gtaatcacca	atagaaaagt	gtatctgtag	3360
atgatcaatt	taagtcattg	ttagtttgta	tcccaagagg	attgtgtttt	gcaatgtaac	3420
ctacttgtaa	tctcccttga	taccttgta	atcgattttg	aagtgtaaac	ctaacctttg	3480
aagactctgt	atttcccttct	tgagactgta	tccccagat	atatctccta	acctttgaag	3540
actctgtatt	tcatttttga	gactgtattc	cccaggattt	atctcctaac	ctttgtagac	3600
tctgtatttc	gtttttgaga	ctgtctttcc	cagcatatat	ctcctgacct	ttgacaactc	3660
tgtatttcgt	ttttgagact	gtattcccca	gcatatatct	cctgaccttt	gaagaccctg	3720
cattttgttt	ttgagatgga	attcaacagc	atatatctcc	taatctttga	tgactctgta	3780
ttttgttttt	gagattgtat	tccccagcat	atatctccta	acctttgaag	actctgtatt	3840
tcatttttga	gactgtattc	cccaacgtgt	atctcctaac	ctttgaataa	tctccacttt	3900
gtttttgaga	ctgtattccc	cagcatatat	ctcctaacct	ttgactctgt	actttgtttt	3960
tgagagtgta	ttccc					3975

<210> 29  
 <211> 536  
 <212> DNA  
 <213> Homo sapiens

<400> 29	
tctgaaattt	ttattcattt
tgacatcaag	aactactcaa
acacacacac	caatatatat
agacctataa	aacctatgtt
agtatttcca	tacctacca
atgtttcttg	ataatttaag
aaaattttca	gaatttttaag
atggaggggaa	aaaaaggtct
aaaattaaca	taaggcttca
catatatag	gatttagctg
agacacattg	tgtgtgtata
acacacacat	atatatatgt
tgtgggtttt	tttttttttt
gtgctaggta	tggtactatc
ttatgctgct	ggtatatctt
gtagaaaaat	ttagcaaaac
taaaagccag	tgagagtatg
tggctggagg	aaataaaaact
actttttctaa	
cacacacaca	
atatatctaa	
cttttcccat	
tggatacctc	
ccagtaatat	
caaaagagaa	
taatgggaaa	
ggatgg	
60	
120	
180	
240	
300	
360	
420	
480	
536	

<210> 30  
 <211> 2059  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> mRNA  
 <222> (1) ... (2059)  
 <223> putative nucleotide binding protein,  
 estradiol-induced (E2IG3)

<400> 30	
gcgccgccca	agcgatccct
gtgacgcact	ttacggcggc
gtggcgccmg	sasgmrggtt
gctccgcgcg	acaactgcgtg
gtgacgctcg	tcagtggctt
tgcttccttc	tacagccaat
cccgcgcacg	cagagaggcg
cagttcacas	
atgaaaaggc	
60	
120	
180	

-28-

ctaagttaaa	gaaagcaagt	aaacgcatga	cctgccataa	gcggtataaa	atccaaaaaa	240
agggttcgaga	acatcatcga	aaattaagaa	aggaggctaa	aaagcagggt	cacaagaagc	300
ctaggaaaga	cccaggagtt	ccaaacagtg	ctccctttaa	ggaggctctt	cttagggaag	360
ctgagctaag	gaaacagagg	cttgaagaac	taaaacagca	gcagaaactt	gacaggcaga	420
aggaactaga	aaagaaaaga	aaacttgaaa	ctaactcctga	tattaagcca	tcaaatgtgg	480
aacctatgga	aaaggagttt	gggctttgca	aaactgagaa	caaagccaag	tccgggcaaac	540
agaattcaaa	gaagctgtac	tgccaagaac	ttaaaaagggt	gattgaagcc	tccgatgttg	600
tcctagagggt	ggttgatgcc	agagatcctc	ttggttgca	atgtcctcag	gtagaagagg	660
ccattgtcca	gagtggacag	aaaaagctgg	tacttatatt	aaataaatca	gatctggtac	720
caaaggagaa	tttgagagc	tggtctaaat	atttgaagaa	agaattgcca	acagtgggtg	780
tcagagcctc	acaacaaacca	aaggataaag	ggaagataac	caagcgtgtg	aaggcaaaga	840
agaatgctgc	tccattcaga	agtgaagtct	gctttgggaa	agagggcctt	tggaaacttc	900
ttggaggttt	tcaggaaact	tgacagcaag	ccattcgggt	tggagtaatt	ggtttcccaa	960
atgtggggaa	aagcagcatt	atcaatagct	taaaacaaga	acagatgtgt	aatgtttggtg	1020
tatccatggg	gcttacaagg	agcatgcaag	ttgtcccctt	ggacaaacag	atcacaatca	1080
tagatagtcc	gagcttcac	gtatctccac	ttaattcctc	ctctgcgctt	gctctgcgaa	1140
gtccagcaag	tattgaagta	gtaaaaccga	tggaggctgc	cagtgccatc	ctttcccagg	1200
ctgatgctcg	acaggtagta	ctgaaatata	ctgtcccagg	ctacaggaat	tctctggaat	1260
tttttactat	gcttgctcag	agaagaggta	tgacacaaaa	aggtggaatc	ccaaatgttg	1320
aagggtgctgc	caaactgctg	tggtctgagt	ggacagggtgc	ctcattagct	tactattgcc	1380
atccccctac	atcttggaact	cctcctccat	attttaatga	gagtattgtg	gtagacatga	1440
aaagcgggctt	caatctggaa	gaactggaaa	agaacaatgc	acagagcata	agagccatca	1500
agggccctca	tttggccaat	agcatccttt	tccagtcttc	cggctctgaca	aatggaataa	1560
tagaagaaaa	ggacatacat	gaagaattgc	caaacgggaa	agaaaggaag	caggaggaga	1620
gggaggatga	caaagacagt	gaccaggaaa	ctgttgatga	agaagttgat	gaaaacagct	1680
caggcatggt	tgctgcagaa	gagacagggg	aggcacttct	gaggagacta	cagcagggtga	1740
acagtctaca	aggtctttta	tcttgataa	aatcattgaa	gaggatgatg	cttatgcttt	1800
cagtacagat	tatgtgtaac	agaacaatgg	ctttttatga	tttttttttt	taacatttta	1860
agcagactgc	taaactgttc	tctgtataag	ttatggtatg	catgagctgt	gtaaaattttg	1920
tgaatatgta	ttatatataa	accaggcaac	ttggaatccc	taaattctgt	aaaaagacaa	1980
ttcatctcat	tgtgagtggg	agtagttatc	tgggaataaaa	aaagaagata	cctattgaaa	2040
aaaaaaaaaa	aaaaaaaaaa					2059

<210> 31  
 <211> 1943  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> mRNA  
 <222> (1)...(1943)  
 <223> mouse mrg-1

<400> 31	
cctggcgggtc	ttgctccagc
ttgctccagc	ggctgctgca
ccatcggtctg	tccctctatg
gtgttccgag	cagaaatcgc
atgaaccacg	ggcgttccc
atgggcatgg	ggcagttccc
ttcaacgccc	tcatgggcca
ggcatcaggc	acgccatggg
gccccggccg	ccaggtttta
ggctccctgc	cggccagcat
ccctaccccc	acaaccacta
gggacaaacc	agcaacttcg
ggcgggtgcg	gtggcagcgg
ggcagcagcg	cgggcggcac
cccgcggcaa	tgtgtccgcc
atgtccttag	tgatagaaat
gggcaaaatg	agtttgattt
ctagggcagc	ggaggaaaag
agacctcggc	gccaacctcg
tgctgctgag	ccggtcctgg
aaagacggaa	ggactggaaa
cgaacggcacc	aacgggctgc
gagcccgcac	catcaccagc
gacatacac	tacggcgcgg
gccggggact	gtgaacgggg
caactcccag	ttcatgggtc
gcagctgcag	aagctcaaca
catgctgat	ttgcacccca
agattgcaac	cccaagcaca
caacccccgc	ggctccggcg
agcagcagcc	gcacctcggg
tgcaacgagc	cggcgcggtg
gagcgctctg	ggctcacgtc
cagccaggga	ggaagtgtct
caaccatcac	actctggctg
ccagatgaac	cagcagagtc
cagcagagtc	

-29-

agctgttgac	tcggttaacc	tcgcaggcgg	aaacaaatca	ccctcccccac	cccaccccca	1080
cccccaactt	cttcggtgtg	aattaaaaaa	aaaacaaaaa	aacaaacatt	cccttagacg	1140
cagtatctcg	cttttcagat	cctgaaaggg	ttgagaacct	ggaaacaaag	taaactataa	1200
acttgtacaa	attggtttaa	aaaaaaaaaa	agattgctgc	cactttttcc	tattcttggt	1260
tcgttttttg	tagccttgac	attcacctcc	cttatgtagt	tgaaatatct	agctaacttg	1320
gctctttttt	gttggttggt	tttactcctt	tatttcctca	ctttatttcc	tcactttctc	1380
ccgtgtctcaa	ctgttagata	ttaagcttgg	caaactgctt	aatcttgtgg	attttgtaga	1440
tggtttcaaa	tgactgcgct	gctttcagat	tcattgagtga	aaggaaacat	tgcatattgt	1500
ggctgcatga	tctttgaagg	gcagatatta	ctgcacaaac	tgcatctctg	cttcattttt	1560
tttaactatg	cattcgagta	cagacttaag	ttttcaaata	tgctaaactg	gaagattaaa	1620
catgtggggc	aaaccgttct	ggatcaggaa	aagtcatacc	gttcactttc	aagttggctg	1680
tctccctcc	cccatatgta	cagacaataa	taggggtgtg	aatgtcgtca	gtggcaaaca	1740
tttcacagat	ttttattttg	tttctgtctt	caacattttt	gacactgtgc	taatagttat	1800
attcagtaca	tgaaaagata	ctactgtgtt	gaaagctttt	taggaaattt	tgacagtatt	1860
tttgtacaaa	acattttttt	gagaaaatac	ttgttaattt	attctatttt	aatttgccaa	1920
tgtcaataaa	aagttaagaa	ata				1943

&lt;210&gt; 32

&lt;211&gt; 6324

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; mRNA

&lt;222&gt; (1)...(6324)

&lt;223&gt; human p35srj

&lt;400&gt; 32

gatcaagtta	acatgaggcc	agtaggagaa	gccctaattcc	aaaaggacta	gagtccttgt	60
caaaagggga	actttggaca	cagagataca	catacagggg	ggcggggggg	ggaaaacgtc	120
acatgaagat	gaaggtgggg	atcagtgtga	tgcatctaca	agtcaagggg	caccaaagat	180
tgccgggaaa	ccaccaaaaag	ccaggaaaag	gacacggaat	agattctctc	tcacggtctt	240
cagaaccaac	cctgccaaaca	acttggcctt	gtacctctag	cctccagaac	tgtgagacaa	300
taatgttttg	ttgtttaaaag	cttgatcagc	cttaagtttg	tattagactg	gtgcaaaaagt	360
aattacagtt	ttcgccattg	ctttcaatgg	caaaaatcac	aattactttt	gcaccaacct	420
aaatagtact	gtgttatggc	agctctggga	aatgaataca	accattcagt	gctgtgaggg	480
ccacagacag	atcacttgct	cgctcaccca	ggttcacggg	ataaaccttg	gttatacggg	540
acttctggga	gccctgggtt	actgtaagt	ccccctaact	ggactccctg	tttctgtct	600
tactttctct	aaccattctc	cacagcactg	ccctgatctt	tctaaaaatcc	aaatctttcc	660
tatctcatgg	cttcacaagc	ttttacctgc	ctcccaatgt	ctttgggata	cagcaaaaatt	720
tctcagcttg	aggccacaat	gcccttggca	tccggcccca	gcataatttct	ccaaccttat	780
ttctctcatc	tttgatttca	ctccctagcc	atacattttc	taccccactc	ctaattgggac	840
caaacttcca	ttcatcctga	ggcctccact	tagtcaccat	ctccaccgga	aagccttccc	900
aaagcaccca	ggaggggggt	aggtgtccct	cctatgtgct	ctccaaagcg	ctttccttca	960
atgcctttgt	ggcattttatc	acagtgtgtt	caaggcctgt	ttgtcagttt	tctccctgtg	1020
accatgagtt	cctatcttgt	ttgtatctcc	aggcaccaag	aaagcacttg	gcacttgagg	1080
gacattcagt	ggacggatga	gaataaatga	acaaagcatg	ccatgttcca	accagctggt	1140
cccagaacta	ttttgttctc	ctttaaggga	tgggggatgg	gcaggtgacc	tttccaggga	1200
tttcccaata	gtaggtagaa	ccactggagc	tggatggagc	tccaccttcc	cttagtggtt	1260
gcaagaggaa	tttagattag	acattcaaaa	gctgtttctt	gtgtcgaaag	acacttgacg	1320
tacaaagaag	ggaaagtaaa	caatcccgcg	atttttcagg	ttgggtttta	ccaatatatt	1380
agaatctggt	tttttatagg	aagtggcccc	ttcaggatatc	caagcctctg	atacggtaaa	1440
ctgcagtctc	tgacctacag	gtaaagggtg	tgggaggtta	ggagaatagg	gaattgttgc	1500
aactaacaat	gcaatgtgtc	atgtgcccgt	atctctaaaa	agtaaatatt	tttgaggttt	1560
aaaaattatt	tgcctgcacg	gtttgccgga	gagcctggaa	gaggaaagaa	gacaagacac	1620
aaagtaacaa	cattttacaaa	aatatgcctg	actaggaaaa	gacagagggg	tcatagacga	1680
aaataatcag	gattgggtct	cttttgcaaa	ttcctgaacg	gggaaatgta	tcagaatttc	1740
cagtcctcaa	gaaacagggc	ctttaaaagt	cttgtgtgca	agaaggggga	aaaagacgag	1800
ggggggggcg	ggaggcggac	tcgctcttcg	cagcaggaag	tcttcaatgg	ctatcgagtt	1860
atgaagaaac	aactgcccag	aagtccttat	tcggagcgct	aaactcgatt	ttaccacata	1920
aagagcaatg	taaaagctca	gaacagcccc	atcatggtgt	tggggaaaca	actcggcttc	1980

cccatgtgag	aaagccagag	agctccgact	tggtagtagc	ccagacctgt	gttaggggtt	2040
ttatttgcaa	gtcaatgaac	caaacgggcg	accaggctcg	ttgtgccgcg	ttgtggaagc	2100
aaggttatta	ttatcgccca	ttgccccact	gaacaatttc	actgaaaagg	aagagtccca	2160
gccgtgtgtg	tgcgctggtg	gccatacggg	acgtgcagct	acgtgcccac	ctccagaacg	2220
actttattta	caaagcgatt	accacgttat	ctatttgttt	tcctttttcca	gcaagagcag	2280
ccttactcag	ccctcaaatt	tcttaattac	aaaccogttt	gcttctaaat	caaccccaaa	2340
ccgtcaggca	gagcccggag	ggaggctctg	caagtttgta	cacaccccca	cctcccggat	2400
ccagggaac	agcagaagca	agtaactgtg	tatgtgcaaa	aaggtggatc	tggggacgag	2460
gatcgctgag	tttgtttaca	gagcagagac	gcctcagctc	ggatgccaaa	gctaccaaga	2520
gctgcaaacg	caaacttagc	agaagcacac	gtaccccggg	agcggcaggc	gggcccgaaa	2580
gcgcggaactg	gaattccagg	gcgcgggagc	gggggtggcc	gggcccctcg	gcgcgtccg	2640
tccacctgca	gcggtgccc	ctccccggcc	ccagctcctg	tccttgaaag	gagtgaggga	2700
aaaaaatgca	tctacaagcg	gtgatctaga	gtaggtctac	ccactgcccg	tatgaaaaca	2760
caaaggcaca	gcctaggaag	gcgcgctcag	gaaagggcgc	attatttgtc	cgggtcttta	2820
aaaccacaact	cgaggaagca	cagccattct	tcgctgcctg	tggaagcttt	tgcaaaaccg	2880
gggaggcaca	agggcactct	ggagggcggg	gggcgctggg	cgagtcccct	tttcccgtag	2940
agagcggggc	agatcgctag	gtgaaccgag	tgagaaagct	gggggtgggg	tagatccagc	3000
ctgagggggg	cggtgagctc	tcctcgtagc	tatcccggca	ggctctacct	tcgggcgggg	3060
cggcagggga	ggattttccc	cctgcctcgg	gggtggctga	gccaacctcg	cgtttctggg	3120
ccgggaagaa	accagagtcg	gggggagcag	gggcgactgg	gcggcccccg	ggccccgcag	3180
cctctgcagc	acgtgccgcg	ggcgggcggg	acgcggctcc	gggaccgggt	ccagggtggt	3240
cgcggtgttc	cggaatccgc	gtcttggcgc	cgccccccct	ggaggctctc	gctccgcctt	3300
tccgaaatgc	ctatattaac	tgtggccaaa	gccctaagaa	acacagctca	ttgttggcag	3360
ctgccggggc	gtcctgccga	gctgtgaggg	caacggaggg	gaaataaaaag	ggaacggctc	3420
cgaatctgcc	ccagcggccg	ctgcgagacc	tcggcgccga	catcgcgaca	gcgaagcgct	3480
ttgcacgcca	ggaaggctcc	ctctatgtgc	tgctgagccg	gtcctggacg	cgacgagccc	3540
gcccctcggtc	ttcgagagcag	aaatcgcaaa	aacggaaggt	aagcgcgacg	ggcgaagctg	3600
gctggggctc	ttgccagccc	agtcctccga	gggcagggtt	tgcccggagg	aagaacgtga	3660
ggcgaaactg	gggaataaca	acaggatgtg	ctacaacagg	atgaggaggg	ctgatttaat	3720
gcctgaagtt	cgcagcaggg	ctacggggca	cttcccttta	taggccactt	cggggagcaa	3780
agggggtgtg	ggctcgggtc	cccccgcccg	atcgcagggg	aaggggctgt	ttgtgcagcg	3840
tccggctgtg	ttatgagtg	tagctcttcc	gtggtggcta	gcccgggtgc	acaggctggt	3900
agtgggatct	tgggggtgg	ggttcgcagc	cgacgtgcgc	ccgggaatcc	tggggggcag	3960
aggcgagcaa	aagtggggtg	cgctgtggtg	ggcgacacgt	gtggcgcggg	tctcattatc	4020
tgcctttttc	acttccagga	ctggaaatgg	cagaccatat	gatggccatg	aaccacgggc	4080
gcttccccga	cggcaccaat	gggtcgcacc	atcaccctgc	ccaccgcatg	ggcatggggc	4140
agttccccgag	cccccatcac	caccagcagc	agcagcccca	gcacgccttc	aacgccctaa	4200
tgggcgagca	catacactac	ggcgcgggca	acatgaatgc	cacgagcggc	atcaggcatg	4260
cgatggggcc	ggggactgtg	aacggagggc	accccccgag	cgcgctggcc	cccgcggcca	4320
ggtttaacaa	ctcccagttc	atgggtcccc	cgggtggccag	ccagggaggc	tccttgccgg	4380
ccagcatgca	gctgcagaag	ctcaacaacc	agtattttcaa	ccatcacccc	tacccccaca	4440
accactacat	gccggatttg	caccctgctg	caggccacca	gatgaacggg	acaaaccagc	4500
acttccgaga	ttgcaacccc	aagcacagcg	gcggcagcag	cacccccggc	ggctcggggc	4560
gcagcagcag	ccccggcggc	tctggcagca	gctcgggcgg	cggcgcgggc	agcagcaaca	4620
gcggcgggcg	cagcggcagc	ggcaacatgc	ccgcctccgt	ggcccacgtc	cccgtgcaa	4680
tgctgccggc	caatgtcata	gacactgatt	tcctgcagca	ggaagttctt	atgtccttgg	4740
tgatagaaat	gggtttggac	cgcatacagg	agctgcccga	actctggctg	gggcaaaacg	4800
agtttgattt	tatgacggac	ttcgtgtgca	aacagcagcc	cagcagagtg	agctgttgac	4860
tcgatcgaaa	ccccggcgaa	agaaatcaaa	cccccaactt	cttcggcgtg	aattaaaaga	4920
aacattccct	tagacacagt	atctcacttt	tcagatcttg	aaagggttga	gaacttggaa	4980
acaaagtaaa	ctataaaactt	gtacaaattg	gttttaaaaa	aaattgctgc	cacttttttt	5040
tcctgttttt	gtttcgtttt	tgtagccttg	acattcaccc	acctccctta	tgtagttgaa	5100
atatctagct	aacttggtct	ttttcgttgt	ttgtttttac	tcctttccct	cactttctcc	5160
agtgctcaac	tgtagatat	taatcttggc	aaactgctta	atcttgtgga	ttttgtagat	5220
ggtttcaaat	gactgaactg	cattcagatt	tacgagtga	aggaaaaatt	gcattagttg	5280
gttgcatgaa	cttcgaaggg	cagatattac	tgcacaaact	gccatctcgc	ttcatttttt	5340
taactatgca	tttgagtaca	gactaatttt	taaaatatgc	taaactggaa	gattaaacag	5400
atgtggggcca	aactgtttctg	gatcaggaaa	gtcatactgt	tcactttcaa	gttggctgtc	5460
ccccccgcg	cccccccca	cccccatatg	tacagatgat	aatagggtgt	ggaatgtcgt	5520
cagtggcaaa	catttcacag	atttttattt	tgtttctgtc	ttcaacattt	ttgacactgt	5580
gctaatagtt	atattcagta	catgaaaaga	tactactgtg	ttgaaagcct	tttaggaaat	5640

-31-

tttgacagta	tttttgtaca	aaacattttt	ttgaaaaaat	acttgtaaat	ttattctatt	5700
ttaatttgcc	aatgtcaata	aaaagttaag	aaataacttg	ttttctagaa	gtcatttggg	5760
ggtggttgt	ccctttggtg	gcttttttcc	ccccgtcttt	gagttgaaca	ctattgatga	5820
gagtaagcat	tccaaaggat	aaattacagg	acactaaaac	aggtcatgat	gagcttaagc	5880
ggagagcagg	atttaacata	attggcataa	tgcttcattg	ttatcattgt	aacatgcctc	5940
ttggtgtgct	ttaatcaaaa	gctgcaaagt	tgctactgct	tttttttttt	tcttaattgc	6000
catcatatca	agtgtactcc	agagttagaa	aggtttgcaa	tactcaacat	tatctttttc	6060
aatgggcagg	aggcaaaaaa	aatcaagtgt	ttctgtttat	acctgattca	actacttaaa	6120
tagaggtaga	ttggaataat	acactgattg	attgatgggt	ggcattaaat	ataaatctac	6180
ctttatctcc	agtgatgaga	gttttatttc	tcagcaaaag	tgccaaggat	aggtacatat	6240
tttctagcgt	aatctctgaa	acatgtctga	ctggtttata	gttctgagaa	gaagagcgaa	6300
atcccccttg	aagcctttgt	ccca				6324

&lt;210&gt; 33

&lt;211&gt; 1919

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; mRNA

&lt;222&gt; (1)...(1919)

&lt;223&gt; human p35srj (MRG1)

&lt;400&gt; 33

gtcctgccga	gctgtgaggg	caacggaggg	gaaataaaaag	ggaacggctc	cgaatctgcc	60
ccagcgcccg	ctgcgagacc	tcggcgccga	catcgcgaca	gcgaagcgct	ttgcacgcca	120
ggaaggtccc	ctctatgtgc	tgctgagccg	gtcctggacg	cgacgagccc	gccctcggtc	180
ttcgagcag	aaatcgcaaa	aacggaagga	ctggaaatgg	cagaccatat	gatggccatg	240
aaccacgggc	gcttccccga	cggcaccaat	gggctgcacc	atcaccttgc	ccaccgcatg	300
ggcatggggc	agttcccgag	ccccatcac	caccagcagc	agcagcccca	gcacgccttc	360
aacgccctaa	tgggcgagca	catacactac	ggcgcgggca	acatgaatgc	cacgagcggc	420
atcaggcatg	cgatggggcc	ggggactgtg	aacggagggc	accccccgag	cgcgctggcc	480
cccgcgccca	ggtttaacaa	ctcccagttc	atgggtcccc	cgggtggccag	ccagggaggc	540
tccctgccgg	ccagcatgca	gctgcagaag	ctcaacaacc	agtatttcaa	ccatcacccc	600
tacccccaca	accactacat	gccggatttg	cacctgtctg	caggccacca	gatgaacggg	660
acaaaccagc	acttccgaga	ttgcaacccc	aagcacagcg	gcggcagcag	cacccccggc	720
ggctcgggcg	gcagcagcac	ccccggcggc	tctggcagca	gtcggggcgg	cggcgcgggc	780
agcagcaaca	gcggcgggcg	cagcggcagc	ggcaacatgc	cgcctccgt	ggcccacgtc	840
cccgtgcaa	tgctgccgcc	caatgtcata	gacactgatt	tcatogacga	ggaagttctt	900
atgtccttgg	tgatagaaat	gggtttggac	gcgatcaagg	agctgcccgga	actctggctg	960
gggcaaaacg	agtttgattt	tatgacggac	ttcgtgtgca	aacagcagcc	cagcagagtg	1020
agctgttgac	tcgatcgaaa	ccccggcgaa	agaaatcaaa	cccccaactt	cttcggcgctg	1080
aattaaaaga	aacattccct	tagacacagt	atctcacttt	tcagatcttg	aaaggtttga	1140
gaacttggaa	acaaagtaaa	ctataaaactt	gtacaaattg	gttttaaaaa	aaattgctgc	1200
cacttttttt	tcctgttttt	gtttcgtttt	tgtagccttg	acattcaccc	acctccctta	1260
tgtagttgaa	atatctagct	aacttggctt	ttttcgttgt	ttgtttttac	tcctttccct	1320
cactttctcc	agtgtcaac	tgtagatat	taatcttggc	aaactgctta	atcttgtgga	1380
ttttgtagat	ggtttcaaat	gactgaactg	cattcagatt	tacgagtga	aggaaaaatt	1440
gcattagttg	gttgcattgaa	ctttgaaggg	cagatattac	tgacaaaact	gccatctcgc	1500
ttcatttttt	taactatgca	tttgagtaca	gactaatttt	taaaatatgc	taaactggaa	1560
gattaaacag	atgtggccca	aactgttctg	gatcaggaaa	gtcatactgt	tcactttcaa	1620
gttggtgtgc	ccccccgccc	ccccccccca	cccccatatg	tacagatgat	aataggggtg	1680
ggaatgtcgt	cagtggcaaa	catttcacag	attattttgt	ttctgtcttc	aacatttttg	1740
acactgtgct	aatagttata	ttcagtacat	gaaaagatac	tactgtgttg	aaagcctttt	1800
aggaaatttt	gacagtattt	ttgtacaaaa	catttttttg	aaaaaatact	tgtaatttta	1860
ttctatttta	atttgccaat	gtcaataaaa	agttaagaaa	taaaaaaaaa	aaaaaaaaaa	1919

**THIS PAGE BLANK (USPTO)**



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

